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Summary 
 
Cell membranes are highly enriched in arachidonic acid (AA), which serves as a source for the 
activity-dependent generation of eicosanoids including the cytochrome P450-derived 
epoxyeicosatrienoic acids (EETs). EETs are hydrolyzed to supposedly less active 
dihydroxyeicosatrienoic acids (DHETs) by microsomal and soluble epoxide hydrolase (mEH and 
sEH). Research efforts spanning over decades implicated EETs and to a marginal extent DHETs 
in various physiological processes. However, little is known about their potential role in synaptic 
physiology.  
This dissertation addressed the question if and how EETs and DHETs modulate neuronal 
excitability and synaptic transmission using the patch-clamp technique. We showed that in 
particular 11,12-EET and -DHET are capable of modulating neuronal excitability and synaptic 
transmission in hippocampal pyramidal cells (PCs) with 11,12-EET decreasing and -DHET 
increasing hippocampal excitability as a net effect. Our results suggested that EETs and DHETs 
likely mediate their effects via a combination of pre- and postsynaptic effectors. We found that 
11,12-EET activates a postsynaptic G-protein coupled inwardly rectifying K+ (GIRK) channel in 
CA1 PCs, leading to hyperpolarization and thus decreased excitability of the respective neuron. 
Additionally, 11,12-EET reduced the release of glutamate onto CA1 PCs via one or several 
presynaptic mechanism(s). Interestingly, 11,12-DHET counteracted the 11,12-EET effects and 
increased excitatory transmission, reflected by an increase in field excitatory postsynaptic 
potentials (fEPSPs) recorded at the Schaffer collateral-CA1 synapse.  
Voltage-gated K+ channels appeared to be the most promising molecular targets mediating EET 
and DHET effects. In hippocampal PCs, Kv1.1 and 1.2 channels are expressed presynaptically 
and regulate the release of glutamate, whereas Kv4.2 channels are expressed postsynaptically and 
regulate dendritic excitability. We expressed these three channels in heterologous cells and tested 
the effect of 11,12-EET and -DHET. The effect of 11,12-DHET was evaluated at a single 
depolarizing test potential of +10 mV and +40 mV for Kv1.2 and Kv4.2, respectively. 11,12-
DHET significantly blocked Kv1.2 by 11.92±3% at the single test potential of +10 mV, whereas 
Kv4.2 was significantly blocked by 24.5±5.6% at a test potential of +40 mV. By contrast, 11,12-
EET increased Kv1.2 currents by 4.9±1.5% at a single depolarizing test potential of +10 mV. 
Moreover, we tested the inhibitory effect of 11,12-DHET on Kv1.2 and Kv4.2 using a multiple 
current (I)-voltage (V) step protocol. In this paradigm, 11,12-DHET blocked Kv1.2 by 29.7±9% 
at +40 mV and Kv4.2 channels by 36.8±5.3% at +10 mV. These EET and DHET-mediated 
activation and inhibition of Kv channels, respectively, are consistent with decreased and 
increased excitatory synaptic transmission at the CA3-CA1 synapse in brain slices.  
Since mEH and sEH determine the EET:DHET ratio due to their ability to hydrolyze EETs, they 
might act as ‘physiological switch’ between inhibition and excitation. We tested this notion using 
three strains of transgenic mice, which either lacked mEH or sEH or expressed a hyperactive 
mEH variant (mEH E404D). The basal synaptic activity measured as input-output curves was 
significantly reduced in slices from mEH KO and sEH KO compared to WT mice. By contrast, 
slices from mEH E404D mice with higher EH activity and thus higher turnover to DHETs 
showed higher basal synaptic transmission relative to WT at the hippocampal CA3-CA1 
synapse. Thus, EHs most likely play an important role in setting the level of excitability in the 
CNS. 
The second project of this dissertation focused on the involvement of CYP-epoxygenase-derived 
fatty acids (FA) epoxides in morphine-mediated antinociception. Using the tail flick paradigm, 
we found that sEH KO mice exhibited significantly higher morphine-mediated antinociception at 
a subcutaneously applied dosage of 1 mg/kg compared to WT mice. This might be due to an 
accumulation of FA epoxides such as EETs, although other levels of FA epoxides such as those 
of epoxydocosapentaenoic acids (EpDPEs) or epoxyeicosatetraenoic acid (EpETEs) are also 
known to be enhanced in sEH KO relative to WT brain. We tested 14,15-EET as a potential 
modulator of mu-opioid receptor (MOR) signaling in HEK-293T cells, as morphine exerts its 
effects primarily through the MOR. However, 14,15-EET neither by itself nor when co-
administered with the selective MOR agonist DAMGO showed any effect. This led to the 
conclusion, that either another FA epoxide (EpDPEs, EpETEs) modulates MORs or HEK-293T 
cells lack a crucial molecular component for enhancing EET-mediated MOR signaling. 
Taken together, our findings implicate EETs and DHETs as endogenous neuroactive lipid 
mediators, which regulate neuronal excitability and synaptic transmission possibly via activating 
or inactivating K+ channels, namely GIRK, Kv1.2, and Kv4.2 channels in hippocampal PCs. 
Furthermore, the results of this dissertation offer mechanistic explanations for attenuated 
epileptic symptoms observed in sEH KO relative to WT mice described in earlier studies. 
Zusammenfassung 
Zellmembranen enthalten grosse Mengen an Arachidonsäure, die als Ausgangsstoff für die 
Synthese von Eikosanoiden dient. Ein Beispiel für solche Eikosanoide sind die sogenannten 
EETs (abgeleitet vom englischen Wort epoxyeicosatrienoic acids), die in einer durch Cytochrom 
P450-katalysierten Reaktion entstehen. In einem zweiten Schritt können EETs von der 
mikrosomalen oder löslichen Epoxidhydrolase zu sogenannten DHETs (abgeleitet vom 
englischen Wort dihydroxyeicosatrienoic acids) hydrolysiert werden, wobei DHETs generell als 
weniger biologisch aktiv als EETs gelten. EETs, und zu einem geringen Ausmass auch DHETs, 
sind in eine Vielzahl von physiologischen Prozessen involviert – allerdings ist wenig über ihre 
Rolle in synaptischer Transmission bekannt.  
In dieser Arbeit wurde der Frage nachgegangen, ob, und wenn ja auf welche Weise, EETs und 
DHETs neuronale Erregung und synaptische Transmission modulieren. Wir konnten zeigen, dass 
insbesondere 11,12-EET und -DHET diese beiden Prozesse in hippokampalen Pyramidenzellen 
beeinflussen. Dabei dämpft 11,12-EET die Netzwerk-Aktivität, während 11,12-DHET diese 
erhöht. Diese Effekte werden mechanistisch über prä- und postsynaptisch lokalisierte Zielkanäle 
vermittelt. So aktiviert 11,12-EET einen postsynaptischen G-Protein gekoppelten einwärts 
rektifizierenden K+ (GIRK) Kanal in CA1 Pyramidenzellen, was zur Hyperpolarisation der Zelle 
und dadurch zu reduzierter Erregung führt. Zudem verringert 11,12-EET die Freisetzung von 
Glutamat an der CA3-CA1 Synapse über verschiedene präsynaptische Mechanismen. 11,12-
DHET wirkt den 11,12-EET-vermittelten Effekten interessanterweise entgegen und erhöht die 
exzitatorische Transmission, wie die Potenzierung von fEPSPs (field excitatory postsynaptic 
potentials ) unter DHETs an der CA3-CA1 Synapse gezeigt hat.  
Spannungs-gesteuerte K+ Kanäle erschienen als wahrscheinlichste Zielkanäle für EETs und 
DHETs. Kv1.1 und 1.2 Kanäle finden sich auf der Präsynapse von Pyramidenzellen und 
regulieren die Freisetzung von Glutamat. Kv4.2 Kanäle sind hingegen in Dendriten exprimiert 
und beeinflussen die dendritische Erregungsleitung. Diese drei Kanal-Typen wurden in CHO- 
und HEK-Zellen exprimiert und der Effekt von 11,12-EET und –DHET auf diese untersucht. Die 
Wirkung von 11,12-DHET auf Kv1.2 und Kv4.2 wurde bei Einzelspannungen von +10 mV bzw. 
+40 mV gemessen. 11,12-DHET blockierte den Kv1.2 Kanal zu 11.92±3% bei einer 
Testspannung von +10 mV und Kv4.2 zu 24.5±5.6% bei +40 mV. Im Gegensatz dazu erhöhte 
11,12-EET Kv1.2-vermittelte Ströme um 4.9±1.5% bei einer Spannung von +10 mV. Zudem 
wurde der Effekt von 11,12-DHET auf Kv1.2 und Kv4.2 noch in einer Strom (I)-Spannungs (V)-
Kurve untersucht, in der die Spannung in +10 mV-Inkrementen kontinuierlich bis +80 mV 
erhöht wurde. Hier blockierte 11,12-DHET Kv1.2-Kanäle zu 29.7±9% bei einer Spannung von 
+40 mV und Kv4.2-Kanäle zu 36.8±5.3% bei einer Spannung von +10 mV. Diese EET-
vermittelte Aktivierung bzw. DHET-vermittelte Inhibition von Kv -Kanälen stimmt mit der von 
uns in hippokampalen Hirnschnitten beobachteten Netto-Wirkung der Fettsäuren überein, 
nachdem EETs dämpfend und DHETs potenzierend auf die exzitatorische Netzwerk-Aktivität 
wirken. 
mEH und sEH beeinflussen nachhaltig das Verhältnis von EETs zu DHETs, da sie die Hydrolyse 
von ersterem zu letzterem katalysieren. Aufgrund der gegensätzlichen Wirkung von EETs und 
DHETs könnten Epoxidhydrolasen als eine Art Schalter zwischen Inhibition und Exzitation in 
Netzwerken fungieren. Wir testeten diese Hypothese, indem wir die basale Transmission in 
Hirnschnitten von gentechnisch veränderten Mäusen massen; diesen Mäusen fehlten entweder 
das sEH oder mEH Protein oder sie exprimierten eine mEH-Variante mit deutlich erhöhter 
Aktivität (mEH E404D) anstelle der WT mEH. Die basale synaptische Aktivität wurde in Form 
von Input-Output-Kurven ermittelt und war in Schnitten von mEH KO und sEH KO Mäusen 
deutlich reduziert im Vergleich zu WT Kontrollschnitten. Hingegen zeigten Schnitte von mEH 
E404D Mäusen erhöhte Aktivität im Vergleich zu WT Kontrollen. Das Fehlen von 
Epoxidhydrolasen, das zu einer Erhöhung der freien EET- und Reduktion der freien DHET-
Konzentration relativ zu WT Kontrollen führt, geht mit gedämpfter exzitatorischer Transmission 
einher; erhöhte EH Aktivität, die zu erniedrigten EET- und erhöhten DHET- Konzentrationen 
führen sollte, geht mit erhöhter Transmission einher. Epoxidhydrolasen spielen folglich eine 
wichtige Rolle, wenn es darum geht, den Grad an Exzitabilität im ZNS zu bestimmen.  
Im zweiten Projekt dieser Arbeit wurde die Rolle von CYP-Epoxygenase-generierten Fettsäure-
Epoxiden in der Morphin-vermittelten Antinozizeption untersucht. sEH KO Mäuse sprachen 
deutlich länger und verstärkt auf subkutan appliziertes Morphin (Dosis: 1 mg/kg) an als WT 
Kontrollmäuse. Aufgrund des Fehlens der sEH reichern sich freie Fettsäure-Epoxide in sEH KO 
Mäusen in grösseren Mengen an als in WT Mäusen. Zu diesen Fettsäure-Epoxiden zählen EETs, 
aber auch EpDPEs (epoxydocosapentaenoic acids) oder EpETEs (epoxyeicosatetraenoic acid). 
Diese Fettsäure-Epoxide könnten über eine Modulation des mu-Opioid-Rezeptors (MOR), über 
den Morphin hauptsächlich seine Wirkung entfaltet, die erhöhte Antinozizeption in sEH KO 
Mäusen verursachen. Wir untersuchten daher die Wirkung von 14,15-EET an in HEK-Zellen 
exprimierten MORs. Allerdings zeigte 14,15-EET weder allein appliziert, noch in Kombination 
mit dem selektiven MOR-Agonisten DAMGO irgendeine Wirkung. Folglich modulieren 
entweder andere Fettsäure-Epoxide wie EpDPEs oder EpETEs die Aktivität von MORs in sEH 
KO Mäusen oder HEK-Zellen fehlt eine essentielle molekulare Komponente, die für die erhöhte 
MOR Aktivität wesentlich ist.  
Zusammengenommen zeigen unsere Resultate, dass EETs und DHETs als endogene Lipid-
Signalmoleküle in der neuronalen Transmission wirken. Wahrscheinlich regulieren sie neuronale 
Erregung und synaptische Transmission, indem sie K+ Kanäle aktivieren bzw. inaktivieren. In 
hippokampalen Pyramidenzellen dürften dies in erster Linie GIRK-Kanäle, Kv1.2- und Kv4.2-
Kanäle sein. Zudem bieten die Resultate dieser Arbeit eine mechanistische Erklärung für die 
reduzierte Suszeptibilität von sEH KO Mäusen gegenüber Epilepsie-generierenden Pharmaka im 
Vergleich zu WT Kontrollmäusen. 
 
 
 
Chapter 1  
General Introduction 
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1.1. The hippocampal formation in mouse brain 
The hippocampal formation (HF) is a well-characterized structure in terms of histology, 
connectivity, and electrophysiology, which makes it a suitable experimental system to study 
synaptic physiology. Therefore, mouse hippocampal slices were used as an experimental 
system in this dissertation to study the effect of lipid mediators on synaptic physiology. The 
following subsections will give a brief overview of mouse HF in terms of cytoarchitectonic 
organization, connectivity-information flow, and electrophysiological properties of the 
constituting neurons.  
1.1.1. Neurotransmission in the hippocampus 
Neurons in the hippocampus can be grouped into two categories based on their functionality, 
namely excitatory pyramidal cells (PCs) and the inhibitory interneurons (INs). PCs are 
excitatory and employ glutamate as the primary neurotransmitter, whereas INs are inhibitory 
and employ γ-aminobutyric acid (GABA) as the primary neurotransmitter (Taupin, 2007). 
Glutamate released at excitatory synapses can act on three ionotropic glutamate receptors, N-
methyl-D-aspartate receptor (NMDAR), α-amino-3-hydroxy-5-methylisoxazole-4-propionic 
acid receptor (AMPAR) and kainate receptors (KAR) (Traynelis et al., 2010). Ionotropic 
AMPARs, NMDARs, and KARs are expressed postsynaptically. At resting membrane 
potential, NMDARs are non-conducting due to the block produced by extracellular Mg2+. 
Typically, activation of AMPARs leads to the inward flux of Na+ which results in 
depolarization of the postsynaptic membrane. This initial AMPARs-mediated depolarization 
removes the Mg2+ block of NMDARs which further allows an influx of Na+ as well as Ca2+ 
ions into the postsynaptic neuron. The AMPAR-, NMDAR- and KAR-mediated inward 
conductances of cations give rise to excitatory postsynaptic currents/potentials (EPSC/Ps). 
The inhibitory neurotransmitter GABA activates postsynaptic ionotropic GABAARs, which 
conduct chloride currents. They give rise to inhibitory postsynaptic currents/potentials 
(IPSCs/Ps). Inhibitory INs can innervate PCs dendritically or perisomatically. INs, via 
dendritic and perisomatic inhibition, regulate input and output of PCs. Dendritic inhibition 
controls the efficacy of excitatory inputs, while perisomatic inhibition, particularly at the axon 
hillock, controls the generation of action potentials (Miles et al., 1996).  
1.1.2. Dentate gyrus granule cells and the mossy fiber synapse 
Dentate gyrus granule cells (DGGCs) are tightly packed in the granule cell layer and have a 
typical cone-shaped tree of apical dendrites. The main afferents of DGGCs originate in the 
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EC layer II and synapse on the apical dendrites of DGGCs to form the perforant pathway 
(Amaral et al., 2007). DGGCs send their main output to CA3 PCs through distinctive 
unmyelinated axonal projections called mossy fibers (Mfs). Mfs synapse on dendrites of CA3 
PCs in a narrow zone termed stratum lucidum. Mf synapses are excitatory in nature and are 
unique in many aspects; most importantly, there are three different types of presynaptic 
terminals of DGGC axons: 1. Large mossy fiber boutons (MfBs); 2. Small filopodial 
extensions of MfBs and 3. en passant terminals (Fig. 1.1). These terminals are functionally 
specialized. Large MfBs selectively contact and excite CA3 PCs while filopodial extensions 
and en passant terminals contact and activate inhibitory INs (Danzer et al., 2008). Mf 
synapses exhibit short-term plasticity in form of a large paired-pulse facilitation (PPF) with 
ratio>3 in most cases. Additionally, marked frequency facilitation is observed at Mf synapses. 
An increase in the frequency of stimulation from 0.5 Hz to 1 Hz results in several folds of 
potentiation in synaptic strength. The frequency facilitation observed at the Mf synapse is 
attributed to the low initial release probability of glutamate, which is presumably maintained 
via presynaptic A1 receptors (Nicoll et al., 2005).  
 
1.1.3. Hippocampal PCs and the Schaffer collateral-CA1 synapse 
CA3 and CA1 PCs have pyramidal shaped somas, which are tightly packed in the pyramidal 
cell layer. Both CA3 and CA1 PCs give rise to basal and apical dendritic trees studded with 
dendritic spines on which they receive inputs. CA3 PCs have an additional specialized class 
of spines called ‘thorny excrescences’ on which they receive input from the Mf pathway. CA3 
PCs send axonal fibers to CA1 PCs to form Schaffer collaterals (SCs), which synapse on 
basal and apical dendrites (Fig 1.2).  
Fig.1.1. The Mf synapse, adapted from (Nicoll et al., 2005) 
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In addition, CA1 PCs receive input from different parts of the entorhinal cortex (EC) 
depending on the location of the PC on the transverse axis. CA1 PCs also project extensively 
to the adjoining subiculum (Andersen, 2007). 
1.1.4. Field recordings in the hippocampus 
Field excitatory postsynaptic potential recordings (fEPSPs) are extracellular recordings from 
populations of neurons as opposed to the conventional intracellular recording from single 
neurons. The hippocampus is amenable to extracellular field recordings due to the following 
reasons: 
Since dendrites and axons of PCs and DGGCs are arranged in a parallel manner, activation of 
neighboring synapses adds up their effect linearly, giving rise to a cumulative change in the 
extracellular potential. Synaptic currents flow into the dendrites of the activated region and 
generate a so-called ‘current sink’, while they exit at the somas generating a so-called ‘current 
source’. For example, stimulation of SCs generates negative fEPSPs in stratum radiatum (a 
current sink), while the polarity reverses as the recording electrode moves closer to the soma 
(current source) with respect to the ground electrode (Andersen, 2007). The sub-threshold 
stimulation of afferents, below the threshold to fire action potentials (AP) in target neurons, 
gives rise to the summation of pure synaptic events, field excitatory postsynaptic potentials 
(fEPSPs). The fEPSP signal contains two parts, the smaller downward deflection called fiber 
volley, which is followed by the larger downward deflection, the actual field. The fiber volley 
reflects the pre- and the field the postsynaptic component, respectively (Fig. 1.3A-B). Further 
increase in stimulation intensity eventually stimulates the target neurons to fire APs and gives 
rise to a synchronous discharge called ‘population spike’ (Fig. 1.3C). (Andersen, 2007; 
Buzsáki et al., 2012). 
Fig.1.2. (A) Hippocampal CA fields and (B) Schematic showing hippocampal connectivity between CA fields, 
adapted from (Deng et al., 2010) 
A B 
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1.1.5. Modulators of synaptic transmission 
1.1.5.1. G-protein-coupled receptors (GPCRs)  
GPCRs or metabotropic receptors are the largest and most diverse class of membrane proteins 
and characteristically consist of seven hydrophobic transmembrane domains. GPCRs are 
coupled to receptor-specific heterotrimeric G-proteins: α-, β- and γ-subunits. GPCRs, on 
ligand binding, activate associated G-proteins, which through intracellular secondary 
messengers produce cellular effects (Borroto-Escuela et al., 2017). Associated Gα proteins 
such as Gαq, Gαs can stimulate downstream signaling, Gi/o inhibit downstream signaling. 
A. Cannabinoid receptors 
Endocannabinoids are arachidonic acid (AA)-derived endogenous metabolites and act as key 
modulators of synaptic functions. Endocannabinoids are synthesized in situ in an activity-
dependent manner from AA, which is released from the neuronal membrane. N-arachidonoyl 
ethanolamine (anandamide) and 2-arachidonoyl glycerol (2-AG) are the two best-investigated 
endocannabinoids. Endocannabinoids are synthesized in the postsynaptic neuron and act on 
cannabinoid 1 (CB1) receptors, expressed on the presynaptic neuron, thus acting in a 
retrograde manner. Activation of presynaptic CB1 receptors suppresses the neurotransmitter 
release at glutamatergic as well as GABAergic synapses. CB1 receptors are coupled to the 
Gαi/o protein, from which the βγ subunit dissociates and presumably blocks voltage-gated 
calcium channels (VGCChs) (Castillo et al., 2012). Endocannabinoid-mediated suppression 
of GABA release via retrograde signaling was termed depolarization-induced suppression of 
inhibition (DSI), while endocannabinoid-mediated suppression of glutamate release termed as 
depolarization-induced suppression of excitation (DSE) (Diana et al., 2004). After eliciting 
pharmacological actions, endocannabinoids are promptly degraded by fatty acid amide 
Fig. 1.3 (A) Schematic showing the site of stimulation and recording for fEPSP. Representative examples of a 
fEPSP and a population spike are shown in (B) and (C), respectively.  
A B C 
fiber volley 
field 
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hydrolase (FAAH) and monoacylglycerol lipase (MAGL). FAAH and MAGL hydrolyze 
anandamide and 2-AG, respectively (Jhaveri et al., 2007). 
B. Opioid receptors 
Mu- (MORs) and delta-opioid receptors (DORs) are GPCRs and the major opioid receptors 
activated by a family of pituitary-derived endogenous neuropeptides called endorphins. In the 
hippocampus, MORs and DORs are predominantly expressed on GABAergic interneurons 
projecting on the perisomatic and dendritic area of CA1 PCs, respectively (Erbs et al., 2015; 
Svoboda et al., 1999). On a cellular level, MORs are expressed in both axon terminals and in 
the somatodendritic compartment of interneurons (Drake et al., 1999). MORs are coupled to 
Gi/o proteins and generate site-dependent effects. Activation of axonal MORs suppresses the 
release of GABA from GABAergic terminals via Gβγ-mediated inhibition of VGCChs; 
activation of somatodendritic MORs activates G-protein coupled inwardly rectifying K+ 
(GIRK) channels presumably via interaction with Gβγ protein, which results in 
hyperpolarization of PCs (Al-Hasani et al., 2011; Svoboda et al., 1999). MOR-mediated 
suppression of GABA release results in the prolongation of excitatory activity in the 
hippocampus through disinhibition of PCs (McQuiston et al., 2003; Zieglgansberger et al., 
1979).  
In addition to endorphins, exogenous opioids such as morphine and DAMGO activate opioid 
receptors with differential affinity and efficacy. Compared to morphine, DAMGO acts as a 
full and selective agonist on MORs (Onogi et al., 1995). Prolonged and repeated exposure to 
agonists can result in progressively decreased efficacy of MOR activation, leading to a 
phenomenon known as ‘tolerance’. The underlying molecular mechanisms of tolerance 
remain uncertain, but there is accumulating evidence linking it to MOR desensitization 
phosphorylation, arrestin association, endocytosis and recycling (Dang et al., 2012). 
Prolonged morphine exposure results more rapidly in the development of tolerance compared 
to that of DAMGO (Williams et al., 2013). 
1.1.5.2. Voltage-gated potassium channels (VGPChs) 
VGPChs have emerged as important regulators of synaptic transmission. Structurally, 
VGPChs are constituted of homo- or heterotetramer of pore-forming α-subunit isoforms. The 
stoichiometry of these α-subunits fine-tune the conductance and kinetic properties of the 
resulting channel (Coleman et al., 1999; Wang et al., 1993). Moreover, accessory subunits 
such as Kvβ can co-assemble with heteromultimeric channels to influence the gating 
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properties, axonal/somatodendritic targeting and surface expression of the associated VGPChs 
(Pongs et al., 2010; Rhodes et al., 1997). Based on their sub-cellular localization VGPChs 
exert different effects: When localized to the somatodendritic compartment they might alter 
the integration of synaptic inputs. By contrast, VGPChs present in axon terminals may 
modulate the shape of incoming APs and thus impact the release of neurotransmitter 
(Trimmer, 2015). 
Recent studies have shown that CA1 and CA3 dendrites express VGPChs including those 
from the Kv4 subfamily (Spruston, 2008). The expression density of Kv4 shows a linear 
increase with the distance from cell soma of the hippocampal CA1 PCs (Hoffman et al., 
1997). These Kv4 channels conduct rapidly inactivating transient A-type (IA) potassium 
currents, which modulate negatively the backpropagation of APs, the firing frequency, and 
integration of synaptic inputs in the hippocampal PCs (Fransén et al., 2010; Hoffman et al., 
1997). Moreover, blocking of IA current increases temporal summation of the postsynaptic 
potential and thus the intrinsic neuronal excitability in rat CA1 PCs (Rathour et al., 2016).  
VGPChs from the Kv1 subfamily are predominantly expressed in axonal initial segments and 
presynaptic terminals. They regulate spike frequency/duration and neurotransmitter release 
from axon terminals (Trimmer, 2015). Kv1.1, 1.2 and 1.4 are the most common isoforms 
expressed in hippocampal PCs. In terms of stoichiometry, Kv1.1 almost always heteromerizes 
either with Kv1.2 or in some instances with Kv1.4 and gives rise to the so-called D-type 
currents (ID) (Ovsepian et al., 2016; Wang et al., 1993). Axonal Kv1 channels are important 
regulators of axonal AP generation and conduction along the axon proper to presynaptic 
terminals (Kole et al., 2012). Blocking of axonal Kv1 channels with a local puff of the Kv1-
specific blocker Dendrotoxin (DTx), with a laser or via mechanical axotomy significantly 
increases excitability recorded in the soma of CA3 PCs (Rama et al., 2017). Moreover, 
Kv1.1/1.4 channels, which are expressed in the presynaptic terminals of Mfs, regulate the 
release of glutamate by controlling Ca2+ influx into MfBs (Geiger et al., 2000). Additionally, 
the loss of function mutations in the human KCNA1 gene is linked to the hyperexcitability 
disorder epilepsy, further pointing towards a crucial role for Kv1 channels in the regulation of 
neuronal excitability (Ovsepian et al., 2016).  
There are a few other Kv channels such as Kv3 channels and calcium-activated BK (BKCa) 
channels, which are expressed in presynaptic axon terminals. However, their potential 
contribution to glutamate release has not been determined or found to be non-significant at 
basal transmission level (Hu et al., 2001; Trimmer, 2015).  
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1.2. Polyunsaturated fatty acids and their function in the CNS 
Polyunsaturated fatty acids (PUFAs) are fatty acids (FAs) that contain more than one double 
bond in their backbone. Based on the position of the double bond from the methyl end, they 
are subdivided into omega-3 and omega-6 FAs. Omega-3 FAs include α-linolenic acid 
(ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), while omega-6 FAs 
include linoleic acid (LA) and arachidonic acid (AA). In mammals, AA cannot be 
biosynthesized de novo from acetyl-CoA; it is biosynthesized from its precursor LA. LA is an 
essential FA and needs to be supplemented through diet. Consumed PUFAs are absorbed 
from the gastrointestinal tract and packaged into hepatic lipoproteins and transported to the 
brain via cardiovascular circulation, however, the precise mechanism of transport across the 
blood-brain barrier (BBB) remains controversial (Mitchell et al., 2011). In brain, AA and 
DHA are the most important and biologically relevant FAs (Bazinet et al., 2014). AA is 
typically esterified to the sn-2 position of glycerophospholipids of the plasma membrane and 
the endoplasmic reticulum (ER). It is released by cytoplasmic phospholipase A2 (cPLA2), an 
intracellular calcium-dependent enzyme that selectively hydrolyzes the sn-2 ester bond 
(Farooqui et al., 2004; Farooqui et al., 1997). Activation of cPLA2 is coupled to a number of 
stimuli, including depolarization-induced increase in intracellular calcium, activation of 
serotoninergic, dopaminergic and cholinergic receptors or pathological processes such as 
ischemia, inflammation, and excitotoxicity (Bazinet et al., 2014). Activity-dependent cPLA2-
mediated release of AA is a major source of free AA in neurons. Free AA can participate 
directly in signaling or serve as a precursor for the synthesis of a plethora of bioactive 
molecules (Bazinet et al., 2014). 
The reported plasma concentration of free AA is in the lower micromolar range (Abdelmagid 
et al., 2015; Brash, 2001; Elinder et al., 2017; Shinde et al., 2012). However, these 
concentrations are not a useful indicator of local concentration at the potential site of action or 
in a given microenvironment. Pathological events such as ischemia, hypoxia, and 
experimentally-induced epilepsy dramatically increase plasma AA concentration by several 
folds (Bazan et al., 1986; Bazán, 1970; Gardiner et al., 1981; Siesjö et al., 1989). 
To make matters more complex, AA can be either re-esterified or metabolized further 
Specifically, AA can be oxidized by three distinct enzymatic systems, namely by 
cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450 (CYPs) 
monooxygenase (Fig. 1.4) (Spector et al., 2004). COX oxidizes AA to unstable cyclic 
endoperoxide intermediates, prostaglandins H2 (PGH2), which serve as precursors for various 
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other prostaglandins such as PGD2, PGE2, PGI2 and thromboxanes (TxA2). LOX metabolizes 
AA to hydroperoxyeicosatetraenoic acids (HpETEs) and hydroxyeicosatetraenoic acids 
(HETEs) and subsequently to lipoxins and leukotrienes (Samuelsson, 1987). COX and LOX 
derivatives have been studied extensively and are implicated in several pathophysiological 
processes (Funk, 2001; Harizi et al., 2008). The CYP-epoxygenase pathway is the least 
explored, however, in recent years, numerous studies have added to a better understanding. 
 
1.2.1. Effects of AA in the CNS 
Earlier studies suggested that AA or one of its metabolites may modulate synaptic 
transmission, particularly long-term potentiation (LTP). LTP is characterized by a persistent 
increase in synaptic strength following high-frequency stimulation and is considered 
instrumental for learning and memory (Lynch et al., 1989; Williams et al., 1989). PLA2 
activation is critical for the expression, but not for the maintenance of LTP in the CA1 region 
of the hippocampus (Massicotte et al., 1990). Moreover, in vivo studies corroborated the 
involvement of AA or its metabolites on LTP and thus in learning and memory. In rats, 
pharmacological inhibition of PLA2 in combination with the inhibition of nitric oxide 
synthase activity impaired spatial memory performance in the Morris water maze (Hölscher et 
al., 1995). Similarly, specific inhibition of PLA2 activity diminished memory retrieval after 
avoidance training in rats (Schaeffer et al., 2007).  
Fig. 1.4 COX, LOX and CYP-epoxygenases pathway of AA metabolism  
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These effects of PLA2 inhibition on LTP were further evaluated experimentally by employing 
exogenous AA. Application of AA enhanced LTP, generated by weak stimulation of the 
perforant path in anesthetized rats and in rat hippocampal slices; co-application of a LOX 
inhibitor did not antagonize the effect of AA (Williams et al., 1989). Consistent with these 
findings, AA in presence of weak tetanic stimulation produced long-lasting potentiation in the 
CA1 region of the hippocampus. However in this case, the effect of AA was antagonized by a 
LOX inhibitor, suggesting the potential contribution of LOX metabolites (Drapeau et al., 
1990). Moreover, some reports implicated COX metabolites in the regulation of synaptic 
transmission and LTP (Sang et al., 2005; Sang et al., 2007). 
The notion of AA acting as a ‘retrograde messenger’ was proposed and explored by several 
earlier studies (Lynch et al., 1991; Lynch et al., 1993; Williams et al., 1989) and countered by 
others (Fitzsimonds et al., 1998; O'dell et al., 1991). However, more recently convincing 
evidence for AA acting as retrograde messenger was presented: In a study by Carta and 
colleagues, AA released from postsynaptic CA3 PCs blocked presynaptic Kv channels on Mf 
boutons. This resulted in robust facilitation of excitatory neurotransmission at the Mf-CA3 
synapse in mouse hippocampus (Carta et al., 2014). 
1.2.2. Molecular targets of AA 
AA effects in the CNS are attributed to the potential modulation of classical voltage-gated ion 
channels such as voltage-gated sodium channels (VGSChs), VGCChs and VGPChs in 
combination with other ion channels including the transient receptor potential (TRP), store-
operated calcium entry (SOCE) channels and two-pore domain K+ (K2P) channels (Boland et 
al., 2008; Kim, 2003; Meves, 2008; Schmitt et al., 1995). AA and most other PUFAs decrease 
the availability of VGSChs, resulting in an increased threshold for AP firing in cells such as 
cardiac myocytes (Kang et al., 1995). Moreover, AA inhibits L-type, T-type, and N-type 
calcium channels in excitable cells (Boland et al., 2008; Schmitt et al., 1995).  
In particular, VGPChs such as Kv4.x and Kv1.x are modulated by AA. AA and its non-
metabolizable analog 5,8,11,14-eicosatetraynoic acid (ETYA) inhibit the amplitude of peak IA 
currents in oocytes (Villarroel et al., 1996) and native neurons (Meves, 2008). AA and ETYA 
inhibit IA currents and enhance the amplitude of back-propagating APs in CA1 PCs (Colbert 
et al., 1999). AA not only blocks the peak IA, but also significantly increases the IA 
inactivation in neurons (Boland et al., 2008). However, this effect of AA on kinetics was 
absent in heterologously expressed Kv channels. Evidently, co-expression of accessory Kv 
channel interacting proteins (KChIPs) is required for the modulatory effect of AA on IA 
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kinetics (Holmqvist et al., 2001). Moreover, 10 µM of AA applied extracellularly exert a 
similar effect as 1 pM of AA applied intracellularly; the former blocks IA by 54.3±7% 
(Holmqvist et al., 2001), the latter by 56.5±8%, respectively (Bittner et al., 1999). Thus, the 
LTP-potentiating effect of AA can be at least partly attributed to its ability to inhibit IA 
currents (mediated by Kv4 channels) in hippocampal PCs (Ramakers et al., 2002). 
Presynaptically, AA most probably blocks Kv1.x channels, which are known to regulate 
glutamate release (Trimmer, 2015). Inhibition of presynaptic Kv channels in MfBs by AA 
broadens presynaptic APs and enhances glutamate release to facilitate synaptic transmission 
(Geiger et al., 2000; Carta et al., 2014). Moreover, AA inhibits Kv1.4 channels heterologously 
expressed in HEK-293T cells (Angelova et al., 2009). Finally, AA is capable of endowing 
non-inactivating Kv1 channels with an uncharacteristic voltage-dependent inactivation and as 
such converts ID currents into inactivating transient IA currents (Oliver et al., 2004).  
The exact molecular mechanism underlying AA-mediated modulation of VGPChs is not well 
understood to date. AA-mediated effects on A-type VGPChs are not occluded by the classical 
pore blocker tetraethylammonium (TEA) chloride, suggesting the involvement of alternate 
mechanism(s) or sites (Oliver et al., 2004). Moreover, AA-mediated inhibition of IA was 
abolished in the presence of an antioxidant, suggesting the involvement of oxidative pathways 
(Angelova et al., 2006). Alternatively, the esterification of AA into the lipid membrane and 
the resulting alteration of membrane fluidity might influence the activity of channels (Boland 
et al., 2008). Potential binding sites for PUFAs (termed PUFA 1-5) have been proposed to be 
located on VGPChs; specific lipoelectric interaction with these sites might possibly underlie 
the AA effects on these channels (Elinder et al., 2017).  
1.2.2.1. The cytochrome P450 monooxygenase-derived eicosanoids 
CYPs are a superfamily of heme-containing enzymes, which catalyze the addition of oxygen 
to the aliphatic position of diverse chemical entities and are thus also referred to as 
monooxygenases. NADPH-CYP-reductase (CPR) and cytochrome-b5 together with NADH-
b5-reductase are indispensable for CYP-mediated monooxygenation reactions. CYPs are 
traditionally known for their role in xenobiotic metabolism of structurally diverse compounds 
ranging from environmental carcinogens/toxins to xenobiotic small molecule drugs such as 
isoniazid, fluoxetine or complex antibiotics such as rifampicin. They are most abundantly 
expressed in liver, the major site of xenobiotic metabolism, but also in extrahepatic tissue 
such as brain. Importantly, CYPs are also capable of oxidizing endogenous compounds such 
as FAs (Persson et al., 2014).  
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CYP isozymes capable of epoxygenating membrane-derived AA are collectively termed 
CYP-epoxygenases. CYP-epoxygenases oxidate AA by inserting an oxygen atom at one of 
the four double bonds of AA, which results in the generation of four distinct regioisomers: 
5,6-, 8,9-, 11,12- and 14,15-EET. Several CYP isoforms are capable of epoxygenation of AA, 
including CYP-1A, CYP-2B, CYP-2C, CYP-2D, CYP-2J, CYP-4F (Kaspera et al., 2009) and 
the human orphan isoform CYP-4x1 (Stark et al., 2008). However, members from the CYP-
2C and -2J family are most noted for their epoxygenase activity (Iliff et al., 2010). 
CYP-isozymes exhibit specific preferences for generating regioisomer(s) and/or 
stereoisomer(s) of EET(s). This results in CYP-isozyme-specific mixtures of EET 
regio/stereoisomers (Rifkind et al., 1995). For example, purified CYP-2C8 from human liver 
generates 11,12- and 14,15-EET in a 1:1.25 ratio. By contrast, human CYP-2C9 produces 8,9-
, 11,12- and 14,15-EET in a ratio of 2.3:1.0:0.5. Generally, 11,12- and 14,15-EET seem to be 
the main EET regioisomers in most mammalian tissues, as 11,12- and 14,15-EET account for 
67–80% of total EETs synthesized by the major CYP-epoxygenases CYP-2C8, CYP-2C9, 
and CYP-2J2 (Spector et al., 2015). The stereoselectivity of these enzymes also varies in an 
isoform-specific manner with CYP-2C8 producing the (S, R)- and (R, S)-11,12-EET 
stereoisomers in a 20:80 ratio, while CYP-2C9 produces them in a 70:30 ratio (Daikh et al., 
1994).  
1.2.3. CYP-epoxygenases in the CNS 
CYP-epoxygenated AA-metabolites were first reported in anterior pituitary cells of rat brain 
(Snyder et al., 1983). Following studies reported the biosynthesis of EETs by vascular 
endothelium (Amruthesh et al., 1992; Medhora et al., 2001) and astrocytes (Alkayed et al., 
1996) and suggested an important role for EETs in cerebrovascular function (Iliff et al., 
2010). The following CYP-epoxygenase isoforms have been identified in the mouse brain at 
transcript and/or protein level: CYP-2C, CYP-2J and CYP-4x1 (Al‐Anizy et al., 2006; Iliff et 
al., 2010). CYP-2C immunoreactivity (IR) was detected in rat hippocampal PCs (Riedl et al., 
2000) and CYP-2J transcripts were found in the mouse hippocampus [Allen brain atlas, (Lein 
et al., 2007)]. Moreover, microsomal preparations derived from mouse hippocampus are 
capable of synthesizing EETs in vitro (Marowsky et al., 2009). The majority of CYPs are 
localized in the ER with only a few CYPs located in mitochondria (Bhagwat et al., 1995; 
Iscan et al., 1990; Omura, 2006). 
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1.2.4. Modulation of CYP-epoxygenase activity 
Many chemicals known to modulate hepatic CYP expression/activity also modulate CYPs 
expressed in the brain. For example, phenobarbital induces the expression of CYP-2B in rat 
liver as well as in brain (Schilter et al., 2000). Moreover, the aromatic hydrocarbon receptor 
(AHR) activator, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP-1A transcription 
and in turn increases epoxygenase products of AA in vivo (Diani-Moore et al., 2014). CYP 
induction can also be organ-specific, as chronic nicotine treatment induces the drug 
metabolizing CYP-2D isoform in monkey brain, but not in liver (Mann et al., 2008). 
Doxorubicin treatment leads to upregulation of CYP-epoxygenases and a concomitant 
increase in EETs production in rat kidney while an increase in CYP-mediated ω-
hydroxylation products (20-HETE) was observed in rat liver (Zordoky et al., 2011).  
Genetic polymorphisms also influence CYP activity and potentially EETs biosynthesis. 
Genetic polymorphisms of CYP-epoxygenases are associated with the risk of cardiovascular 
diseases. The CYP-2J2 polymorphism rs890293, which leads to the reduced expression of 
CYP-2J2 mRNA, is associated with an increased risk of coronary artery diseases (Spiecker et 
al., 2004) and premature myocardial infarction (Liu et al., 2007). Moreover, allelic variants of 
CYP-2C9 with reduced activity is associated with higher risk of myocardial infarction (Visser 
et al., 2007). The CYP-2J2 rs890293 polymorphism has been associated with an increased 
risk of late-onset Alzheimer’s disease in Chinese population (Yan et al., 2015).  
1.2.5. The biological fate of EETs 
The majority of biosynthesized EETs are re-esterified into membrane glycerophospholipids. 
The functional implication of EETs incorporation is not completely clear, but membrane 
lipids may act as a temporary storage for EETs until they can be released on demand (Spector 
et al., 2004). Other pathways of EETs metabolism include binding to fatty acid binding 
proteins (FABPs) (Widstrom et al., 2001), beta-oxidation, chain elongation and glutathione 
conjugation (Spector et al., 2004). However, enzymatic hydrolysis of EETs by epoxide 
hydrolases represents the major pathway of EETs metabolism.  
1.2.6. Soluble and microsomal epoxide hydrolase 
Epoxide hydrolases (EHs) comprise a family of enzymes that catalyze the hydration of 
electrophilic epoxides by adding a water molecule to form the corresponding vicinal diols. 
(Arand et al., 2005). The first EH to be characterized was mammalian microsomal EH (mEH, 
encoded by EPHX1) (Oesch, 1973), followed by soluble EH (sEH, encoded by EPHX2) 
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(Hammock et al., 1976). Recently, two new members, EH3 and EH4 were added to the EH 
family (Decker et al., 2012). Both mEH and sEH are involved in the detoxification of 
potentially carcinogenic epoxides with differential efficacy and substrate specificity (Decker 
et al., 2012). Furthermore, sEH has received a lot of attention for its role in metabolizing 
bioactive endogenous epoxy FAs such as EETs to their corresponding diols (El-Sherbeni et 
al., 2014). mEH was considered mainly as detoxifying enzyme until recent evidence showed 
that mEH is also involved in turnover of endogenous FA epoxides and might play important 
physiological roles (Marowsky et al., 2017). Although sEH and mEH catalyze the same 
reaction, they differ in tissue expression, subcellular localization, substrate preferences and/or 
functions.  
mEH is an ER-resident enzyme anchored to the membrane by a single N-terminal anchor. It 
hydrolyzes a very broad range of structurally diverse epoxides, ranging from drug epoxide 
intermediates such as carbamazepine-10,11-epoxide to procarcinogenic epoxides such as 
styrene-7,8-oxide and epoxides derived from polycyclic aromatic hydrocarbons like 
naphthalene and anthracene. Cis-substituted lipophilic epoxides are excellent substrates for 
mEH, while trans-substituted epoxides such as trans-stilbene oxide are poorly metabolized by 
mEH (Decker et al., 2009). 
sEH is primarily localized in the cytosol except in a few cell types (e.g. proximal renal tubule 
cells), where it is found in the cytosol and peroxisomes (Marowsky et al., 2010). Unlike 
mEH, sEH inactivates both cis- and trans-substituted epoxides, provided the side chains are 
not excessively bulky as in trans-diphenyl-propene oxide and trans-stilbene oxide (Arand et 
al., 2005; Decker et al., 2009). Moreover, sEH is a bifunctional enzyme with its C-terminal 
domain exhibiting EH activity and its N-terminal domain exhibiting phosphatase activity 
(Cronin et al., 2003).  
1.2.7. sEH and mEH expression in the CNS 
In human brain, mEH immunoreactivity (IR) is found in neurons and some astrocytes in the 
substantia nigra, raphé nuclei, pons, locus coeruleus, vestibular nuclei, motor nuclei and in the 
thalamus (Farin et al., 1993). sEH IR is detected in neurons, with particularly strong IR found 
in cerebral cortex, in oligodendrocytes and smooth muscle cells surrounding arterioles in 
human brain (Sura et al., 2008). Conflicting data have been presented for the mouse brain. 
Zhang and colleagues detected sEH in cell bodies of striatal and cortical neurons and in 
cerebral blood vessels (Zhang et al., 2007). However, our group found sEH protein to be 
mainly located in astrocytes throughout the whole mouse brain and in neurons of the central 
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amygdala. In contrast, mEH was found to be strongly expressed in several neuronal subtypes, 
including hippocampal PCs with the strongest expression observed in CA3 PCs, mossy cells, 
and DGGCs. Furthermore, mEH IR was detected in striatal neurons and in neurons of the 
central amygdala. Non-neuronal expression of mEH was detected in cells of the choroid 
plexus, endothelial cells and smooth muscle cells (Marowsky et al., 2009).  
1.2.8. Modulation of sEH and mEH activity 
Several inducers and repressors have been reported for both sEH and mEH. Expression of 
hepatic mEH is induced by phenobarbital, methylcholanthrene, polychlorinated biphenyls, 
trans-stilbene oxide, peroxisome proliferators and heavy metals (Newman et al., 2005). 
Suppression of hepatic mEH activity has been reported in alloxan or streptozotocin-induced 
diabetes model in rats (Thomas et al., 1989). Moreover, glucocorticoid treatment markedly 
down-regulates the mEH gene; this effect has been directly attributed to the interactions with 
the 50-flanking sequence of the Ephx1 gene (Bell et al., 1990).  
Similarly, sEH expression is modulated by several compounds. Clofibrate, an activator of 
peroxisome proliferator-activated receptor-α (PPARα), induces sEH activity in rodent liver 
(Hammock et al., 1983). Moreover, the potent endogenous vasoconstrictor Angiotensin-II 
upregulates sEH expression in rat vascular endothelial cells in vitro and in vivo (Ai et al., 
2007). Interestingly, sEH expression shows sexual dimorphism in an organ-specific manner: 
Expression of sEH in rat kidneys is 283% higher in males than in females, while a difference 
of only 55% was observed in rat liver (Pinot et al., 1995). However, no indication for sexual 
dimorphism has been observed in mouse brain. (Marowsky et al., 2009).  
Human mEH and sEH genes are also subjected to genetic polymorphism. Several alleles have 
been identified with moderate effects on the enzyme half-life (Hosagrahara et al., 2004; 
Przybyla-Zawislak et al., 2003; Sandberg et al., 2000). mEH polymorphisms are often linked 
with an increased susceptibility to develop different types of cancers. For instance, the single 
nucleotide polymorphism (SNP) (rs1051740, T337>C in exon 3 leading to 113Tyr->His), 
leading to an increased mEH activity, has been associated with an elevated risk to develop 
exposure-related lung carcinoma (Václavíková et al., 2015). Apart from cancer, this 
polymorphism has been linked to the increased risk of pre-eclampsia (Zusterzeel et al., 2001) 
and perinatal mortality (Raijmakers et al., 2004). By contrast, slower mEH variants were 
correlated with increased susceptibility to emphysema (Smith et al., 1997). sEH 
polymorphisms have been linked to vascular diseases among others. The R287Q SNP with 
lower sEH activity was linked to the reduced risk of coronary heart disease and K55R, a SNP 
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with decreased phosphatase activity, was linked to the reduced risk of ischemic stroke (Harris 
et al., 2013). 
1.2.9. The role of sEH and mEH in the hydrolysis of EETs  
sEH hydrolyzes FA epoxides such as EETs and epoxy-octadecenoic acids (EpOMEs) to their 
supposedly less active diols, dihydroxyeicosatrienoic acid (DHETs) and dihydroxy-12Z-
octadecenoic acid (DiHOMEs), respectively. Although mEH is predominantly considered as a 
detoxifying enzyme, a very old study reported endogenous substrates for mEH such as steroid 
estroxide and androstene oxide (Vogel et al., 1982). More recently, mEH was found to also 
metabolize FA epoxides such as EETs and EpOMEs. Indeed, recent evidence points toward a 
substantial contribution of mEH to the metabolism of FA epoxides (Marowsky et al., 2009; 
Marowsky et al., 2017). Although mEH and sEH both metabolize FA-derived epoxides, they 
differ substantially in their activity and preference. 
Based on the catalytic efficiency (kcat/Km), mouse mEH prefers 11,12-EET >8,9-EET =14,15-
EET >>5,6-EET, while mouse sEH prefers 14,15-EET =11,12-EET >8,9-EET >5,6-EET 
(Table 1.1). (Marowsky et al., 2009). The catalytic efficiency of sEH is orders of magnitude 
higher than the one of mEH for all EET regioisomers. sEH is a faster enzyme at saturating 
substrate concentration as indicated by a higher Vmax (maximum velocity). For instance, sEH 
hydrolyzes 20,000 nmol/mg/min of its favored substrate, 14,15-EET. By contrast, mEH only 
hydrolyzes 130 nmol/mg/min of its preferred substrate, 11,12-EET. Owing to its higher 
activity, sEH presumably metabolizes the bulk of EETs under saturating conditions. 
Nevertheless, mEH has a higher apparent affinity for EETs under non-saturating conditions as 
indicated by a lower Km (Km: the substrate concentration at which the reaction rate is half of 
its maximum value) compared to sEH (Marowsky et al., 2009). In acutely dissociated mouse 
hippocampal cells, mEH contributed considerably to the turnover of 11,12-EET (25%) and 
8,9-EET (20%), but far less to the turnover of 14,15-EET (5%) (Marowsky et al., 2009). In 
addition to sEH and mEH, the newly identified EH3 also exhibits appreciable EET- 
metabolizing capability. However, its contribution to EET metabolism in mouse brain has yet 
to be determined (Decker et al., 2012).  
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 Recombinant mouse mEH Recombinant mouse sEH 
substrates  Vmax 
[nmol/mg/
min] 
Km [μM] kcat./Km 
[M−1×s−1] 
Vmax 
[nmol/mg/
min] 
Km1*(Km2) 
[μM] 
kcat./Km* 
[M−1×s−1]  
 
5,6-EET 5 1 5×103 300 6 (12) 5×104 
8,9-EET 100 1 1×105 2400 2 (11) 5×105 
11,12-EET 130 0.5 2×105 11,000 0.6 (6) 5×106 
14,15-EET 25 0.25 1×105 20,000 2 (20) 5×106 
Pharmacological inhibition of sEH has been proven to be an efficient strategy to enhance EET 
levels and in turn decrease the production of DHETs. This altered EET:DHET ratio translates 
into several beneficial therapeutic effects (Imig et al., 2009). Therefore, sEH emerged as a 
therapeutic target and a diverse class of chemical entities including amides, ureas, thioamides, 
thioureas, carbamates, and acyl hydrazones were developed as sEH inhibitors (sEHis) (Shen, 
2010). sEHis are widely employed to study the role of EETs in vivo in experimental animals; 
they are also explored as potential clinical therapeutics for several vascular disorders 
(Ingraham et al., 2011; Imig et al., 2009).  
1.3. The role of EETs in the CNS 
1.3.1. EETs and the vascular system 
EETs are best known for their vasodilatory potential and their role in neurovascular coupling. 
Neurovascular coupling refers to the increase in local blood flow in response to increased 
neuronal activity (functional hyperemia). It involves neurons, glia, and vascular cells (Imig et 
al., 2011). Astrocytes as well as endothelial cells are probably capable of generating EETs 
(Alkayed et al., 1996; Medhora et al., 2001). Astrocyte-derived EETs dilate blood vessels via 
activating BKCa channels in vascular smooth muscles (Imig et al., 2011). Owing to its 
endothelial origin and potent vasodilatory effects, EETs have been identified as endothelium-
derived hyperpolarizing/relaxing factors (EDH/RF) in some vascular beds (Campbell et al., 
1996; Fisslthaler et al., 1999). Also, EETs have been shown to be angiogenic in cerebral 
vasculature (Zhang et al., 2002).  
Table 1.1 Kinetic parameters of EETs turnover by recombinant mouse EHs [adapted from (Marowsky et al., 
2009)]. Km1 and 2 in table refer to the first and second association of a substrate molecule to the homodimeric 
sEH, respectively.  
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EETs are neuroprotective probably due to their pronounced vasodilatory, angiogenic and anti-
inflammatory effects (Yang et al., 2016). The neuroprotective potential of EETs could also be 
beneficial in cerebrovascular pathologies such as stroke. Indeed, sEH inhibition has been 
shown to be protective against ischemic brain damage in vivo presumably by a mechanism 
linked to enhanced cerebral blood flow (Zhang et al., 2007). Moreover, genetic 
polymorphisms in CYP-epoxygenases and/or sEH, resulting in increased EET-generation or 
prolongation of EET activity, are associated with the reduced risk of cerebral ischemia (Iliff et 
al., 2010). Pharmacological inhibition of sEH by means of sEHis and resultant stabilization of 
neuroprotective EETs have been explored as a therapeutic target for stroke (Iliff et al., 2009; 
Liu et al., 2016b; Zhang et al., 2007).  
1.3.2. EETs in morphine-mediated antinociception  
Transgenic mice with an inability to generate FA epoxides such as EETs due to a neuron-
specific ablation of CYP-reductase exhibit highly attenuated morphine-mediated 
antinociception (Conroy et al., 2010). These transgenic mice also exhibit a compromised 
stress-induced antinociception, which involves activation of the endogenous opioid signaling 
(Hough et al. 2014). Moreover, microinjection of CC12, a CYP-epoxygenase inhibitor, in the 
rostral ventromedial medulla of WT mice inhibits morphine-mediated antinociception 
(Conroy et al., 2013). All these findings collectively point towards the potential involvement 
of CYP-epoxygenases-derived FA epoxides(s) in opioid singling. Moreover, a recent study 
corroborated the involvement of CYP-epoxygenase by employing a cluster knock out strategy 
wherein the genetic ablation of CYP-2C (known for epoxygenase activity), but not CYP-2D 
and CYP-3A, reduced subcutaneously administered morphine-mediated antinociception by 
41% (Hough et al., 2015).  
CYP-derived FA epoxides also include docosahexaenoic acid-derived 
epoxydocosapentaenoic acids (EpDPEs), eicosapentaenoic acid-derived 
epoxyeicosatetraenoic acid (EpETEs) and linoleic acid derived epoxyoctadecenoic acid 
(EpOMEs). Amongst these FA epoxides, EETs are one of the best studied mediators and have 
been suggested to exhibit antinociceptive effects in rat neuropathic and inflammatory pain 
models (Wagner et al., 2013). Moreover, direct evidence implicating EETs in opioid-
mediated antinociception comes from a study demonstrating strong antinociception after 
microinjection of 14,15-EET into the periaqueductal gray (PAG)-a brain region involved in 
the descending pathway of opioid antinociception, presumably by activating endogenous 
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endorphin release (Terashvili et al., 2008). These studies point towards the potential 
involvement EETs in opioid-mediated anti-nociception.  
1.3.3. EETs in neuronal excitability and synaptic transmission 
Genetic ablation/pharmacological inhibition of sEH and potential metabolic stabilization of 
EETs have been linked to beneficial effects in several animal models of epilepsy. sEH 
inhibition or administration of a regioisomeric mixture of EETs delay the onset of seizures 
induced by a GABA antagonist in mice (Inceoglu et al., 2013). Moreover, sEHis in 
combination with diazepam prevent progression of tetramethylenedisulfotetramine (TETS)-
induced tonic seizures and lethality in mice. This antiepileptic effect of sEHis is attributed to 
the ability of EETs to tackle neuro-inflammation associated with epileptogenesis (Vito et al., 
2014). On similar lines, sEH inhibition is beneficial in two distinct models of temporal lobe 
epilepsy (pilocarpine-induced and amygdala kindling) (Hung et al., 2015). Epilepsy is a 
disorder of hyperexcitability and the reported antiepileptic potential of EETs, in addition to 
the proposed mechanisms, might be due to the potential of EET-mediated modulation of 
neuronal excitability. The only study investigating the direct effects of EETs on basal synaptic 
neurotransmission in slices from pre-frontal cortex reports that application of the sEHi 12-(3-
adamantan-1-yl-ureido) dodecanoic acid (AUDA) or exogenous 14,15-EET enhances 
excitatory synaptic neurotransmission, reflected by increase in fEPSP slopes (Wu et al., 
2015).  
1.3.4. Molecular targets of EETs  
EETs, acting in autocrine and paracrine manner, exhibit a plethora of bioactivities. However, 
the exact molecular targets for these diverse effects remain largely unknown. 
1.3.4.1. Potassium channels  
The BKCa channel is the best-characterized effector for EET-mediated vasodilation so far. 
Application of exogenous EETs increased the open probability of BKCa channels in coronary, 
renal, cerebral vascular smooth muscle cells (Campbell et al., 2007; Earley et al., 2005; Zou 
et al., 1996). EETs might not directly activate BKCa channels, since they lack any effect on 
heterologously expressed BKCa channels in inside-out patch recordings from HEK-293T cells. 
However, the effect could be restored by the inclusion of equivalent GTP in the external 
compartment, suggesting the requirement of GTP for EET-mediated action (Fukao et al., 
2001). This notion is further strengthened by the observation that inhibition of G-proteins by 
GDPβS and anti-Gsα antibody block the effect of 11,12-EET on BKCa channels (Li et al., 
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1997; Li et al., 1999). However, the molecular identification and characterization of putative 
BKCa-coupled EETs receptor(s) remain unknown to date. EETs also activate KATP channels, 
likely via activation of protein kinase A (Lu et al., 2006).  
1.3.4.2. TRP channels  
EETs modulate TRPV4 channels, calcium conducting member from the TRPV family, which 
are gated by physical stimuli and synthetic ligands alike (White et al., 2016). Indeed, so far 
the TRPV4 channel is the only ion channel known to be activated directly by EETs. Both, 
5,6- and 8,9-EET, but not 11,12- and 14,15 EET, activate TRPV4 at submicromolar 
concentrations (Watanabe et al., 2003). Moreover, TRPV4 forms a novel complex with 
ryanodine receptors and BKCa channels that elicits smooth muscle hyperpolarization and 
dilation in response to the application of 11,12-EET (Earley et al., 2005). 5,6-EET is released 
on neuronal activation and modulates nociceptor sensitivity via regulation of TRPA1 channels 
in vitro (Sisignano et al., 2012). Overexpression of CYP-2C9 or application of exogenous 
11,12-EET increases the translocation of TRPC6 channel to the membrane in endothelial cells 
(Fleming et al., 2007). Moreover, 11,12-EET activates a TRPV4–TRPC1–KCa1.1 complex to 
induce smooth muscle relaxation in human internal mammary arteries (Ma et al., 2015).  
1.3.4.3. Putative EETs-GPCR  
Multiple in vitro binding studies have suggested the presence of a specific, high-affinity 
membrane binding site (Kd in the nM range) for 14,15-EET in guinea pig mononuclear cells 
(Wong et al., 1992; Wong et al., 2000) and monocytes (U-937) (Wong et al., 1997). 
Moreover, membrane binding sites for synthetic radiolabeled EET agonist and antagonist 
have been demonstrated in U-937 cells (Chen et al., 2009; Yang et al., 2008). EETs may also 
act as GPCR blockers, as 14,15-EET acts as a competitive, selective antagonist on the 
thromboxane prostaglandin (TP) receptors in isolated vascular and respiratory smooth muscle 
cells (Behm et al., 2009). Recently, Liu and colleagues screened 105 GPCRs for high-affinity 
binding and described activation of multiple GPCRs by 14,15-EET. The top five hits were 
from prostaglandin receptor subtypes (PTGER2, PTGER4, PTGFR, PTGDR, PTGER3 IV), 
but none of them had a high affinity for 14,15-EET (Liu et al., 2016a).  
Taken together, these studies strongly point towards a so far unidentified putative EET-GPCR 
as a molecular target for EETs. A few studies suggested the potential modulation of 
intracellular effectors such as FABPs (Widstrom et al., 2001) and nuclear receptors such as 
PPAR-γ by EETs (Liu et al., 2005; Samokhvalov et al., 2014). 
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1.4. DHETs and their biological activity  
DHETs are considered inactive catabolic products of bioactive EETs. However, a few studies 
have suggested that DHETs are bioactive in some non-neuronal systems. 8,9-, 11,12- and 
14,15-DHET produce vasodilation in isolated canine coronary arterioles via activation of 
charybdotoxin-sensitive Ca2+ activated potassium channels (IKCa) (Oltman et al., 1998). 11,12-
DHET activates BKCa channels, which hyperpolarize rat coronary vascular smooth muscles 
and consequently lead to vasodilation (Lu et al., 2001). BKCa-mediated vasodilation is also 
reported with 14,15-DHET in bovine coronary arteries (Campbell et al., 2002) and with 8,9-, 
11,12- and 14,15-DHET in isolated human coronary arterioles (Larsen et al., 2006). 14,15-
DHET is also known as a potent activator of PPAR-α in COS-7 cells (Fang et al., 2006). 
Moreover, 11,12-DHET modulates the progenitor cell proliferation in mice, likely via 
stimulating Wnt signaling (Frömel et al., 2012) and is essential for orchestrating monocyte 
chemotaxis and thus inflammatory response in mice (Kundu et al., 2013).  
1.5. Aims of the dissertation 
The main aims of this dissertation were as follows:  
1. To investigate the potential role of AA-derived eicosanoids such as epoxyeicosatrienoic 
acids (EETs) and dihydroxyeicosatrienoic acids (DHETs) in neuronal transmission, using the 
patch-clamp technique in mouse brain slices. 
2. To explore the potential role of sEH and mEH, the two major enzymes responsible for 
EETs metabolism to DHETs, in synaptic physiology using a combination of 
electrophysiological tools and transgenic mice (expressing ablated or hyperactive EHs).  
3. To identify and characterize putative molecular targets underlying the effects exerted by 
EETs and DHETs.  
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ABSTRACT  
 
Recent studies suggest a role for the arachidonic acid-derived epoxyeicosatrienoic acids (EETs) in attenuating epileptic 
seizures. However, their effect on neurotransmission has never been investigated in detail. Here, we studied how 11,12- and 
14,15 EET affect excitability and excitatory neurotransmission in mouse hippocampus. 11,12 EET (2 µM), but not 14,15 EET 
(2 µM), induced the opening of a hyper-polarizing K+ conductance in CA1 pyramidal cells. This action could be blocked by 
BaCl2, the G protein blocker GDPβ-S and the GIRK1/4 blocker tertiapin Q and the channel was thus identified as a GIRK 
channel. The 11,12 EET-mediated opening of this channel significantly reduced excitability of CA1 pyramidal cells, which 
could not be blocked by the functional antagonist EEZE (10 µM). Furthermore, both 11,12 EET and 14,15 EET reduced 
glutamate release on CA1 pyramidal cells with 14,15 EET being the less potent regioisomer. In CA1 pyramidal cells, 11,12 
EET reduced the amplitude of excitatory postsynaptic currents (EPSCs) by 20% and the slope of field excitatory postsynaptic 
potentials (fEPSPs) by 50%, presumably via a presynaptic mechanism. EEZE increased both EPSC amplitude and fEPSP 
slope by 40%, also via a presynaptic mechanism, but failed to block 11,12 EET-mediated reduction of EPSCs and fEPSPs. 
This strongly suggests the existence of distinct targets for 11,12 EET and EEZE in neurons. In summary, 11,12 EET 
substantially reduced excitation in CA1 pyramidal cells by inhibiting the release of glutamate and opening a GIRK channel. 
These findings might explain the therapeutic potential of EETs in reducing epileptiform activity. 
 
 
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/by/4.0/).  
 
 
 
2.1. Introduction 
Lipid signaling molecules in the central nervous system (CNS) are diverse, 
including prominent eicosanoids such as the arachidonic acid (AA) 
derivatives endocannabinoids and prostaglandins. Lesser known are the AA-
derived epoxyeicosatrienoic acids (EETs), which are synthesized by 
cytochrome P450 (CYP) epoxygenases. Due to the four double bonds in AA, 
four EET regioisomers are formed: 5,6-, 8,9-, 11,12- and 14,15-EET, with 
each regioisomer consisting of a mixture of R/S and S/R enantiomers 
(Capdevila et al., 2000). Although often considered as a single entity, several 
studies suggest that EETs act in a regioisomer- and enantiomer-specific 
manner (Ding et al., 2014; Lu et al., 2002; Node et al., 2001; Wang et al., 
2008; Zou et al., 1996). 
 
 
 
* Corresponding author.  
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Generally, the relative quantities of EET regioisomers vary with the CYP 
isoenzyme present in the respective tissue. Of the 160 CYP isoenzymes in the 
mouse, members of the CYP2C and CYP2J family are most commonly 
considered to exert the highest epoxygenase activity toward AA (Spector and 
Norris, 2007). However, it should be noted that several other CYP isoforms 
also act as epoxygenases and generate EETs such as rat CYP2D18 
(Thompson et al., 2000) and mouse CYP4X1 (Al-Anizy et al., 2006). The 
CNS cell types expressing epoxygenases comprise endothelial cells, 
astrocytes and neurons (reviewed in (Iliff et al., 2010b)). Specifically, the 
epoxygenases CYP4X1 (Al-Anizy et al., 2006), CYP2C29, CYP2C38 (Luo et 
al., 1998), CYP2J9 (Qu et al., 2001), CYP2J8, CYP2J11, CYP2J13 (Graves et 
al., 2013) and CYP2J5 (Allen brain atlas (Lein et al., 2007), 
http://www.brainmap.org) were identified in mouse brain. EETs are released 
in a calcium- and activity-dependent manner from diverse CNS cells, 
including sensory neurons (Sisignano et al., 2012) and astrocytes (Alkayed et 
al., 1997). However, if they are exclusively  
 
http://dx.doi.org/10.1016/j.neuropharm.2017.05.013  
0028-3908/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 
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synthesized on demand like most AA metabolites or released from 
endogenous EET pools, in which they are present as esters of 
glycerophospholipids (Capdevila et al., 2000), is still disputed.  
Earlier studies established EETs as potent vasodilators with a central role in 
neurovascular coupling, the linking of neuronal activity via astrocytes to 
evoke cerebral arteriolar dilatory responses (Imig et al., 2011). Furthermore, 
EETs display angiogenic, anti-apoptotic and anti-inflammatory properties, 
which together with the vasodynamic effect probably underlie EET-mediated 
neuro-protection (Koerner et al., 2007; Li et al., 2012; Liu et al., 2016b). 
Further EET-mediated effects in the CNS include the release of neuropeptides 
(Iliff et al., 2010a) and powerful anti-nociception, which is observed after 
injection of 14,15 EET into the periaqueductal gray, the primary control 
center for descending pain modulation (Terashvili et al., 2008). The 
bioactivity of EETs is limited by their hydrolysis to, reportedly, less active 
diols (dihydroxyeicosatrienoic acids, DHETs), a reaction catalyzed 
predominantly by soluble epoxide hydrolase (sEH) in the mouse brain (Zhang 
et al., 2007). Consistent with this, inhibitors of sEH (sEHi) effectively 
increase EET levels in vivo and have garnered widespread attention for their 
potential therapeutic use in multiple disorders such as hypertension, stroke, 
dyslipidemia, pain, immunological and neurological diseases (Shen, 2010). 
Still, the exact mechanisms by which EETs exert their various effects remain 
poorly defined. It is generally agreed that EETs may function as autocrine and 
paracrine effectors. Potential molecular targets include the KATP channel (Lu 
et al., 2002) and the calcium-activated BK channel (BKCa) (Campbell et al., 
1996; Li and Campbell, 1997). More recently, EET-mediated modulation of 
TRP channels has received attention with several studies reporting effects of 
EETs on TRPV4 (Earley et al., 2005; Vriens et al., 2005; Watanabe et al., 
2003), TRPC6 (Fleming et al., 2007), TRPA1 (Sisignano et al., 2012) and 
TRPV4-TRPC1 (Ma et al., 2015). However, EETs are less likely to bind to 
and activate an ion channel directly. They are rather thought to activate a G 
protein-coupled receptor (Carroll et al., 2006; Hayabuchi et al., 1998; Li and 
Campbell, 1997), which activates a signal transduction pathway that 
ultimately modulates ion channel functions. 
Even though most of the channels modulated by EETs are widely expressed 
in the CNS, little is known about the effects of EETs on neuronal excitability 
and transmission. Three recent studies suggest a possible involvement of 
EETs in the attenuation of pharmacologically-induced epileptic seizures in 
mice: i) Seizures generated by inhibition of the GABAergic system, but not 
by inhibition of 4-AP sensitive K+ channels, were attenuated by prior 
application of a sEHi (Inceoglu et al., 2013); ii) Diazepam in combination 
with a sEHi prevented progression of tetramethylenedisulfotetramine-induced 
tonic seizures and lethality in mice (Vito et al., 2014), and iii) sEHi treatment 
led to significant suppression of pilocarpine-induced seizures and an increase 
in the seizure-induction threshold of fully kindled mice compared to non-
treated animals (Hung et al., 2015). However it should be noted that EETs are 
not the only sEH substrates in the brain; other substrates include epoxides 
from docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which 
exert at least partially similar effects to those observed with EETs (Morisseau 
et al., 2010). While these reports implied that EETs suppress rather than 
increase neuronal excitation, the only study examining EET-mediated effects 
on neurotransmission did not affirm this notion. Indeed, 14,15-EET and the 
sEHi AUDA were both shown to enhance excitatory synaptic transmission in 
mouse prefrontal cortex, presumably by promoting the insertion of 
glutamatergic receptors in the postsynaptic membrane (Wu et al., 2015). 
In light of the recent evidence that EETs help to suppress epileptic seizures, 
we hypothesized that EETs are strong 
 
modulators of excitatory synaptic transmission and neuronal excitability in 
the hippocampus, a brain region central for memory and learning and often 
the starting point for temporal lobe epilepsy. Specifically, we wanted a) to 
identify potential pre- and/or postsynaptically located molecular targets, 
underlying the EET-mediated effect and b) to test, if the so-called functional 
EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE) (Gauthier et al., 
2002) is able to counteract EET-mediated actions on neuronal transmission 
and excitability. 
In this study, we recorded from CA1 pyramidal cells (PCs) in mouse 
hippocampus, using the patch-clamp technique and field potential recordings, 
as well as the respective pharmacology to isolate excitatory events. Finally, to 
address the question how endogenous EETs affect epileptic seizures, the 
effect of the selective sEHi tAUCB was studied on epileptiform activity in the 
hippocampus. 
2.2. Materials and methods 
All experiments were performed in accordance with regulations of the 
University of Zurich and the veterinary department of the canton of Zurich, 
Switzerland, for animal handling and experimentation. 
2.2.1. Immunohistochemistry 
Distribution of CYP2J protein was visualized by immunoperoxidase staining 
of parasagittal sections from perfusion-fixed tissue of male 10 week-old 
C57Bl/6 mice. Mice were deeply anesthetized with Nembutal and perfused 
with 4% paraformaldehyde in 0.15 M phosphate buffer (pH 7.4). Brains were 
post-fixed for 3 h, cryoprotected with sucrose and sectioned with a microtome 
(40 µm). Sections were incubated overnight at 4 °C with the CYP2J antibody 
(rabbit, diluted 1:1000 (Qu et al., 2001) in Tris buffer, pH 7.4 containing 2% 
normal goat serum and 0.2% Triton-100. The next day, a biotinylated 
secondary antibody directed against rabbit (1:300 Jackson ImmunoResearch, 
West Grove, PA, USA) was applied for 30 min, followed by Vectastain elite 
kit processing (Vector Laboratories, Burlingame, CA, USA) and incubation 
with diaminobenzidine as chromogen. Sections were mounted onto gelatin-
coated glass slides, air-dried, dehydrated, and cover-slipped with Eukitt. 
Images were digitized with a high-resolution camera and processed using the 
software Mosaic (ExploraNova, La Rochelle, France). 
2.2.2. Hippocampal slice preparation 
C57Bl/6J mice were obtained from Charles River laboratories (Freiburg, 
Germany). Transverse hippocampal slices (350-400 µm thick) of male, 3-4 
week old mice were obtained using a vibrating blade microtome, HM 650 V 
(Thermo Scientific, UK). Briefly, a mouse was anaesthetized and euthanized 
by decapitation. The brain was extracted and immediately transferred into ice-
cold artificial cerebrospinal fluid (ACSF) equilibrated with 95% O2 and 5% 
CO2 containing (in mM) NaCl (125), CaCl2 (2.5), MgCl2 (1), NaHCO3 (26), 
KCl (2.5), NaH2PO4 (1.25) and glucose (10). Slices were immediately 
transferred to an incubating chamber with ACSF at 35 °C for 20 min and 
thereafter kept at room temperature. 
2.2.3. Electrophysiology 
Slices were mounted on poly-L-lysine-coated coverslips and transferred to the 
recording chamber, where they were continuously superfused with ACSF at a 
rate of 1.8 ml/min. All experiments were performed at 30-32 °C using an in-
line heating system. 
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Hippocampal formation and CA1 PCs were visualized by using an upright 
microscope (BX51Wl, Olympus), equipped with a 20x water-immersion 
objective, infrared/differential interference contrast (DIC) optics and an 
infrared video imaging camera (VX55, Till Photonics). 
Patch pipettes with tip resistances of 3-5 MΩ were pulled from borosilicate 
glass (GC150F-10, Harvard apparatus, UK) with a horizontal puller (Zeitz 
instrument, Germany). For most experiments, pipettes were filled with a K-
gluconate based internal solution containing (in mM): K-gluconate (145), 
EGTA (1), HEPES (10), MgATP (5), NaGTP (0.5) and NaCl (5). The pH was 
adjusted to 7.3 with KOH; osmolarity was 295-305 mOsm. For one set of 
experiments a CsCl-based internal solution was used containing (in mM): 
CsCl (100), MgCl2 (2), EGTA (0.1), MgATP (2), NaGTP (0.3) and HEPES 
(40). The pH was adjusted to 7.3 with CsOH; osmolarity was 290-300 mOsm. 
For the recordings of evoked excitatory post-synaptic currents (EPSCs), CA1 
PCs were held at a holding potential of Vh = -70 mV and a glass capillary 
filled with ACSF was placed in stratum radiatum on Schaffer collaterals 
(SCs). Stimuli were given at 0.1 Hz. Bicuculline (25 µM) was present 
throughout the entire experiment to block inhibitory transmission. To assess 
the paired pulse ratio, paired stimuli with interstimulus intervals of 50 ms 
were given. For miniature EPSCs (mEPSCs) recordings, tetrodotoxin (TTX, 1 
µM) and bicuculline (25 µM) were added to the bath solution. Ramp 
recordings were carried out in presence of TTX (1 µM) with CA1 PCs 
initially voltage clamped at Vh = -70 mV and then ramped from -120 mV to -
50 mV in 0.6 s. Before the start of a ramp experiment, cells were held in 
current clamp mode and current pulses of -10 pA were injected to determine 
the resting membrane potential (RMP), capacitance, and the input resistance 
Rinput of the cell. EET-induced currents were normalized to cell capacitance 
and expressed as pA/pF. To monitor series resistance RS and Rinput throughout 
voltage-clamp recordings, a hyperpolarizing pulse of -5 mV (50 ms) was 
given at constant intervals. Recordings, in which RS changed more than 20% 
were discarded. To assess the spiking ability of CA1 PCs, cells were held in 
current clamp and a rectangular current (0.8 s) was injected every minute with 
the amplitude adapted to the individual cell such that a robust number of 
action potentials was evoked. EET- and EEZE-induced changes in RMP and 
the numbers of action potentials were analyzed. Field excitatory postsynaptic 
recordings (fEPSPs) were recorded in 400 µm thick hippocampal slices with 
an ACSF-filled glass pipette used as recording pipette. fEPSPs were evoked 
by stimulating SCs at 0.1 Hz, using a wide-tip ACSF-filled glass capillary. 
Stimulation intensity, ranging from 20 to 150 µA, was adapted for each 
recording to obtain a sub-maximal fEPSP signal with minimal non-synaptic 
contamination. For the recording of population spikes and bicuculline-
induced epileptic discharges, the stimulating electrode was again placed on 
SCs, the recording electrode on stratum pyramidale. 
Data were recorded with a Multiclamp 700B amplifier (Axon instruments), 
filtered at 3-10 kHz and digitized at 20 kHz (A/D hardware from National 
instruments). Data were acquired and analyzed with IGOR Pro software 
(Wave Metrics, Lake Oswego). Spontaneous events were analyzed off-line 
with the Mini Analysis Program (Synaptosoft). Prism 5 (GraphPad, USA) 
was used for statistical analysis and preparation of the graphs. Appropriate 
statistical tests were employed as indicated. Results of several experiments 
are presented as average values ± standard error of mean (SEM). 
2.2.4. Pharmacology 
All drugs were bath applied except GDPβS, which was dissolved in the 
internal solution. Stock solutions of tAUCB (trans-4-(4-[3- 
 
 
adamantan-1-yl-ureido]-cyclohexyloxy)-benzoic acid; 10 mM; kindly 
provided by C. Morisseau) and bicuculline (Tocris) were prepared in DMSO. 
Stocks for Guanosine-5’-O (2-thiodiphosphate)(GDPßS)sodium salt (10 mM; 
Biolog, Germany), BaCl2 (1 M; Sigma-Aldrich, Germany) and tetrodotoxin 
citrate (1 mM; ANAWA, Switzerland) were prepared in purified water 
(Millipore Systems, USA). EEZE, (±) 11,12- and (±)14,15-EETs as well as 
11,12-DHET were obtained from Cayman (Adipogen, Switzerland), dissolved 
in ethanol. They were dried under nitrogen gas and re-dissolved in ACSF (1-
10 mM) before bath-application. 
 
2.3. Results 
2.3.1. CYP2J epoxygenase expression in mouse hippocampus 
Detailed expression pattern for CYP epoxygenases in mouse hippocampus are 
rare. To our knowledge, the only cellular distribution pattern so far available 
is the one for the isoenzyme CYP2J5, which is however based on mRNA 
expression (Allen brain atlas (Lein et al., 2007)). We studied the expression 
pattern of CYP2J proteins (as an example for a family of epoxygenases) by 
immunohistochemistry in brain slices from C57Bl/6J mice, using a CYP2J 
pan antibody (Qu et al., 2001). In the hippocampus, strong CYP2J 
immunoreactivity (IR) was detected in cell bodies of CA1-CA3 PCs as well 
as in their apical and basal dendritic fields with particularly strong IR detected 
in apical dendrites of CA1 PC in the stratum radiatum (See Fig. 2.1a). 
2.3.2. Effects of tAUCB, 11,12-EET and EEZE on CA1 synaptic 
transmission 
To ensure that exogenously applied EETs were not immediately eliminated 
by sEH, the dominant epoxide hydrolase in mouse hippocampus (Marowsky 
et al., 2009), the potent and selective sEHi tAUCB (Hwang et al., 2007) was 
used. In a first experiment, we tested if tAUCB alone exerted any effects on 
synaptic transmission. Stimulating SCs, we recorded EPSCs in CA1 PCs; 
tAUCB (1 µM) was bath-applied. EPSC amplitude, kinetic parameters (rise 
time and decay constants) as well as the holding current Ihold were not affected 
by tAUCB (Fig. 2.1b, Suppl.Table 1). All subsequent experiments in which 
EETs were applied were therefore carried out in presence of 1 µM tAUCB. 
Of the four EET regioisomers, we chose the ones synthesized in highest 
quantities in the hippocampus, 11,12 and 14,15 EET (Sanchez-Mejia et al., 
2008). The focus was on the 11,12-regioisomer, additional experiments were 
conducted with 14,15 EET for comparison. First, we evaluated the effect of 
11,12 EET on EPSCs in CA1 PCs, voltage-clamped at Vh = -70 mV. EPSCs 
were evoked by two consecutive stimuli with an interstimulus interval of 50 
ms in presence of bicuculline (25 µM) to block inhibitory transmission. Bath-
application of 11,12 EET (2 µM) led to a rapid and significant reduction of 
both EPSC amplitudes with the first amplitude reduced to 78 ± 5% (n = 5, 
paired Student's t test, p = 0.0256*) and the second to 86 ± 4% (p = 0.0481*, 
Fig. 2.1c, c1, e). Comparison of the paired pulse ratio (PPR: Amp2/Amp1) 
under control conditions and in presence of EETs revealed an increase from 
1.94 ± 0.13 to 2.15 ± 0.1 (paired Student's t test, p = 0.032*). Such a change 
in paired-pulse facilitation is usually an indication for a presynaptic site of 
action. We next tested if the antagonist EEZE is able to block the EET-
induced reduction of EPSCs. Application of EEZE (10 µM) significantly 
potentiated both EPSC amplitudes (Fig. 2.1d, d1) to 141 ± 10% (Amp1, n = 9, 
paired Student's t test, p = 0.0026**) and 119 ± 8, respectively (Amp2, p = 
0.043*). The concomitant change in the PPR from 2.13 ± 0.11 to 1.77 ± 0.10 
(Fig. 2.1f; p = 0.00078***) again pointed to a presynaptic site of 
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Fig. 2.1. 11,12 EET reduces, but EEZE potentiates EPSCs recorded in CA1 PCs.  
a) CYP2J expression in mouse hippocampal formation illustrated by immunoperoxidase staining. Note the strong CYP2J IR in pyramidal cell bodies and particularly in CA1 dendrites,  
while dentate gyrus granule cells are spared. Scale bar: 250 µm; b) Representative traces of EPSCs before (upper graph) and after tAUCB (lower graph); summary of EPSC parameters are presented 
in Suppl. Table 1; c) Plot of EPSC peak amp 1 vs. time for a representative CA1 PC with the horizontal line indicating the time of bath-application of 2 µM 11,12 EET; c1) Average of 10-20 traces 
from c) before and after application of 11,12 EET; d) Plot of EPSC peak amplitude vs. time for a representative CA1 PC exposed to the functional EET-antagonist EEZE (10 µM), followed by 11,12 
EET (2 µM) as indicated by the horizontal lines; d1) Average of 10-20 traces before and after application of EEZE and 11,12 EET; e) Summary of the effect of 11,12 EET (2 µM), EEZE (10 µM) and 
11,12 EET (2 µM) +EEZE(10 µM) on EPSC amp; 1-way-ANOVA followed by Bonferroni, post-hoc analysis; for detailed data and statistics see Suppl. Table 2; f) Application of 11,12 EET, EEZE or 
11,12 EET in presence of EEZE significantly changes the PPRs, suggesting presynaptic molecular targets for these compounds. p < 0.05*, p < 0.01**, p < 0.001***. Abbreviations: CA cornu 
ammonis; DG dentate gyrus; DGGC dentate gyrus granule cells; SR stratum radiatum. 
 
action. Surprisingly, prior application of EEZE followed by 11,12 EET was 
unable to prevent EET-mediated reduction of EPSC amplitudes (Fig. 2.1d). 
Moreover, even in the presence of EEZE, EETs still seemed to exert their 
effect by a presynaptic mechanism as indicated by the change in the PPR 
(Fig. 2.1f). (Detailed data for evoked EPSC recordings are shown in Suppl. 
Table 2).  
To examine in more detail the presynaptic actions of EETs and EEZE, we 
next recorded mEPSCs in CA1 PCs in presence of TTX (1 µM) to abolish 
action potentials. mEPSCs are due to random release of single presynaptic 
glutamate vesicles at different synaptic sites. While application of 11,12 EET 
affected neither mEPSC amplitude nor frequency (n = 5, Fig. 2.2a-a2, c), 
EEZE led to a rapid increase in the occurrence of mEPSCs, shown in Fig. 
2.2b, b1 and d (n = 5). However, EEZE had no consistent effect on mEPSC 
amplitudes in CA1 PCs (Fig. 2.2b2, d). (Detailed data for mEPSCs recordings 
are shown in Suppl. Table 3). A change in mEPSC frequency is usually 
attributed to effects on quantal transmitter release and as such the effect is 
undisputedly of presynaptic origin. Taken together, the results indicate that 
EEZE affects transmitter release in the absence of action potentials, whereas 
11,12 EET has no effect under these conditions. This strongly suggests two 
different pre-synaptic molecular targets. 
In addition to the effect on EPSC amplitude, we observed another striking 
effect in some of the evoked EPSC and mEPSC experiments: The holding 
current Ihold was substantially modulated by 11,12 EET (see Figs. 2.2a and 
2.3a), in a manner compatible with an increase in outward current. Re-
analysis of the EET-mediated effect on Ihold in mEPSC recordings revealed 
that on 
 
 
average Ihold increased robustly by +21 ± 4 pA (n = 6, Student's paired t test p 
= 0.00615**, Fig. 2.3c, Suppl. Table 3). This increase in Ihold was 
accompanied by a decrease in input resistance (Fig. 2.3d), indicative of 
channel opening and the activation of a conductance. To gain further insight 
into the nature of the conductance, we repeated these experiments with a 
CsCl-based internal solution, as Cs+ is known to block K+ -conducting ion 
channels. Under these conditions, relative to the control, ΔIhold and Rinput were 
unchanged upon application of EETs (Fig. 2.3c,e). This demonstrates that no 
further conductance was activated and suggests that 11,12 EET activates a 
postsynaptic K+ current. 
2.3.3. Characterization of the 11,12 EET-induced current 
For a more detailed characterization of the EET-activated current, we 
investigated its current-voltage relationship. To this end, current-voltage 
curves were obtained (n = 5) in the presence of TTX (1 µM). The 11,12 EET-
induced current reversed at -102 ± 6 mV (Fig. 2.4a). These experiments were 
carried out with an extracellular K+ concentration of 2.5 mM and an internal 
K+ concentration of 145 mM (using a K-gluconate internal solution), therefore 
according to the Nernst equation the calculated K+ reversal potential was -106 
mV at 32 °C. The reversal potential determined by us was compatible with a 
K+ current. For comparison, the same experiment was conducted with 14,15 
EET (2 µM, n = 4); however, 14,15 EET failed to open any conductance in 
CA1 PCs (Fig. 2.4b). To narrow down the spectrum of possible K+ channel 
candidates, we bath-applied 500 µM BaCl2, a classical inhibitor of G protein-
coupled 
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Fig. 2.2. EEZE modulates mEPSC frequency.  
a) Representative trace of a mEPSC recording in a CA1 PC with application of 11,12 EET (2 µM) indicated by the horizontal line. Short horizontal lines marked with A) and B) denote stretches that 
are shown enlarged below to resolve the individual events, marked by asterisks; a1) Frequency histogram for the mEPSC trace to the left; a2) Cumulative probability plot depicting mEPSC amplitudes 
before and after addition of 11,12 EET for the mEPSC recording to the left. b) Representative trace of a mEPSC recording in a CA1 PC with application of EEZE (10 µM) indicated by the horizontal 
line. Horizontal lines marked with C) and D) denote short stretches shown enlarged below; b1) Frequency histogram for the mEPSC trace to the left; b2) Cumulative probability plot depicting mEPSC 
amplitudes before and after addition of EEZE for the mEPSC recording to the left; c) Summary of the 11,12 EET effect on mEPSC frequency and amplitude in CA1 PCs; d) Summary of the EEZE 
effect on mEPSC frequency and amplitude in CA1 PCs. 
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Fig. 2.3. 11,12 EET opens a postsynaptic Cs-sensitive conductance.  
a) and b) representative traces of mEPSCs, Vh = -70 mV, recorded with a K-gluconate -based (a) and a CsCl-based (b) internal solution with 11,12 EET (2 µM) application indicated by horizontal 
lines. 11,12 EET potentiates the outward current only with the K-gluconate-based internal solution; c) and d) Summary of 11,12 EET-mediated changes in Ihold and Rinput, recorded in CA1 PCs with the 
two different internal solution. p < 0.05*, p < 0.001***. 
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Fig.2.4. 11,12 EET activates a GIRK1/4 conductance in CA1 PCs.  
a)Voltage-clamp recordings of CA1 PCs with a K-gluconate-based internal solution. Red trace: A voltage ramp from -120 to -50 mV was applied in control condition and after bath application of 
11,12 EET (2 µM). Control traces were subtracted from EET traces; the red trace represents the average of n = 5 cells. Blue trace: The same voltage ramp was applied in presence of 500 µM BaCl2 
followed by 11,12 EET (2 µM). BaCl2 traces were subtracted from BaCl2 + 11,12 EET traces. The blue trace represents the average of n = 8 cells. b) The same as a) with 14,15 EET (2 µM). The trace 
represents the average of n = 4 cells. Due to the lack of effect of 14,15 EET, no experiments were carried out in presence of BaCl2; c) Example of current-clamp recordings of CA1 PCs to monitor 
RMP. The control cell (white circles) was dialyzed with normal K-gluconate based internal solution, while the other (gray circles) was dialyzed with the same internal solution containing 1 mM 
GDPβS. 11,12 EET (2 µM) was applied as indicated by the horizontal line; d) Average effect of 11,12 EET (2 µM) on RMP of control cells with normal internal solution; e) Comparison of 11,12 
EETs-induced RMP change between control cells and those dialyzed with 1 mM GDPβS; f) Application of EEZE (10 µM) prior to 11,12 EET (2 µM) did not prevent EET-induced hyperpolarization 
in CA1 PCs, example trace of a representative cell; g) Application of 11,12 DHET had no effect on RMP, example trace of a representative cell; h) Summary graph of RMP changes after application 
of 11,12 EET (2 µM) or EEZE (10 µM) or 11,12 DHET (5 µM) alone, and in slices pretreated with EEZE (10 µM) or the selective GIRK1/4 blocker tertiapin Q (TTQ, 1 mM) followed by 11,12 EET 
(2 µM). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
 
 
inward rectifier potassium (GIRK) channels (Sodickson and Bean, 1996), 
prior to 11,12 EET application (n = 8; Fig. 2.4a). In the presence of BaCl2, 
11,12 EET was unable to open a conductance. Since activation of GIRK 
channels modifies substantially the RMP of a neuron to more negative values, 
we next recorded CA1 PCs in current-clamp mode and monitored RMP 
before and after application of 11,12 EET; kynurenic acid and bicuculline 
were present throughout the experiment to suppress any spontaneous synaptic 
transmission. 11,12 EET hyperpolarized CA1 PC from -67.8 ± 1.8 mV to -
70.9 ± 1.6 mV (Fig. 2.4d; n = 9, paired Student's t test p = 0.000217***) with 
an average of ΔRMP of -3.1 ± 0.5 mV (Fig. 2.4h). 
EETs may open a GIRK channel either directly or via a G protein. To 
distinguish between these two scenarios, the G protein blocker GDPβS (1 
mM) was included in the internal solution; to ensure complete diffusion, cells 
were dialyzed 20 min before the start of the recording (n = 5). GDPβS 
completely abolished EET-mediated hyperpolarization (Fig. 2.4c,e), verifying 
the involvement of a G-protein and refuting the notion of direct activation of a 
GIRK conductance by EETs. Final evidence for the EET-mediated activation 
of a GIRK current was obtained by bath-application of the selective GIRK1/4 
(Kir3.1/3.4) blocker tertiapin Q (TTQ, 1 µM) prior to application of EETs. 
Under these conditions, 11,12 EET was unable to open an additional 
hyperpolarizing membrane conductance, and cells tended to depolarize 
slightly instead (n = 5, Fig. 2.4h). 
EEZE alone had no effect on RMP and was unable to block EET- 
 
 
 
induced hyperpolarization in CA1 PCs, when washed in prior to 11,12 EET 
(Fig. 2.4f, h). Furthermore, the diol, 11,12 DHET (5 µM) was unable to 
induce a significant change in the RMP of CA1 PCs (Fig. 2.4g and h). Taken 
together, these results show that 11,12 EET opens, via a G protein-coupled 
mechanism, a GIRK 1/4 conductance in CA1 PCs, which leads to the 
observed hyperpolarization in these cells.  
To assess if, and to what degree, the EET-activated GIRK current affects 
excitability of CA1 PCs, we studied the spiking ability of these cells in 
presence of 11,12 EET and EEZE. CA1 PCs were held in current-clamp mode 
and injected with a current pulse (Fig. 2.5a) to elicit a short train of action 
potentials. The injected current was adapted to the individual cell, ranging 
from +70 to +150 pA. Bath-application of 11,12 EET led to a 
hyperpolarization similar to that seen before ( -3.4 ± 0.5, n = 9, data not 
shown) and reduced significantly the number of spikes to 76±%3 (n = 9, 
paired Student's t test p = 0.00012***; Fig. 2.5b). In presence of EEZE, the 
number of spikes was unchanged (n = 7, paired Student's t test, p = 0.175, Fig. 
2.5c and d), and subsequent application of 11,12 EET reduced the number of 
spikes in a similar manner to that observed with 11,12 EET alone (75.0 ± 6%, 
paired Student's t test, p = 0.00018***; Fig. 2.5c and d). 
2.3.4. Net effects of EETs and EEZE on hippocampal fEPSPs 
Next, we addressed if as a net effect in the hippocampus EETs and EEZE 
dampen or increase excitatory neurotransmission. To this 
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Fig. 2.5. 11,12 EET decreases excitability in CA1 PCs.  
a) Representative current-clamp recording of a CA1 PC with response to somatic current injection (80 pA) before (left) and after the application of 11,12 EET (2 µM, right); b) Graph showing how 
the number of spikes in individual CA1 PCs (black circles) changes in presence of 11,12 EET (2 µM). The average of all cells is shown in gray circles; c) Representative current-clamp recording of a 
CA1 PC with response to somatic current injection (130 pA) before (left) and after the application of EEZE (10 µM, middle), followed by application of 11,12 EET (2 µM, right); d) Graph showing 
how the number of spikes in individual PCs (black circles) changes in presence of EEZE (10 µM) followed by 11,12 EET (2 µM). Average of all cells is shown in gray circles. p < 0.001***.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2.6. 11,12 EET and 14,15 EET decrease, EEZE potentiates hippocampal fEPSPs.  
a) Schematic drawing of a hippocampal slice, showing the localization of recording and stimulation electrode; b) Representative fEPSP slope vs. time graph with the application of 11,12 EET (2 µM) 
indicated by the gray horizontal line; b1) Average of 20-30 traces before and after application of 11,12 EET; c) and c1) Same as b) and b1) for 14,15 EET (2 µM); d) and d1) Same as b) and b1) for 
EEZE (10 µM); e) Summary graph showing the effects of the different compounds on fEPSP slope 1; 1-way ANOVA followed by Bonferroni post hoc analysis: all comparisons p < 0.001*** except 
for tAUCB vs 14,15 EET. For further statistics employing paired Student's t test see Table 2.1; f) Both EET regioisomers and EEZE change the respective PPRs significantly, pointing towards a 
presynaptic mechanism. DG dentate gyrus; SC Schaffer collaterals. p < 0.01**. 
 
end stimulating and recording electrodes were both placed in stratum 
radiatum on SCs (see scheme, Fig. 2.6a) and fEPSPs, evoked by two 
consecutive stimuli with an interstimulus interval of 50 ms, were recorded 
with inhibitory transmission left intact. Although under these conditions 
inhibition is not recorded directly, it is  
 
 
known to substantially modulate and shape hippocampal fEPSPs (Chapman et 
al., 1998). Unexpectedly, application of tAUCB (1 µM) resulted in a small, 
but significant decrease of fEPSP slopes and amplitudes, presumably due to 
effects exerted by accumulation of endogenous EETs (Fig. 2.6e, Table 2.1). 
Subsequent application of 11,12 
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Table 2.1            
Summary of effects on fEPSPs.           
       
Substance Slope 1 Slope 2 Amp1 Amp2 n Compared to 
           
tAUCB (1 µM) 89.2 ± 3.2* 90.8 ± 3.0* 91.4 ± 3.2* 92.2 ± 3.1* 8 untreated 
11,12 EET (2 µM) 52.4 ± 4.5*** 60.2 ± 4.0*** 52.8 ± 4.6*** 59.4 ± 5.2** 7 tAUCB 
14,15 EET (2 µM) 80.8 ± 4.6* 85.5 ± 4.2* 84.5 ± 5.0* 86.1 ± 4.3* 7 tAUCB 
EEZE (10 µM) 142.2 ± 4.6*** 123.3 ± 3.0** 136.1 ± 9.1** 125.5 ± 5.3** 7 untreated 
              
Values are given as mean percentage ±SEM. For each compound normalized comparisons were carried out as indicated in the furthest column to the right. Asterisks indicate the significant difference 
obtained from these comparisons. (p < 0.05*, p < 0.01**, p < 0.001***, paired Student's t test). n number of experiments performed. 
 
EET led to a significant reduction of fEPSP slope1 to 52.4 ± 4.5% and slope2 
to 60.2 ± 4.0%, respectively (Fig. 2.6b,b1,e; for detailed data and fEPSP 
statistics, see Table 2.1). In comparison to 11,12 EET, 14,15 EET was less 
potent, only reducing fEPSP slope1 to 80.8 ± 4.6% of baseline values (see 
Fig. 2.6c, c1, e). Both 11,12 EET and 14,15 EET significantly increased the 
PPR (Fig. 2.6f), further supporting the existence of a presynaptic target. By 
contrast, EEZE markedly potentiated fEPSP slope 1 and amplitude 1 to 140% 
and 136%, respectively (Fig. 2.6d, d1, e). Since the potentiating effect was 
less pronounced for the second slope and amplitude, the PPR decreased under 
EEZE (Fig. 2.6f), again consistent with previous observations pointing 
towards a presynaptic site of action. Taken together, 11,12 and 14,15 EETs 
both reduce excitatory neurotransmission in the hippocampus with 11,12 EET 
being the more potent of the two. By contrast, EEZE increases excitatory 
transmission in the hippocampus, and is not capable of antagonizing the EET-
mediated reduction. 
2.3.5. tAUCB effect on epileptic discharges in the hippocampal 
formation 
The tAUCB-mediated reduction of fEPSPs suggested that recordings from a 
population of neurons (rather than from a single neuron) might allow for the 
detection of effects exerted by endogenous EETs, released and accumulated in 
the brain slice. In a 
 
 
 
final experiment we, therefore, addressed the effect of tAUCB on epileptiform 
activity in brain slices. It is known that reduced GABAergic inhibition easily 
leads to large-scale synchronization and epileptic discharges in the 
hippocampal network. Thus, we applied bicuculline and, to get a better 
estimate of the synchronous action potential firing, recorded population spikes 
by placing the recording electrode on the stratum pyramidale. As expected, 
bicuculline (25 µM) led to a dramatic change in the waveform of single-pulse 
evoked population spikes (see Fig. 2.7a) and also substantially increased their 
amplitude and duration. To quantify the intensity of these epileptic-like 
bursts, we chose the so-called coastline bursting index CBI (Korn et al., 1987; 
Riekki et al., 2008). Essentially, beginning and end of the burst waveform 
were marked and the total duration was measured (see arrows in Fig. 2.7a). 
After 10 min, application of bicuculline resulted in a marked increase in CBI 
from 25.6 ± 1.5 to 62.0 ± 3.7 ms (p = 0.00062***, n = 5, paired Student's t 
test). By contrast, tAUCB (1 µM) reduced the CBI slightly, but significantly 
(Fig. 2.7b, d; p = 0.0077**, n = 6). When bicuculline was subsequently 
applied, it led to much less dramatic bursting (Fig. 2.7b,d) compared to 
bicuculline alone (Fig. 2.7e, unpaired Student's t test p = 0.000136***). This 
showed that tAUCB, most likely via stabilizing endogenous EETs, is capable 
of reducing epileptiform discharges in brain slices consistent with recent data 
obtained in systemic epilepsy models in rodents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7. tAUCB attenuates burst-like activity in the hippocampal formation.  
a) Representative graphs of single-pulse evoked population spikes recorded from stratum pyramidale under control conditions (untreated slice; left) and 10 min after washing in of  
bicuculline (25 µM; right). Arrows indicate the total duration, used to calculate the respective CBI; b) Representative graphs of single-pulse evoked population spikes recorded under control 
conditions (untreated slice; left), after application of tAUCB (1 µM; middle), which was followed by application of bicuculline (25 µM; right). tAUCB and bicuculline graphs were taken each 10 min 
after start of bath-application of the respective compound; c) Summary graph for a), showing how CBI in individual experiments changes after application of bicuculline; d) Summary graph for b), 
showing how CBI changes under tAUCB and subsequently under bicuculline; e) Comparison of the normalized CBI observed under bicuculline on untreated slices and the CBI observed in slices 
pretreated with tAUCB. p < 0.01**; p < 0.001***. 
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2.4. Discussion 
The present study has four major findings: First, 11,12 EET and to a lesser 
degree 14,15 EET inhibit EPSCs and fEPSPs in the hippocampus, thus 
reducing excitatory transmission. Second, 11,12 EET exerts its effect by 
acting on both pre- and postsynaptic targets in CA1 PCs, whereas the 14,15 
EET-mediated effect seems limited to a presynaptic target. Third, 
postsynaptically, 11,12 EET opens a K+ conductance via activation of a G 
protein, resulting in hyperpolarization and attenuated excitability of CA1 PCs. 
Finally, the functional antagonist EEZE seems to exclusively act via a 
presynaptic target, which with high probability differs from the one activated 
by 11,12 EET. 
2.4.1. 11,12 EET-mediated hyperpolarization involves the opening of 
GIRK1/4 channels most likely via activation of Gαi/o proteins 
We observed a 11,12 EET-specific opening of a hyperpolarizing current, 
which we identified as a K+ current due to its reversal potential and the fact 
that it could be blocked by intracellular Cs+. Since dialyzing the cell with the 
G protein blocker GDPβS prevented the EET-mediated opening of the K+ 
current, a direct effect of EETs appeared unlikely and suggested that the 
activation of a G protein is a prerequisite. Both BaCl2 and tertiapin Q blocked 
the 11,12 EET-mediated opening of the K+ conductance and these findings 
together with the IV-curve (Fig. 2.4a) provide compelling evidence that 11,12 
EET opens a GIRK channel in CA1 PCs. GIRKs usually require activation by 
the β/γ subunit of Gi/o proteins, whereas Gs proteins only activate GIRK under 
nonphysiological conditions (e.g. following overexpression) (Dascal and 
Kahanovitch, 2015). However, studies focusing on intracellular pathways 
activated by EETs exclusively reported the involvement of Gs proteins. It 
needs to be noted, however, that all these studies used non-neuronal cells, e.g. 
endothelial cells (Ding et al., 2014; Node et al., 2001), preglomerular 
microvessels (Carroll et al., 2006), coronary arteries (Li and Campbell, 1997) 
and HEK cells (Fukao et al., 2001), implying that the cell type is of central 
importance as to which G protein is activated by EETs. Taken together, our 
discovery of the 11,12 EET-mediated opening of a GIRK channel, including 
the activation of Gi/o proteins, constitutes a so far undescribed, new cellular 
pathway. This result may also shed new light on previous findings that EETs 
contribute to µ-opioid receptor-mediated anti-nociception (Conroy et al., 
2010; Terashvili et al., 2008), a GPCR system commonly linked to Gi/o 
proteins. 
2.4.2. Potential postsynaptic targets for 11,12 EET in CA1 PCs 
A large body of data, accumulated over the last three decades, suggests that 
EETs act through a specific binding site, most likely a cell surface receptor 
(Chen et al., 2009; Falck et al., 2003; Snyder et al., 2002). Because the 
majority of EET-mediated physiological responses occur with nanomolar 
concentrations, the existence of a high-affinity EET-receptor was proposed. 
We used low micro-molecular concentrations (2 µM) of 11,12 EET 
throughout our study, but it is difficult to relate that to the final concentration 
reaching to the recording spot in brain slice. Tissue preparations are notorious 
for their ability to take up and sequester lipophilic, detergent-like compounds 
like EETs, which was also evident in our recordings as EET-mediated effects 
were difficult to reverse via wash out (see Fig. 2.6b with the effect lingering 
for 20 min after EET application). Furthermore, in our hands 11,12 EET 
concentrations in the nanomolar range produced extremely inconsistent 
results, often failing to elicit any response, which we attributed to the highly 
lipophilic nature of the compound. As a result, it was not possible to establish 
a meaningful dose-response relation and we decided to use a fixed 
 
 
concentration that gave reproducible results.  
Although an EET-specific GPCR still awaits identification, some well-
characterized GPCRs have been identified to which EETs, and specifically 
11,12 EET, reportedly bind; these include the cannabinoid receptors CB1 and 
CB2, the dopamine receptor D3 and the GPR40. However, it takes 11,12 EET 
concentrations in the 100 micromolar range to displace high-affinity radio 
ligands from CB1, CB2 and D3 receptors (Inceoglu et al., 2007). EC50 values 
for the human GPR 40 are in a comparatively lower range with 6-8 µM (Itoh 
et al., 2003). Still, the GPR 40 constitutes an unlikely candidate for two 
reasons: 1.) EETs and DHETs were shown to activate the GPR40 to a similar 
degree (Itoh et al., 2003), while in our study only 11,12 EET, but not the 
corresponding DHET, was capable to activate a GIRK channel (see Fig. 
2.4g). Furthermore, the GPR 40 is reportedly coupled to Gq/11 (Briscoe et al., 
2003) and thus highly unlikely to activate a GIRK channel, which is 
classically linked to Gi/o proteins (Dascal and Kahanovitch, 2015). Recently, 
105 GPCRs were screened for their ability to respond to 14,15 EET, but 
unfortunately not 11,12 EET. While several GPCRs responded to 
micromolecular concentrations of 14,15 EET (the top five all being 
prostaglandin receptors), none could be identified meeting the criteria for a 
high-affinity receptor (Liu et al., 2016a). Similar unsatisfactory results with a 
smaller number of GPCRs, none of them responsive to 14,15 EET, were 
reported earlier in a study by Behm and colleagues (Behm et al., 2009), in 
which 14,15 EET was ultimately identified as an antagonist of native 
thromboxane receptors. Given our results, in which 11,12 EET shows distinct 
actions on GIRKs, it seems desirable to repeat these screenings with 11,12 
EET. 
2.4.3. Presynaptic effects mediated by 11,12 EET and possible 
molecular targets 
Both EET regioisomers and EEZE modulate the PPR of evoked EPSCs and 
fEPSPS, which is consistent with a presynaptic mechanism. Notably, EEZE 
can a) not block the 11,12 EET-mediated reduction of EPSCs and b) changes 
mEPSC frequency, which 11,12 EET does not. These observations suggest 
distinct molecular mechanisms and targets for EEZE and EET. Specifically, 
the inability of 11,12 EET to alter mEPSC frequency strongly implies that its 
potential target requires action potential-induced depolarization. Possible 
candidates include therefore voltage-dependent ion channels such as Ca2+ or 
K+ channels. The BKCa channel is an attractive candidate, given both the 
extensive data on its interaction with EETs and the fact that it is located on 
presynaptic sites in the CNS. However, at the CA3-CA1 synapse, from which 
we recorded, BKCa channels are not recruited under basal condition, but only 
under extreme conditions as in epileptic states and ischemia (Hu et al., 2001; 
Runden-Pran et al., 2002). The cardiac L-type Ca2+ channel may be another 
possible target. Interestingly, it is inhibited by nanomolar concentrations of 
11,12 EET (Chen et al., 1999), but activated by higher concentrations of 
EETs via the cAMP/PKA system (Xiao et al., 1998, 2004). However, data 
showing CNS-residing Ca2+ channels interacting with EETs are still lacking. 
Finally, members of the TRPV family might be activated by EETs in the 
hippocampus. Particularly the TRPV1 channel family seems an eligible 
target, as it depresses glutamatergic synaptic transmission upon activation by 
another AA derivative, 12-(S)-HPETE (Gibson et al., 2008). While this effect 
seems similar to the one we observed with EETs, TRPV1 channels are 
exclusively located at excitatory synapses on hippocampal interneurons, 
excluding them as possible EETs targets on CA3-CA1 synapses. 11,12 EET 
was also reported to activate a TRPV4-TRPC1-BKCa complex in smooth 
muscle cells (Ma et al., 2015), but it remains to be proven if such channel 
complexes are also existent in neurons. More work is needed to identify the 
proper presynaptic targets for 11,12 and 
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14,15 EETs as well as EEZE. 
2.4.4. EEZE effects on hippocampal neurotransmission 
It is difficult to clearly conclude from our experiments, if the presynaptic 
effect exerted by EEZE is attributable to the antagonization of EET- mediated 
action or if EEZE elicits an effect by itself. Importantly, at least in two types 
of experiments EEZE was applied alone (mEPSC recordings, Fig. 2.2b; 
fEPSP recordings, Fig. 2.6d) on slices, which were not pretreated with 
tAUCB (tAUCB application was limited to experiments in which EETs were 
washed in). Thus, levels of ambient EETs were not elevated, making it less 
plausible that EEZE action reflects the blockade of an augmented endogenous 
EET tone. 
On the postsynaptic site, EEZE unarguably failed to elicit any antagonistic 
actions; in fact, it showed no postsynaptic activity at all, since it neither 
modulated mEPSC kinetics and amplitudes, nor did it affect Ihold or RMP. The 
inability of EEZE to antagonize EET activity in neurons is not entirely 
unexpected; EEZE has shown inconsistent effects before with the most 
remarkably being that it vasodilates murine mesenteric arteries to a similar 
extent as a stable EET analog (Harrington et al., 2004). 
2.4.5. tAUCB and its effect on fEPSPs and epileptiform activity in 
brain slices 
The sEHi tAUCB has been used in several recent studies to investigate the 
effect of endogenous EETs (e.g. Akhnokh et al., 2016; Imig et al., 2012). In 
our first experiments focusing on EPSCs in single cells, tAUCB alone did not 
show any effect; however, in field recording, tAUCB significantly reduced 
fEPSP slopes and amplitudes. An explanation might be that the tAUCB effect 
is too small to be successfully measured in a single neuron, but becomes 
apparent when recordings from a whole population of neurons with 
synchronized activity are carried out. In fact, in the current study a similar 
phenomenon could be observed with bicuculline, as the GABAA receptor 
antagonist allowed for the undisturbed isolation of evoked EPSCs in single 
pyramidal cells, but led to epileptiform activity in field recording. 
Interestingly, the tAUCB effect on fEPSPs in absence of any GABAA 
receptor antagonists (Fig. 2.6), thus with intact inhibition, was small, since it 
generated on average only a 10% reduction. Such a slight effect might be due 
to comparatively low spontaneous activity and weak extracellular stimulation 
in the slice, which elicits only low Ca2+ influx into astrocytes and/or neurons 
and results in the release of respectively low quantities of EETs. Nevertheless, 
these amounts of endogenous EETs appeared to be sufficient to dampen 
subsequent bicuculline-induced epileptic bursts recorded from the somata of 
CA1 PCs (Fig. 2.7). However, tAUCB results should be interpreted with 
caution, as DHA or EPA-derived epoxides may also accumulate in the 
presence of tAUCB and are likely capable to interfere with neuronal 
transmission. 
In summary, this study demonstrates for the first time that EETs have 
complex and regioisomer-specific pre- and postsynaptic actions in the 
hippocampus, including the 11,12 EET-mediated opening of a GIRK channel. 
These findings not only reveal a so far unknown signaling pathway of EETs, 
but may also help to explain their therapeutic potential in reducing 
epileptiform activity. 
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CYP: cytochrome P450-dependent monooxygenase 
 
 
DHA: docosahexaenoic acid  
DHET(s): dihydroxyeicosatrienoic acid(s)  
EET(s): epoxyeicosatrienoic acid(s)  
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EPA: eicosapentaenoic acid  
fEPSP: field excitatory postsynaptic potential  
GABA: γ-aminobutyric acid 
GDPβS: guanosine-5’-O-2-thiodiphosphate 
GIRK: G protein coupled/gated inward rectifying potassium  
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Appendix A  
Supplementary Tables 
 
Table 1 
 
Evoked EPSC parameters at Schaffer collateral-CA1 pyramidal cell synapses in absence and presence of tAUCB (1 
µM) 
  n Ipeak (pA) 
10-90% Risetime 
(ms) 
Decay τ (ms) Ihold (pA) Rinput (MΩ) 
              
Baseline  7-10 -274 ± 46 3.2 ± 0.3  10.9 ± 0.8 -80 ± 12 192 ± 24 
tAUCB (1 µM)   -290 ± 50 3.3 ± 0.3 11.9 ± 1.0 -85 ± 19 193 ± 29 
p-value  0.078 0.116 0.093 0.745 0.903 
Mean ± SEM values were determined for EPSCs at 30-32°C. For each cell 30 events were averaged before and after 
application of tAUCB. The current decay τ was fitted with a mono-exponential function. p-values are the results of paired 
Student’s t tests. n number of experiments performed. 
 
 
Table 2                   
Evoked EPSCs at Schaffer collateral-CA1 pyramidal cell synapses  
  n Amp 1 (pA)  p value Amp 2 (pA)  p value 
Baseline 5 -208 ± 39   -393 ± 61   
11,12 EET (2μM)   -164 ± 37 p<0.05* -347 ± 69 p<0.05* 
                    
Baseline 9 -188 ± 11   -397 ± 36   
EEZE (10 μM)   -267 ± 25 p<0.01** -472 ± 55 p<0.05* 
                    
Baseline 5 -206 ± 11   -428 ± 59   
EEZE (10 μM)   -336 ± 26 p<0.01** -587 ± 79 p<0.01** 
11,12 EET (2μM)   -209 ± 19 p<0.001*** -402 ± 44 p<0.01** 
Mean ± SEM values were determined for amplitude 1 and 2 of evoked EPSCs at 30-32°C. For each cell 
30 events were averaged under baseline conditions and after application of the respective drug. p values 
are the result of paired Student's t tests applied to the following comparisons: Baseline vs 11,12 EET; baseline vs EEZE 
and EEZE vs 11,12 EET. n number of experiments performed.  
 
Table 3               
Summary of mEPSC parameters at Schaffer collateral-CA1 pyramidal cell synapses with K- gluconate internal 
solution 
  n Frequency (Hz) Ipeak (pA) 
10-90% risetime 
(ms) 
Decay τ (ms) Ihold (pA) Rinput (MΩ) 
                
Baseline  5 0.66 ± 0.02 -25.8 ± 0.6  1.29 ± 0.12 6.22 ± 0.61 -19.8 ± 3.1 221 ± 21 
tAUCB (1µM)   0.83 ± 0.12 -26.0 ± 0.9 1.28 ± 0.08 6.66 ± 0.37 -28.8 ± 1.6 216 ± 30 
14,15 EET (2 
μM) 
  0.71 ± 0.10 -28.1 ± 1.2 1.21 ± 0.08 6.28 ± 0.69 -28.5 ± 2.7 209 ± 28 
                
Baseline  5-7 1.22 ± 0.36 -17.8 ± 1.3 1.27 ± 0.07 6.33 ± 0.18 -23.0 ± 6.2   242 ± 34 
tAUCB (1µM)   1.17 ± 0.28 -19.1 ± 1.5 1.25 ± 0.06 6.53 ± 0.11 -28.2 ± 5.6 259 ± 38 
11,12 EET (2 
µM) 
  1.09 ± 0.31 -17.8 ± 1.8 1.34 ± 0.08 6.90 ± 0.14 **-6.3 ± 3.5**   213 ± 12* 
                
Baseline  5 0.80 ± 0.15 -21.2 ± 0.9 1.77 ± 0.16 7.70 ± 0.16 -14.4 ± 10.0 225 ± 32 
EEZE (10 µM)      1.21 ± 0.25* -23.5 ± 1.8 1.45 ± 0.18 7.16 ± 0.60 -17.6 ± 8.5  223 ± 24 
Mean ± SEM values were determined for mEPSCs at 30-32°C. For each cell and compound 50-250 events were aligned 
on 50% rising phase and averaged to obtain kinetic parameters; the current decay τ was fitted with a mono-exponential 
function. For each compound the mean values determined were compared as follows: Baseline vs tAUCB, tAUCB vs 
EET, and baseline vs EEZE, respectively. Asterisks indicate the significant differences obtained from these comparisons 
(p<0.05*, p<0.01**, paired Student's t test). n number of experiments performed. 
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Chapter 3  
Epoxide hydrolases act as a switch 
between AA-derived inhibitory EETs and 
excitatory DHETs, which modulate Kv 
channels 
(Manuscript in preparation)  
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3.1. Introduction  
Epoxide hydrolases (EHs) comprise a family of enzymes that catalyze the addition of a water 
molecule to potentially genotoxic epoxides, converting them to the corresponding less toxic diols 
(Arand et al., 2003). Microsomal EH (mEH) and soluble EH (sEH) are the best characterized 
EHs, which differ in their cellular localization (endoplasmic reticulum vs. cytosol) and activity. 
mEH is widely known for its detoxification capabilities of xenobiotic derived epoxides, while 
sEH is best known for its role in the metabolism of endogenous epoxides. Endogenous epoxides 
are generated from fatty acids (FAs) such as arachidonic acid (AA) in a cytochrome P450 (CYP)-
dependent reaction. Several CYP isoenzymes are noted for their particularly high efficiency to 
epoxygenate AA, namely those from the CYP-2C and CYP-2J family (Spector et al., 2015). 
These CYP-epoxygenases oxidize either of the four double bonds of AA, generating four epoxide 
regioisomers: 5,6-, 8,9-, 11,12-, 14,15-epoxyeicosatrienoic acids (EETs), which can further be 
hydrolyzed by EHs to the corresponding dihydroxyeicosatrienoic acids (DHETs).  
sEH shows a substantially higher activity in hydrolyzing EETs relative to mEH and is thus 
considered as the main enzyme responsible for the metabolism of EETs (Morisseau, 2013). 
Indeed, under saturating conditions, human sEH is 200 times faster in hydrolyzing 14,15 EET 
than human mEH (Decker et al., 2012). Nevertheless, mEH exhibits a higher apparent affinity 
(lower Km) towards EETs than sEH and is located in physical proximity to CYP epoxygenases. 
Thus, despite its lower activity, it might contribute to a large extent to the hydrolysis of EETs at 
sub-saturating concentrations (Marowsky et al., 2017). In terms of substrates preference, sEH and 
mEH display an almost complimentary preference profile. Based on the catalytic efficiency 
(kcat/Km), mouse mEH prefers 11,12-EET >8,9-EET =14,15-EET while mouse sEH prefers (in 
descending order) 14,15-EET =11,12-EET >8,9-EET (Marowsky et al., 2009). 
EETs are implicated in a variety of physiological processes. In particular, they are recognized as 
potent vasodilators in most vascular beds and known to exert angiogenic, anti-inflammatory, and 
anti-nociceptive effects (Spector et al., 2015). They activate ion channels such as the calcium-
activated BK (BKCa) channels (Campbell et al., 1996; Li et al., 1997); KATP channels (Lu et al., 
2006; Ye et al., 2005) and various transient receptor potential (TRP) channels including TRPV4 
(Watanabe et al., 2003), TRPC6 (Fleming et al., 2007) and TRPA1 (Sisignano et al., 2012). 
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Compared to EETs, DHETs are largely described as less biologically active with only a few 
studies reporting the opposite (Campbell et al., 2002; Kundu et al., 2013; Larsen et al., 2006).  
In brain, earlier studies indicated a role for EETs in opioid-mediated antinociception, stroke, and 
release of neuropeptides (Iliff et al., 2010; Terashvili et al., 2008). More recently, EETs have 
been suggested to attenuate epileptic seizures (Inceoglu et al., 2013; Vito et al., 2014; Hung et 
al., 2015). Their antiepileptic effect might be explained by recent findings from our group that 
11,12-EET activates a G-protein coupled inwardly rectifying K+ (GIRK) channel in CA1 
pyramidal cells (PCs), leading to hyperpolarization and reduced excitability. Moreover, 11,12-
EET decreases the release of glutamate at the CA3-CA1 synapse (Mule et al., 2017).  
Mouse hippocampal CA1-CA3 PCs have been shown to express EET-synthesizing CYP-
epoxygenases [http://mouse.brain-map.org/ (Lein et al., 2007) (Mule et al., 2017)]. Moreover, 
EET-metabolizing EHs are also expressed in a cell type-specific manner in mouse hippocampus: 
sEH is located in hippocampal astrocytes, while mEH is observed throughout all CA1-CA3 PCs 
(Marowsky et al., 2009). Thus, the enzymatic machinery to generate EETs and DHETs is 
principally present in the mouse hippocampus. However, which effects DHETs exert on synaptic 
transmission and through which molecular targets has remained an unexplored question.  
Here, we investigate how 11,12-DHET modulate synaptic transmission at the CA3-CA1 synapse 
in mouse hippocampus. Recording from CA3-CA1 synapse using the patch-clamp technique, we 
further attempted to identify the channels that mediate the 11,12-DHET and 11,12-EET effects. 
To ascertain the molecular targets, the potential candidate Kv channels were heterologously 
expressed in chinese hamster ovary (CHO) cells and screened for possible effects of DHET and 
EETs. Finally, to substantiate the role of EHs in hydrolyzing EETs to DHETs, input-output (I-O) 
curves were constructed in hippocampal slices obtained from WT control, mEH KO, sEH KO 
and mEH E404D mice, the latter expressing a gain of function variant of mEH.  
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3.2.Materials and methods  
3.2.1. Mouse brain slice electrophysiology 
A. Animals 
C57BL/6J, sEH KO (Ephx2 -/-), mEH KO (Ephx1 -/-) and mEH E404D (gain of function variant) 
mice were used in this study. C57BL/6J mice were obtained from Charles River Laboratories, 
Germany. sEH KO (Sinal et al., 2000) and mEH KO mice (Miyata et al., 1999) were kindly 
provided by Dr. F. J. Gonzalez, National Institute of Health, USA. The mouse line carrying the 
mEH E404D mutation was generated and characterized in our laboratory, as described here 
(Marowsky et al., 2016). sEH KO, mEH KO and mEH E404D lines were backcrossed for 7-9 
generations onto C57BL/6J background prior to this study. Prior experiments from our laboratory 
confirmed that there were no differences between sEH and mEH WT littermates in CYP-
epoxygenases and EH-dependent metabolism and thus were employed as WT control in the 
current study. Animals were housed in the institutional animal facility with 12:12 dark:light cycle 
and had ad libitum access to standard chow-food and water. Animals between P20 to P42 days 
were used for the experiments in this study. All experiments were performed in accordance with 
regulations of the University of Zurich and the veterinary department of the canton of Zurich, 
Switzerland for animal handling and experimentation. 
B. Hippocampal slice preparation 
Transverse hippocampal slices (350-400 µm thick) were obtained using a vibrating blade 
microtome, HM 650 V (Thermo Scientific, UK) as described (Mule et al., 2017; Pannasch et al., 
2012) with some modifications. Briefly, a mouse was anesthetized using isoflurane and 
euthanized by decapitation. The brain was extracted and immediately transferred into ice-cold 
artificial cerebrospinal fluid (ACSF) equilibrated with 95% O2 and 5% CO2 containing (in mM) 
NaCl (125), CaCl2 (2.5), MgCl2 (1), NaHCO3 (26), KCl (2.5), NaH2PO4 (1.25) and glucose (10). 
The hippocampi were extracted from the brain and mounted on an ice cold metal block supported 
by agar to obtain transverse hippocampal slices. Slices were collected in an incubating chamber 
containing ACSF maintained at 35°C, where they were allowed to recover for at least one hour. 
Thereafter, they were kept at room temperature until further use. 
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C. Electrophysiology  
Slices were mounted on poly-L-lysine (PLL)-coated coverslips and transferred to the recording 
chamber, continuously perfused with ACSF at a rate of 1.8 ml/min throughout the experiment. 
All experiments were performed at 30-32°C using an in-line heating system. Hippocampal 
neurons were visualized by using an upright microscope (BX51Wl, Olympus) equipped with a 
20x water-immersion objective, infrared differential interference contrast optics and an infrared 
video imaging camera (VX55, Till Photonics, Germany). 
I. Recordings of field excitatory postsynaptic potentials (fEPSPs)  
fEPSPs recordings were carried out in 400 µm thick hippocampal slices with a wide-tip 
borosilicate glass microelectrode (resistance< 2 MΩ) filled with ACSF. fEPSPs were evoked by 
stimulating Schaffer collateral (SC) fibers at 0.1 Hz using a wide-tip ACSF-filled glass capillary 
as shown in Fig.3.3A. The stimulation intensity was adapted for every recording (between 20-150 
μA) to obtain a sub-maximal fEPSP signal with minimal possible non-synaptic contamination. 
The fEPSP amplitude: fiber volley (FV) ratio is considered as an indicator of the brain slice 
health, therefore, only recordings with higher fEPSP: FV ratio (>2-3) were used in this study.  
II. Patch-clamp recordings  
Patch pipettes (tip resistances ~3-5 MΩ) were pulled and fire-polished from borosilicate glass 
(GC150F-10, Harvard apparatus, UK) with a horizontal puller (Zeitz instrument, Germany). 
Patch pipettes were filled with an internal solution containing the following (in mM) K-gluconate 
(145), Mg-ATP (5), Na-GTP (0.5), EGTA (1) and NaCl (5). The pH was adjusted to 7.3 with 1N 
KOH, the osmolarity was 305 mOsm. For recording evoked or spontaneous excitatory 
postsynaptic currents (e/sEPSCs), CA1 PCs were voltage clamped at -70 mV and e/sEPSCs were 
recorded in the presence of bicuculline (25 µM) to block inhibitory neurotransmission. For 
miniature EPSCs (mEPSCs), the sodium channel blocker, tetrodotoxin (TTX, 1 µM) was added 
in addition to bicuculline to block action potential (AP) generation. SC-CA1 recordings, in which 
depolarization-induced potentiation of excitation (DPE) was studied, were carried out in the 
presence of bicuculline (25 µM) and the cannabinoid 1 (CB1) receptor antagonist, AM-251 (1 
µM). 
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3.2.2. Heterologous expression system expressing Kv channels 
A. Cloning  
For the recombinant expression of mouse voltage-gated potassium channels in CHO cells, cDNA 
clones for mKCNA1 (mKv1.1), mKCNA2 (mKv1.2), mKCNAB1 (mKvβ1), and mKCND2 
(mKv4.2) were purchased from Origene Technologies Inc. USA. The respective open reading 
frames were amplified from these clones using Pfu polymerase and the following primer pairs 
(Table 3.1). 
Table 3.1 Primer sequences used for cloning mouse Kv channels. 
mKCNA1for gatcagaattccATGACGGTGATGTCGGGGGAGAA 
mKCNA1rev tatacggccgctaAACATCGGTCAGGAGCTTGCTCTTA 
mKCNA2for gatcagaattccATGACAGTGGCTACCGGAGAC 
mKCNA2rev tatacggccgctaGACATCAGTTAACATTTTGGTAATA 
mKCNAB1for gatcagaattccATGCAAGTCTCCATAGCCTGCACA 
mKCNAB1rev tatacggccgctaTGATCTATAGTCCTTTTTGCTGTAG 
mKCND2for gatcagaattccATGGCAGCCGGTGTTGCAGCATGG 
mKCND2rev tatacggccgctaCAAGGCAGACACCCTGACGATA 
The amplified fragments were subsequently digested with EcoRI and EagI and ligated into the 
EcoRI/NotI-site of the mammalian expression vector pAmCAG_GFP_P2A. This allowed the 
coexpression of the respective potassium channel subunit and GFP from the same transcript, 
using a P2A sequence to afford the synthesis of these as two separate polypeptides. The map of 
pAmCAG_GFP_P2A_mKCNA1 is shown in (Fig. 3.1) to visualize this expression strategy. All 
the final constructs were verified by sequencing to ensure their accordance with the published 
mouse sequences. 
The successful expression of functional Kv channels was verified by recording macroscopic Kv 
currents from Kv transfected CHO cells using patch-clamp technique (transfection and patch-
clamp recording protocols are described below). The mKCND2 plasmid cloned with this 
strategy yielded a suboptimal surface expression of functional mKv4.2 channels, as was evident 
from the lack of measurable Kv currents in CHO cells transfected with this plasmid. Therefore, 
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we obtained commercially available (Cat no: SC115436) human KCND2 cDNA cloned in 
pCMV6-XL5 plasmid from Origene Technologies Inc., USA. Human KCND2 plasmid showed 
optimal surface expression of functional Kv4.2 channels as was evident from measurable Kv4.2 
currents from transiently transfected CHO cells. Therefore, hKCND2 plasmid was used in this 
study instead of mKCND2. Human Kv4.2 and mouse Kv4.2 share 99% amino acid sequence 
homology [UniProt database (Consortium, 2017)], however less likely, the potential species-
specific difference(s) might exist and can be further investigated using mouse Kv4.2 channels.  
 
 
 
 
 
 
 
 
 
 
 
B. Cell maintenance and expression of Kv channels  
CHO cells were maintained in T25 cell culture flask in F12-HAM nutrient mixture medium 
(Invitrogen, USA) supplemented with 5% FCS and 2.5 mM L-glutamine at 37°C under 5% CO2 
in the cell culture incubator. Approximately 50,000 cells were seeded on a PLL-coated glass 
coverslip and allowed to grow overnight. On the following day, CHO cells were transfected with 
either of the following Kv channels (cDNA concentration); mouse Kv1.1 (0.5 µg), mouse Kv1.2 
(0.5 µg) or human Kv4.2 (1 µg) together with eGFP (0.2 µg) cDNA using Jet pei transfection 
reagent as per protocol provided by the manufacturer (link to the online manual provided by 
Polyplus transfection, USA). In another set of experiments, Kv1.1 (0.5 µg) or Kv1.2 (0.5 µg) α-
subunits were co-transfected with accessory Kvβ1 (1.5 µg) subunits to study the influence of 
Kvβ1 subunits on the effects of compounds under study. Glass coverslips with transfected cells 
were used for experimentation 24-48 hours post-transfection. Coverslip was transferred to the 
recording chamber which was super-fused with an external solution. Green fluorescing (eGFP 
expressing) cells were identified and used for electrophysiological recording of Kv currents. 
Fig. 3.1 Map of pAmCAG_GFP_P2A_mKCNA1. P2A sequence interspacing between GFP and mKCNA1 
transgene. is shown in orange color. 
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C. Electrophysiological recordings 
The external solution contained (in mM) NaCl (150), KCl (5.4), MgCl2 (1.0), CaCl2 (2), glucose 
(10) and HEPES (10). The pH was adjusted to 7.4 with 1N NaOH, the osmolarity was 315 
mOsm. Patch pipettes were pulled from borosilicate glass (GC150F-10, Harvard apparatus, UK) 
and had a tip resistance of 2.5 to 3.5 mΩ. They were filled with an intracellular solution 
containing (in mM) K-gluconate (145), Mg-ATP (5), Na-GTP (0.5), EGTA (1) and NaCl (5). The 
pH was adjusted to 7.4 with 1N KOH, the osmolarity was 305 mOsm. All experiments were 
carried out at room temperature; the calculated reversal potential (Erev) for K
+ with given external-
internal combination was -84.4 mV.  
After establishing whole-cell configuration, cells were held at -70 mV. Capacitance (Cm) and 
series resistance (Rs) were compensated and values for Cm and Rs were read from the amplifier 
dial. The voltage-induced macroscopic Kv currents were recorded with an AM2400 patch-clamp 
amplifier (AM systems, USA) and digitized at 10 KHz using Digidata 1400 and pClamp 10 
software suites (Molecular Devices, USA).Voltage-step protocols used to elicit the Kv currents 
were adapted from (Decher et al., 2010; Yeung et al., 1999) with some modifications. 
Protocol I: The patched cell was held at -70 mV and membrane potential was stepped from test 
potentials of -90 to +80 mV in incremental step of +10 mV. After each test potential, the 
membrane potential was stepped back to the original -70 mV holding potential. Outward currents 
elicited by voltage steps were used to plot current-voltage (I-V) curves and to deduce the Erev 
value of elicited Kv currents (Fig 3.2A).  
 
Fig. 3.2 Voltage step protocols used for eliciting Kv currents. (A) A representative Kv1.1 I-V curve and corresponding 
protocol (B) Outward Kv1.1 currents and corresponding single step depolarization protocol 
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Protocol II: The patched cell was held at -70 mV and membrane potential was stepped to the 
depolarizing test potential of +40 mV every 10 seconds to evoke the outward Kv current for all 
the tested Kv channels except Kv1.2 (Fig 3.2B). The outward Kv1.2 currents elicited by 
depolarizing steps of +20, +30 and +40 mV were extremely large (>10 nA) and rendered 
recordings unstable, thus we employed depolarizing step of +10 mV every 10 s for recording 
Kv1.2 currents. All compounds were bath-applied via gravity-assisted perfusion and the effect of 
the test compounds on Kv amplitude at 7-9 min post application was used for analysis 
3.2.3. Pharmacology  
The GABA antagonist bicuculline and the CB1 receptor antagonist AM-251 were obtained from 
Tocris Biosciences, UK. The sodium channel blocker TTX was obtained from Bio-trend, 
Germany. Elaidamide was kindly provided by Dr. Christophe Morisseau, University of 
California, Davis, USA. The fatty acid amide hydrolase (FAAH) blocker URB-597 was obtained 
from Hycultec GmbH, Germany. Parent stocks for all the compounds were prepared and stored at 
-20°C. 11,12-EET and -DHET were obtained from Cayman Chemicals, USA. 11,12-DHET and -
EET were dried under nitrogen gas in an inert single-use container and stored at -20°C until use. 
Dried stocks were re-dissolved in external solution/ACSF just before application. All compounds 
were prediluted and bath-applied in external solution/ACSF. 
3.2.4. Data analysis and statistics 
Electrophysiology data were analyzed with IGOR Pro software (Wave Metrics, USA) or pClamp 
10 suite (Molecular Devices, USA). Spontaneous and miniature events were analyzed with the 
Mini Analysis Program (Synaptosoft, USA). The I-V curves recorded with Kv channels in CHO 
cells were fitted with standard Boltzmann functions using GraphPad Prism 5 (GraphPad, USA). 
Appropriate statistical tests were employed for testing the significance, such as paired/unpaired 
Student’s t-test for comparisons and one-way/two-way-ANOVA followed by a post hoc test for 
multivariate comparisons. Results are presented as mean±standard error of the mean unless stated 
otherwise. GraphPad Prism 5 was used for the statistical analysis and preparation of the graphs. 
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3.3. Results 
3.3.1. 11,12-DHET increases excitatory neurotransmission at the mouse CA3-CA1 synapse  
To investigate the potential effects of 11,12-DHET on hippocampal synaptic transmission, we 
stimulated (paired stimulation with an interstimulus interval of 50 ms, at 0.1 Hz) SCs to record 
fEPSPs at the CA3-CA1 synapse. The fEPSP recordings were made in stratum radiatum (see 
recording scheme, Fig. 3.3A) of WT hippocampal slices. Bath-application of exogenous 11,12-
DHET (3 μM) rapidly increased synaptic transmission measured as fEPSP slopes (Fig. 3.3B-D). 
Slope1 (Fig. 3.3C) and slope2 (Fig. 3.3D) were significantly increased to 145.3±3% (n=5, 
p=0.006**) and 139.7±3.4% (n=5, p=0.019*), respectively.  
 
Significance was tested using paired Student's t-test before vs. after DHET treatment. The 
observed 11,12-DHET-mediated increase in the fEPSP slopes was washable with ACSF. 
Moreover, there was a trend towards a decreased paired-pulse ratio (PPR: slope2/slope1, Fig. 
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Fig. 3.3 11,12-DHET enhances synaptic transmission at the hippocampal CA3-CA1 synapse. 
(A) A schematic illustration showing the site of stimulation (Schaffer collaterals) and recording (stratum radiatum 
of CA1) in the hippocampus. (B) A representative time-course and corresponding traces of fEPSPs showing the 
effect of 11,12-DHET application. Time of DHET application and washing is indicated by red and blue horizontal 
bars, respectively. A summary graph depicting the effect of 11,12-DHET on average (of 20 waves) fEPSP slope 1 
(C) and slope 2 (D). Application of 11,12-DHET (3 µM) significantly increased slope 1 (n=5, p=0.006**) and 
slope 2 (n=5, p=0.019*) as compared to the corresponding baselines. Paired Student's t-test before vs. after 11,12-
DHET treatment was used to test the significance. (E) Paired-pulse ratio (PPR: slope2/slope1) before and after 
application of 11,12-DHET, paired Student's t-test before vs. after 11,12-DHET treatment, (n=5, p=0.0494).  
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3.3E) from 1.96±0.37 to 1.88±0.33 in the presence of 11,12-DHET (n=5, p=0.0494, paired 
Student's t-test before vs. after DHET treatment). Such a change in PPR is commonly interpreted 
as an indication for a presynaptic mechanism. 
3.3.2. Depolarization-induced potentiation of excitation can be observed at the CA3-CA1 
synapse in presence of the CB1 receptor antagonist AM-251. 
Since exogenously applied lipids might not reliably reflect the action of endogenously generated 
lipids, we next attempted to release CYP-epoxygenase products in the brain slice to investigate 
their potential effects on CA1 PCs. A recent study demonstrated that AA can be released from 
CA3 PCs in response to a short depolarizing pulse, which activates the calcium-dependent 
enzyme phospholipase A2 (cPLA2) to release AA from lipid membranes. Moreover, the same 
study showed that in situ released AA and/or AA-derived metabolites from CA3 PCs can act as 
retrograde messengers, which block Kv channels located at presynaptic mossy fiber (Mf) 
terminals and thus facilitate synaptic transmission at Mf-CA3 synapses. This phenomenon was 
dubbed depolarization-induced potentiation of excitation (DPE) (Carta et al., 2014). Notably, the 
Mf-CA3 synapse was investigated in the Carta study, since this particular synapse lacks 
presynaptic CB1 receptors. These receptors would otherwise mediate retrograde 
endocannabinoid-mediated signaling and confound the expression of DPE. However, in the 
presence of CB1 receptor antagonists, a DPE-like phenomenon was also observed and reported at 
the CB1 receptor expressing CA3-CA1 synapse (Carta et al., 2014). 
We, therefore, recorded EPSCs in CA1 PCs in presence of the CB1 receptor antagonist AM-251 
(1 µM) and bicuculline (25 µM) and induced DPE, following the protocol from Carta et al. CA1 
PCs were voltage clamped at -70 mV and depolarized to -10 mV for 9 s. In line with (Carta et al., 
2014), we observed a potentiation of EPSC amplitude 1 (5 min post-depolarization, 120±2.6%; 
n=7; p=0.023*, paired Student's t-test before vs. after depolarization). Unlike in the earlier report 
by Carta, DPE in our experiments continued to increase up to 15 min (Fig. 3.4A-D). Additionally, 
we observed a significant decrease in PPR (Fig. 3.4E) from 2.34±0.18 to 2.21±0.18% (n=7; 
p=0.032*), which confirms the earlier report that DPE is presynaptically expressed.  
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To examine the potential role of CYP-epoxygenase products in the expression of DPE, further 
experiments were conducted, using specific blocker of the respective enzymatic pathways. All the 
following DPE experiments were carried out in the presence of bicuculline (25 µM) and AM-251 
(1 µM). 
3.3.3. DHETs might be potential mediators of DPE at the CA3-CA1 synapse  
In accord with the previously published results the cPLA2 blocker AACOCF3 (10 µM) abolished 
the expression of DPE (Two-way ANOVA, AACOCF3 treatment significantly affected the 
outcome; F=38, p<0.0001), confirming cPLA2-mediated release of AA as requisite for the 
expression of DPE (Fig. 3.5A and B). To exclude the contribution of putative AA metabolites as 
DPE mediators, Carta et al. employed selective blockers of lipoxygenase (LOX) and 
cyclooxygenase (COX), which are involved in the generation of prostaglandins and leukotrienes, 
respectively. However, the possible involvement of CYP-epoxygenase metabolites such as EETs 
and DHETs remained unexplored.  
Fig. 3.4. DPE is expressed at CA3-CA1 synapse in the presence of CB1 receptor antagonist  
(A) A schematic illustration showing the site of stimulation (Schaffer collaterals) and recording  
(CA1 PCs). (B) A representative time-course of EPSC amplitude 1 recorded in a CA1 PCs before and after 
depolarization to -10 mV for 9 s. The red arrow depicts the time of depolarization. (C) Representative traces of 
EPSC amplitude 1 before (average of 30 waves) and 3-7 (average of 24 waves) minutes post-depolarization. (D) 
The summary time-course (n=7) of normalized EPSC amplitude 1 plotted against time. The red arrow depicts the 
time of depolarization. (E) DPE at the CA3-CA1 synapse is expressed presynaptically, as evident from the 
significantly decreased PPR (amp2/amp1), paired Student's t-test before vs. after depolarization (n=7, p=0.032*). 
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DHETs are generated in a two-step reaction (see schematic in Fig. 3.7), catalyzed by two sets of 
enzymes: CYP-epoxygenases, which catalyze the epoxygenation of AA to EETs and 
subsequently the epoxide hydrolases mEH/sEH, which metabolize EETs to DHETs. We 
addressed both enzymatic systems. First, we recorded EPSCs in the presence of the CYP-
epoxygenase blocker MS-PPOH (60 µM). Pre-treatment of MS-PPOH significantly abrogated the 
expression of DPE compared to control experiments (Two-way ANOVA, MS-PPOH treatment 
significantly affected the outcome; F=15.58, p=0.0001). These experiments suggest the potential 
involvement of CYP-epoxygenase-generated metabolites such as EETs and/or DHETs in the 
expression of DPE at the CA3-CA1 synapse (Fig. 3.5C). Our observation of pro-excitatory 
effects of 11,12-DHET at the CA3-CA1 synapse (Fig. 3.3) implied that DHETs rather than 
inhibitory EETs could be the potential mediators of DPE at the CA3-CA1 synapse. Of the two 
prominent EHs responsible for DHET generation, mEH is expressed in CA1 and CA3 PCs 
Fig. 3.5. Pre-treatment with inhibitors of cPLA2 and CYP-epoxygenases abolishes DPE in CA1 PCs. 
(A) Representative EPSC traces recorded under control conditions and after pre-incubation with the cPLA2 blocker 
AACOCF3 (10 µM) and the CYP-epoxygenase blocker MS-PPOH (60 µM). The summary time-course plots of 
SC-EPSC amplitude 1 normalized to the baseline shows that pre-treatment with AACOCF3 (n=3) (B) and MS-
PPOH (n=4) (C) significantly abolished DPE compared to the control experiments (n=7). Two-way ANOVA, 
treatment and time post-depolarization as two variables were employed. Overall, treatment with inhibitors 
significantly affected the results. For AACOCF3 treatment (F=38, p<0.0001) and for MS-PPOH treatment 
(F=15.58, p=0.0001), however, the effects of treatments were not statistically significant at every time point. The 
red arrows depict the time of depolarization.  
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(Marowsky et al., 2009). Therefore, we studied the potential influence of elaidamide, a selective 
mEH inhibitor (Morisseau et al., 2001), on DPE (Fig. 3.6A-B). Elaidamide is degraded by 
FAAH, thus DPE experiments with elaidamide were carried out in the presence of the selective 
FAAH inhibitor URB-597 (1 µM). Expression of DPE at the CA3-CA1 synapse was significantly 
abolished in the presence of elaidamide (Two-way ANOVA, elaidamide treatment significantly 
affected the outcome; F=42.48, p<0.0001). In addition, we studied the expression of DPE in brain 
slices obtained from mEH KO mice (Fig. 3.6C-D).  
 
DPE at the CA3-CA1 synapse was significantly reduced in mEH KO slices compared to those 
from WT slices (Two-way ANOVA, effect of genotype significantly affected the outcome; 
F=12.2, p=0.0006).  
Fig. 3.6. Pharmacological inhibition or genetic ablation of mEH abolishes DPE at the CA3-CA1 synapse 
(A) Representative EPSC traces recorded in CA1 PCs under control condition and in the presence of the mEH 
blocker-elaidamide (10 µM). (B) The summary time-course plot of EPSC amplitude 1 normalized to the baseline 
shows a reduced expression of DPE in the presence of elaidamide (n=3) compared to control experiments (n=7). 
Two-way ANOVA, treatment and time as two variables were employed. Overall, treatment with elaidamide 
significantly affected the results (F=42.48, p<0.0001). However, the treatment effects were not statistically 
significant at every tested time point. (C) Representative EPSC traces recorded in the CA1 PCs from WT and 
mEH KO mice. (D) The summary time-course plot of EPSC amplitude 1 normalized to the baseline show 
reduced expression of DPE in CA1 PCs from mEH KO (n=3) compared to those from the WT mice (n=7). Two-
way ANOVA, genotype and time as two variables were employed. Overall, genotypes significantly affected the 
result (F=12.2, p=0.0006), however the effect of genotype is not significant at every tested time point. The red 
arrows depict the time of depolarization.  
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These findings taken together with the MS-PPOH results strongly suggest that a CYP-
epoxygenase-derived and mEH-generated metabolite such as a DHET might contribute to the 
expression of DPE at the CA3-CA1 synapse. However, additional experiments are needed to 
strengthen these preliminary data.  
  
3.3.4. 11,12-DHET blocks heterologously expressed Kv1.2 and Kv4.2 channels  
Further, we explored the potential molecular target(s) underlying the excitatory effects of 11,12-
DHET and 11,12-EET. It has been shown that AA and its metabolites are capable of modulating 
Fig. 3.7 mEH-derived DHETs as potential DPE mediators 
Depolarization of the postsynaptic CA1 neuron triggers Ca+2 influx via voltage-gated calcium channels (VGCChs) 
which further activates cPLA2 to release AA from the neuronal membrane. AA can be metabolized to EETs and 
DHETs via CYP-epoxygenase and mEH, respectively. We employed pharmacological blockers (marked in red) to 
elucidate the potential DPE mediators. Our results suggest that DHETs generated in the postsynaptic CA1 neuron 
by mEH activity might block presynaptic Kv channels in a retrograde manner to facilitate the release of glutamate 
from CA3 axon terminal.  
VGCChs 
VGCChs 
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several Kv channels (Boland et al., 2008; Oliver et al., 2004). Moreover, presynaptic Kv channels 
have been implicated in DPE at the Mf-CA3 synapse (Carta et al., 2014).  
We investigated the potential effect of 11,12-DHET and -EET-mediated modulation of Kv 
channels in a heterologous expression system. 11,12-DHET did not have any effect on steady-
state currents mediated by Kv1.1 or Kv1.1 in combination with the beta subunit 1 (Fig. 3.8A-B). 
However, 11,12-DHET (1 µM) exhibited a significant voltage-dependent block of Kv1.2 channel, 
particularly at higher depolarizing steps between +50 to +70 mV (Two-way ANOVA, voltage: 
F=65.4, p<0.0001 and DHET treatment: F=11.9, p<0.0001 significantly affected the outcome). 
The voltage dependence of block is evident in the I-V curve (Fig. 3.8C). However, due to the 
instability of recordings at higher depolarizing steps, we had to use suboptimal 10 mV 
depolarizing step to test the effect of 11,12-DHET on steady-state Kv1.2 currents (Fig. 3.8D). 
Nevertheless, 11,12-DHET (1-3 µM) produced a small, but significant block of Kv1.2 by 
11.92±3% (n=5; p=0.002**, paired Student's t-test before vs. after 11,12-DHET treatment). 
Furthermore, 11,12-DHET (1 µM) exerted a significant voltage-dependent block of inactivating 
Kv4.2 channels (Fig. 3.8E) (Two-way ANOVA, voltage; F=30.53, p=0.0007 and DHET 
treatment; F=36.56, p<0.0001 significantly affected the outcome). Specifically, 11,12-DHET 
significantly blocked Kv4.2 peak currents by 24.5±5.6% (n=5; p=0.016*, paired Student's t-test 
before vs. after 11,12-DHET treatment) elicited in response to a depolarizing step of +40 mV 
(Fig. 3.8F). We further tested the potential effect of 11,12-EET on steady-state Kv1.2 currents 
elicited at a +10 mV depolarizing step (Fig. 3.8G). Application of 11,12-EET led to opposite 
effect compared to those exerted by 11,12-DHET. We observed a small increase of Kv1.2 current 
after 11,12-EET (1µM) treatment (4.9±1.5%; n=4; p=0.051, paired Student's t-test before vs. after 
11,12-EET treatment). 
Our results from the heterologous expression system suggest that Kv1.2 and Kv4.2 might be 
molecular targets for 11,12-DHET and -EET.  
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Fig. 3.8 Effect of 11,12-DHET and 11,12-EET on K
v
 channels expressed in the heterologous expression system 
Summary plots and corresponding representative traces showing the effect of 11,12-DHET (1 µM) on (A) K
v
1.1 
currents (n=7, p=0.97, paired Student's t-test) and (B) K
v
1.1+ K
v
β1 currents (n=4, p=0.97, paired Student's t-test) 
elicited at a depolarizing step of +40 mV. (C) 11,12-DHET (1 µM) significantly blocked K
v
1.2 currents measured 
as I-V curves (n=7, two-way ANOVA followed by Bonferroni's post hoc test, p<0.05*, p<0.01**, p<0.001***; Imax 
values were used for normalization and thus were excluded while running ANOVA). (D) 11,12-DHET (1-3 µM) 
significantly blocked K
v
1.2 elicited at a depolarizing step of +10 mV (n=12, p=0.002**, paired Student's t-test), data 
points in this plot are color coded as follows: ● represents 1 µM and ● represents 3 µM. (E) 11,12-DHET (1 µM) 
significantly blocked K
v
4.2 measured as I-V curves (n=4, two-way ANOVA followed by Bonferroni's post hoc test, 
p<0.05*, p<0.01**; Imax values were used for normalization and thus were excluded while running ANOVA) and 
(F) K
v
4.2 elicited at depolarizing step of 40 mV (n=9, p=0.002**, paired Student's t-test). (G) 11,12-EET (1 µM) 
increased the opening of K
v
1.2 elicited at depolarizing step of 10 mV (n=5, p=0.051, paired Student's t-test). 
-100 -80 -60 -40 -20 0 20 40 60 80 100
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
Control
11,12-DHET, 1 M
Vm
N
o
rm
a
liz
e
d
 t
o
 b
a
s
e
lin
e
 I
m
a
x
*
**
Baseline 11,12-DHET
0
500
1000
1500
2000
2500
*
1 M
I k
 a
t 
+
 4
0
 m
V
 (
p
A
)
E
Baseline 11,12-DHET
0
2000
4000
6000
8000
**
1-3 M
I k
 a
t 
+
 1
0
 m
V
 (
p
A
)
-100 -80 -60 -40 -20 0 20 40 60 80 100
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
Control
11,12-DHET, 1 M
*
**
***
Vm
N
o
rm
a
liz
e
d
 t
o
 b
a
s
e
lin
e
 I
m
a
x
C
D
F
Baseline 11,12-DHET
0
1000
2000
3000
ns
1 M
I k
 a
t 
+
 4
0
 m
V
 (
p
A
)
Baseline 11,12-DHET
0
1000
2000
3000
4000
ns
1 M
I k
 a
t 
+
 4
0
 m
V
 (
p
A
)
BA
1.210.80.60.40.2
Time (s) Sw eep:101 Visible:2 of 101
I
m
e
m
b
(
p
A
)
-400
-200
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
2800
3000
0.4 nA
100 ms
baseline
7-9 min post 
11,12-DHET
10.80.60.40.2
Time (s) Sw eep:87 Visible:2 of 87
Im
e
m
b
(
p
A
)
-200
0
200
400
600
800
1000
1200
1400
1600
1800
2000
0.4 nA
100 ms
baseline 7-9 min post 
11,12-DHET
1.41.210.80.60.4
Time (s) Sw eep:3 Visible:2 of 3
Im
e
m
b
(
p
A
)
-1500
-1000
-500
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
1 nA
100 ms
baseline 7-9 min post 
11,12-DHET
340320300280260240220200180
Time (ms) Sw eep:3 Visible:2 of 3
Im
e
m
b
(
p
A
)
-200
-150
-100
-50
0
50
100
150
200
250
300
350
400
450
500
550
0.1 nA
10 ms
baseline
7-9 min post 
11,12-DHET
Baseline 11,12-EET
0
2000
4000
6000
1 M
p=0.051
I k
 a
t 
+
 1
0
 m
V
 (
p
A
)
G
1.41.210.80.60.4
Time (s) Sweep:3 Visible:2 of 3
Im
e
m
b
(p
A
)
-500
0
500
1000
1500
2000
2500
3000
3500
4000
4500
1 nA
100 ms
baseline
7-9 min post 
11,12-EET
72 | P a g e  
 
3.3.5. Genetic ablation/enhancement of EHs result in altered basal synaptic transmission  
Previous studies have indicated that lack of either EHs (mEH KO or sEH KO) reduces the 
synthesis of DHETs, while the presence of hyperactive EH (mEH E404D) results in an increased 
synthesis of DHETs relative to the respective WT controls (Marowsky et al., 2016; Marowsky et 
al., 2017). As EHs control the balance between inhibitory EETs and excitatory DHETs, we 
sought to evaluate if the altered ratio between inhibitory EETs and excitatory DHETs in these 
transgenic animals results in the alteration of basal excitatory neurotransmission. To this aim, we 
generated I-O curves by stimulating SCs with the incremental stimulation intensity from 5 to 45 
µA (input) and recorded CA1 fEPSPs in stratum radiatum (output) (see material methods). We 
recorded I-O curves from WT, sEH KO, mEH KO and mEH E404D mice and compared them 
with corresponding age-matched WT controls. 
 
Our I-O experiments with mEH KO, mEH E404D and age-matched (P20 to P30) WT revealed 
that the genotype significantly affects fEPSP slopes (Two-way ANOVA, WT vs. mEH KO: 
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Fig. 3.9. Genetic ablation of EH activity reduces basal synaptic transmission while genetic enhancement of EH activity 
increases it at the CA3-CA1 synapse 
(A) Representative traces and fEPSP I-O curves obtained from age-matched WT (n=5), mEH KO (n=4) and mEH 
E404D (n=6) mice. Two-way ANOVA, genotype, and time as two variables were employed; overall, genotypes 
significantly affected the fEPSP slopes (WT vs. mEH KO: F = 4.28, p < 0.04 and WT vs. mEH E404D: F = 19.27, 
p <0.0001). Moreover, mEH E404D showed significantly higher slope compared to the mEH KO, Bonferroni's multiple 
comparison post hoc test, p<0.05*, p<0.001** (B) Representative traces and I-O curves obtained from age-matched WT 
(n=6) and sEH KO (n=6) mice. The fEPSP slopes were significantly reduced in sEH KO mice compared to the ones 
from WT mice, unpaired Student’s t-test, WT vs. sEH KO (n=6 each, p<0.05*). 
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F = 4.28, p =0.04 and WT vs. mEH E404D: F = 19.27, p <0.0001). Moreover, Bonferroni’s post hoc 
test revealed that I-O curves recorded in mEH E404D slices showed significantly increased basal 
synaptic transmission (measured as fEPSP slopes) compared to the ones obtained in mEH KO 
slices (Fig. 3.9A). Further, we measured potential genotype-specific differences in sEH KO mice 
compared to the age-matched (P35 to P42) WT mice (Fig. 3.9B). The I-O curves obtained from 
sEH KO mice showed a significant decrease in basal synaptic transmission compared to the ones 
obtained from WT mice (n=6 each, p<0.05*, unpaired Student's t-test). 
Our findings from I-O experiments implicated a role for EHs in the modulation of basal synaptic 
neurotransmission. To substantiate these findings, we recorded s/mEPSCs in CA1 PCs from WT, 
mEH KO, and mEH E404D mice. In addition, we investigated if passive membrane properties 
[resting membrane potential (RMP) and input resistance (Rinput)] of CA1 PCs are altered in these 
mice. Passive membrane properties and sEPSCs/mEPSCs kinetic properties were not influenced 
by genotypes. However, mEH E404D exhibited significantly higher mEPSC frequency (one-way 
ANOVA followed by Bonferroni's post hoc tests, p<0.05*, compared to WT and mEH KO) 
(Table 3.2). Such an increase in mEPSC frequency is generally regarded of the presynaptic 
origin. 
 
Table 3.2. Passive membrane properties and kinetic properties of mEPSCs and sEPSCs recorded in CA1 PCs of 
WT, mEH KO and mEH E404D mice. 
Membrane 
properties
WT (n) mEH KO (n) mEH E404D (n)
RMP (mV) -69.73 ± 0.48 (25) -69.84 ± 0.45 (24) -70.20 ± 0.31 (9)
Rinput (MΩ) 166.99 ± 8.56 (25) 183.44 ± 8.97 (26) 163.89 ± 16.14 (9)
sEPSC WT (n) mEH KO (n) mEH E404D (n)
Amplitude (pA) 27.43 ± 2.30 (10) 24 ± 2.10 (8) 29.53 ± 4.05 (4)
Frequency (Hz) 0.73 ± 0.06 (9) 0.93 ± 0.10 (8) 1.05 ± 0.29 (4)
Rise time (ms) 1.18 ± 0.06 (9) 1.15 ± 0.15 (7) 1.03 ± 0.17 (4)
Decay time (ms) 6.96 ± 0.27 (9) 6.66 ± 0.28 (8) 5.54 ± 0.23 (3)
mEPSC WT (n) mEH KO (n) mEH E404D (n)
Amplitude (pA) 19.86 ± 1.25 (10) 16.23 ± 0.68 (12) 20.55 ± 2.59 (7)
Frequency (Hz) 0.75 ± 0.08 (9) 0.79 ± 0.10 (12) 1.25 ± 0.16* (7)
Rise time (ms) 1.31 ± 0.09 (10) 1.33 ± 0.11 (12) 1.16 ± 0.16 (7)
Decay time (ms) 6.84 ± 0.45 (9) 6.63 ± 0.33 (12) 6.12± 0.32 (6)
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Taken together, both mEH and sEH are likely to play a modulating role in synaptic transmission 
probably via regulating the ratio between inhibitory EETs and excitatory DHETs.  
3.4. Discussion 
Membrane-derived lipids such as AA (or its metabolites) have been shown to alter synaptic 
transmission in the hippocampus via modulation of presynaptic Kv channels (Carta et al., 2014). 
Recently, we have shown that the AA-derived metabolite, 11,12-EET, suppresses excitatory 
transmission at the CA3-CA1 synapse in mouse hippocampus (Mule et al., 2017). EHs 
responsible for metabolizing neuroactive 11,12-EET to 11,12-DHET are expressed in the mouse 
hippocampus and in principle can generate 11,12-DHET. However, the potential influence of 
AA-derived 11,12-DHET on synaptic transmission and its underlying mechanism(s) has not yet 
been reported.  
Here, we demonstrate that exogenous 11,12-DHET enhances excitatory transmission at the CA3-
CA1 synapse in mouse hippocampus. In addition, we showed that in situ released DHETs could 
be one of the mediators of DPE at the CA3-CA1 synapse. Further using heterologous expression 
system, we identified Kv1.2 as a common effector for 11,12-DHET and -EET. In addition, 11,12-
DHET also modulated the Kv4.2 channels. These Kv channels might underlie the excitatory 
effects of 11,12-DHET and inhibitory effects of 11,12-EET. Finally, we observed reduced basal 
synaptic transmission in mice with genetically ablated EHs while it was enhanced in mice 
expressing mEH E404D, a hyperactive variant of mEH. These observations lead to the intriguing 
hypothesis that EHs might act as an endogenous switch between inhibition and excitation in 
mouse hippocampus.  
3.4.1. Exogenous 11,12-DHET is a pro-excitatory lipid mediator 
We investigated the potential influence of exogenous 11,12-DHET on basal synaptic transmission 
using extracellular fEPSP recordings at the CA3-CA1 synapse. Extracellular fEPSP recordings 
are well suited to study the potential net effect of 11,12-DHET application for two reasons: First, 
the fEPSP signals are sampled from an intact network of neurons including inhibitory 
interneurons. Secondly, unlike intracellular patch-clamp recording, extracellular nature of fEPSP 
recording preserves the intracellular milieu of neurons (Andersen, 2007). We observed pro-
excitatory effects of 11,12-DHET on synaptic transmission at CA3-CA1 synapse, probably via 
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presynaptic effector(s) as indicated by a trend towards decreased PPR. Generally, a decrease in 
PPR is regarded as an indication of the underlying presynaptic target(s) but it does not 
categorically rule out the possibility of a combination of pre- and postsynaptic targets. Moreover, 
observed 11,12-DHET-mediated decrease of PPR is small and suggests a combination of pre-and 
postsynaptic effector(s) for DHETs. 
3.4.2. In situ-generated DHETs might be the mediators of DPE 
We adapted DPE protocol for the CA3-CA1 synapse to explore the contribution of CYP-
epoxygenase-generated metabolites to the expression of DPE, which was left unexplored in the 
original report (Carta et al., 2014). Abolition of DPE in the presence of MS-PPOH, a CYP-
epoxygenase blocker, suggested the requisite of CYP-epoxygenase-derived metabolites such as 
EETs or DHETs for the expression of DPE (Fig. 3.5). Reported inhibitory effects of exogenous 
11,12-EET (Mule et al., 2017) and the pro-excitatory effect of exogenous 11,12-DHET in the 
CA3-CA1 synapse (Fig. 3.3) pointed towards the likelihood that DHETs, rather than EETs, could 
be the potential mediators of DPE. Therefore, we employed a combination of pharmacological 
blockers and genetic ablation of EHs to test if EETs or DHETs are the potential mediators of DPE 
(Fig. 3.7). 
sEH and mEH are the two major EHs responsible for the biosynthesis of DHETs and are 
expressed in mouse hippocampus. Owing to its higher activity, sEH is generally considered the 
main EH responsible for the conversion of EETs to DHETs, while the contribution of ‘slower’ 
mEH is considered marginal (Morisseau, 2013). Given the purportedly major role of sEH in 
DHETs biosynthesis, targeting sEH for studying the potential contribution of DHETs to DPE is a 
natural choice. However, mEH in the mouse hippocampal PCs might be equally, if not more, an 
important determinant of DHET synthesis and potentially DPE expression for the following two 
reasons: First, mEH is expressed in the mouse CA1 PCs-a relevant domain for DHET synthesis if 
it were to act as DPE mediator, while sEH is expressed in the astrocytes (Marowsky et al., 2009). 
Secondly, mEH, like the majority of EET-synthesizing CYP-epoxygenase, is an endoplasmic 
reticulum-resident enzyme and it has been proposed that CYP can form a physical complex with 
mEH which might favor efficient DHETs synthesis. Indeed, a recent study from our group 
provided evidence for such a complex formation between EETs-generating CYPs and DHETs-
generating mEH in non-neuronal cells (Leon et al., 2017). Such an arrangement, in theory, might 
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result in substrate channeling (EETs) and efficient mEH-mediated-DHET synthesis in mouse 
CA1 PCs which co-express mEH and CYP. Thus, despite its lower catalytic efficiency, mEH 
might be a major determinant of DHET synthesis in CA1 PCs and thus was targeted in our 
experiments. 
Our data show that pharmacological inhibition or genetic ablation of mEH abolishes DPE, 
suggesting an important contribution of mEH-derived DHETs in the expression of DPE at the 
CA3-CA1 synapse. However, these observations need to be ascertained further by increasing the 
number of experiments (n). Moreover, we have not empirically ruled out the potential 
contribution of sEH-derived DHETs to DPE in our experiments at CA3-CA1 synapse which can 
be investigated by employing sEH inhibitors and/or sEH KO mice. 
3.4.3. Complementary effects of 11,12-DHET and-EET are potentially mediated by pre- and 
postsynaptic Kv channels  
We screened Kv channels as potential molecular target(s) underlying the pro-excitatory effects of 
11,12-DHET and inhibitory effects of 11,12-EET observed in CA3-CA1 synapse by transiently 
expressing candidate Kv channels in CHO cells. Voltage-gated potassium channels from the Kv1 
subfamily are predominantly expressed in the axonal initial segment and presynaptic terminals. 
Kv1.1 and 1.2 are the most common isoforms expressed in the CA1 PCs and conduct non-
inactivating D-type currents (Ovsepian et al., 2016). Kv1.x channels are known to regulate 
neurotransmitter release via altering the presynaptic AP duration and resultant calcium influx in 
the axon terminals (Trimmer, 2015; Geiger et al., 2000). Moreover, inhibition of presynaptic Kv 
channels in MfBs by AA has been shown to increase the glutamate release and contribute to DPE 
(Carta et al., 2014). These observations suggest that modulation of Kv1.1 and Kv1.2 might 
underlie the pro-excitatory effects of 11,12-DHET (as a mediator of DPE) and inhibitory effects 
of 11,12-EET in CA3-CA1 synapse. Indeed, we identified Kv1.2 as a common effector for 11,12-
DHET and -EET, the former blocked, whereas latter showed a trend towards increased 
conductance of heterologously expressed Kv1.2 channels. The opposite effects of 11,12-DHET 
and -EET observed on Kv1.2 channels in CHO cells might explain complementary effects of 
these molecules observed in the CA3-CA1 synapse.  
Although the use of non-neuronal heterologous expression system in our experiments enabled us 
to identify individual Kv channels as 11,12-DHET/EET molecular targets, the extent and 
77 | P a g e  
 
relevance of observed effect in the intact neuronal system is a matter of extrapolation. Especially, 
due to the fact that most abundant Kv1.1 and 1.2 α-subunits in CA3 and CA1 PCs almost always 
exist as heterotetramers (Ovsepian et al., 2016). These heterotetrameric Kv1.1/1.2 channels are 
implicated in the regulation of neurotransmitter release and somatic excitability in PCs (Kole et 
al., 2012; Rama et al., 2017; Trimmer, 2015). To address this, we attempted to express 
heterotetrameric Kv1.1/1.2-channels in CHO cells as they exist in native neurons by co-
transfecting Kv1.1 and Kv1.2 cDNA in varying ratios (1:1 to 1:5). However, due to the differential 
transfection efficiency and/or unitary conductances of constituting Kv channels, we could not 
reliably express heterotetrameric channels in CHO cells and had to study individual 
homotetrameric Kv1.2 channels. Thus, 11,12-DHET/-EET-mediated modulation of Kv1.2 
channels observed in our experiments might be quantitatively different (lower or higher) on 
native neuronal heterotetrameric Kv1.1/1.2 channels. This possibility, ideally, needs to be tested 
with direct patch-clamp recording from the CA3 axon terminals in mouse brain slices, however, 
the small size of the CA3 axonal terminals (unlike MfB) is restrictive.  
In our experiments, the effect of 11,12-DHET was restricted to Kv1.2 while Kv1.1 was unaltered. 
Depending upon the stoichiometry and positioning, presence of blocker sensitive Kv subunit(s) in 
heterotetrameric complex might result in a block of whole heterotetrameric Kv1.1/1.2 channel 
(Al-Sabi et al., 2013). Therefore, it is plausible that 11,12-DHET-mediated block of Kv1.2 
subunits in native heterotetrameric Kv1.1/1.2 channel might be sufficient to block conductance of 
native channels to produce pro-excitatory effects. However, this possibility needs to be 
ascertained in a native neuronal system employing selective Kv1.1/1.2 blockers such as α-
dendrotoxin and tetraethylammonium (TEA) chloride (moderately selective for Kv1.1). Kv 
blockers, in particular, TEA chloride, often exhibits only moderate level of selectivity and might 
block other structurally related Kv1.x channels to a varying degree. This unintended alteration of 
other Kv channels might be a confounding factor.  
Kv4.2 channels, on the other hand, are expressed in the somatodendritic compartment and 
conducts A-type currents which are responsible for regulation of backpropagating AP via 
modulating integration of synaptic inputs (Hoffman et al., 1997; Johnston et al., 2000; Ramakers 
et al., 2002). Moreover, A-type currents have been shown to negatively influence NMDAR-
mediated EPSC amplitude in CA1 PCs: Lack of A-type current (infected with dominant negative 
pore mutant of Kv4.2) showed increased NMDA-EPSC amplitude whereas expression of 
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functionally conducting Kv4.2 channels showed decreased NMDA-EPSC amplitude compared to 
the uninfected controls in CA1 PCs (Jung et al., 2008). These observations point towards the role 
of A-type currents in maintenance of CA1 dendritic excitability. Increased dendritic excitability 
by means of Kv4.2 inhibition might reflect in enhanced EPSC or EPSP amplitude/slope.  
In our slice experiments, application of 11,12-DHET increased fEPSP slopes, potentially via a 
combination of pre- and postsynaptic effectors. Having identified Kv1.2 as a potential presynaptic 
effector for 11,12-DHET, we further screened Kv4.2 channels in CHO cells as a potential 
postsynaptic effector. We observed 11,12-DHET-mediated block of Kv4.2 channels (Fig. 3.8E-
F). in CHO cells which might, at least in part, explain the DHET-mediated increase in fEPSP 
slope observed at CA3-CA1 synapse. Interestingly, our fEPSP recording exclusively measured 
synaptic currents at stratum radiatum of CA1 region without eliciting somatic AP. Being a 
voltage-gated channel, activation of Kv4.2 is coupled to the change in membrane potential and 
intuitively might not contribute to the alteration of synaptic currents in our recording paradigm. 
However, possibility of synaptic currents-mediated change in local dendritic potential leading to 
activation of voltage-gated Kv4.2 channels in our recording paradigm cannot be ruled out.  
Despite the limitation of experimental paradigm used (non-neuronal heterologous system), our 
findings strongly support the likelihood that Kv1.2 and Kv4.2 are molecular targets for DHET-
mediated excitatory effects in hippocampal neurons. Moreover, 11,12-EET-mediated activation 
of Kv1.2 channels might be more pertinent on presynaptic neuronal heterotetrameric channels and 
underlie the inhibitory effects of 11,12-EET observed at the CA3-CA1 synapse. 
3.4.4. The role of EHs beyond detoxification: an endogenous switch between inhibition and 
excitation in the hippocampus? 
We investigated potential consequences of the altered ratio between inhibitory EETs and 
excitatory DHETs by recording I-O curves in transgenic mice (mEH and sEH KO and mEH 
E404D). As expected, we observed significantly enhanced basal synaptic transmission in slices 
from mice expressing mEH E404D while it was reduced in the slices obtained from mEH KO 
mice compared to the WT. Surprisingly, genetic ablation of non-neuronal sEH also resulted in 
significant reduction of basal synaptic transmission compared to the corresponding age-matched 
WT controls. The observed contribution of sEH could be due to several factors: Namely, 
hippocampal astrocytes express the enzymatic machinery to generate EETs and DHETs 
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(Amruthesh et al., 1993; Marowsky et al., 2009). It has been shown that glutamate released at the 
synapse can extrasynaptically activate astrocytic glutamate receptors to increase the cytosolic 
calcium levels. The enhanced cytosolic calcium triggers activation of cPLA2 to release AA from 
astrocytic membrane and subsequently leads to the synthesis of EETs (Stella et al., 1994; 
Alkayed et al., 1997; Haydon et al., 2006). Stimulation of SCs, as in our I-O recording paradigm, 
might result in the activation of such glutamate-induced synthesis of EETs and potentially 
DHETs through astrocytic sEH.  
Another reason could be the fEPSP I-O paradigm used in our experiments to record synaptic 
currents. fEPSP are recorded from populations of neurons (unlike single CA1 PCs in DPE 
experiment) and involves activation of a number of synapses which proportionally enhances the 
likelihood of glutamate-activated EET- and DHET synthesis from astrocytes. Moreover, higher 
catalytic efficiency of sEH might counterbalance its lack of neuronal expression and emerge as 
predominant contributor determining the DHET biosynthesis. These observations taken together 
with our results are compatible with the possibility that sEH-derived DHETs from the astrocytes 
could exhibit pro-excitatory effects at the CA3-CA1 synapse in WT mice. The reduced basal 
synaptic transmission observed in our I-O experiments with sEH KO mice can be attributed to the 
lack of sEH derived DHETs. Given the differential expression, subcellular localization and 
catalytic efficiency of mEH and sEH, it is difficult to predict the relative contribution of mEH and 
sEH to the DHETs biosynthesis relevant for its pro-excitatory effects in mouse hippocampus 
Our recent report of inhibitory effects of EETs in the CA3-CA1 synapse (Mule et al., 2017) taken 
together with the observed excitatory effects of DHETs in the present study at the same synapse 
pose interesting questions: What underlies the reduced basal synaptic transmission observed in 
mice lacking EHs? Whether it is stabilization of inhibitory EETs or absence of pro-excitatory 
DHETs? The lack of a reasonably sensitive analytical method for detecting EETs/DHETs 
concentration at the relevant microenvironment makes it difficult to address these questions 
experimentally. However, these findings lead to the intriguing hypothesis that EHs (sEH and 
mEH) might serve as an endogenous switch between inhibition and excitation by regulating the 
ratio of inhibitory EETs and excitatory DHETs. In addition to our findings presented here, a few 
studies support the notion of an important role of EH in the maintenance of hippocampal 
inhibition-excitation balance. For instance, expression of sEH has been shown to be upregulated 
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in pilocarpine-induced epileptic mice (Vito et al., 2014), this upregulation of sEH potentially lead 
to an imbalance of inhibitory EETs and excitatory DHETs and underlie the pathological 
hyperexcitability associated with epilepsy.  
Based on general consensus that sEH is main determinant of EET:DHET ratio, role of sEH in 
experimentally induced epilepsy has already been investigated in a few studies. Genetic ablation/ 
pharmacological inhibition of sEH attenuated the epileptic seizures in various animal models of 
epilepsy (Inceoglu et al., 2013; Hung et al., 2015; Vito et al., 2014). Our results offer mechanistic 
explanation(s) for antiepileptic effects observed in these studies. Moreover, in addition to sEH, 
our findings strongly suggest an important role for mEH in regulation of excitation and inhibition 
in mouse hippocampus. To best of our knowledge, unlike sEH, mEH inhibition has not been 
explored for potential antiepileptic properties. In light of our results, it is highly desirable to 
explore small molecule mEH blockers for their antiepileptic potential in experimentally induced 
epilepsy.  
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Chapter 4  
Altered susceptibility to morphine-mediated 
antinociception in sEH KO mice  
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4.1. Introduction 
Cytochrome P450 (CYP) epoxygenases catalyze the epoxygenation of fatty acid (FAs) to 
bioactive epoxides. Amongst more than 100 murine CYP isoenzymes, CYP-2C and -2J are most 
commonly noted for their epoxygenase activity (Iliff et al., 2010; Spector et al., 2015). However, 
several other CYP isoenzymes such as CYP-4x1 are capable of FA epoxygenation in mouse brain 
(Al‐Anizy et al., 2006). Arachidonic acid (AA) is amongst the most studied FAs and is 
metabolized by CYP-epoxygenases to four regioisomers: 5,6-, 8,9-, 11,12- and 14,15-
epoxyeicosatrienoic acid (EET), which further can be hydrolyzed to the corresponding less active 
diols by soluble epoxide hydrolase (sEH) and microsomal epoxide hydrolase (mEH) (Miksys et 
al., 2002; Marowsky et al., 2009; Spector et al., 2015). 
In addition to EETs, other CYP-epoxygenase-derived bioactive FA epoxides include 
docosahexaenoic acid-derived epoxydocosapentaenoic acids (EpDPEs), eicosapentaenoic acid-
derived epoxyeicosatetraenoic acid (EpETEs) and linoleic acid-derived epoxyoctadecenoic acid 
(EpOMEs) (Wagner et al., 2014). Amongst these bioactive FA epoxides, EETs are the most 
studied ones and are best known for their potent vasodilatory effects, by virtue of which they play 
an important role in neurovascular coupling (Farr et al., 2011). In addition to their vasodilatory 
effects, EETs exhibit pro-angiogenic and anti-inflammatory properties which collectively might 
underlie the neuroprotective potential of EETs (Iliff et al., 2010; Spector et al., 2015).  
Of the four regioisomers, 14,15- and 11,12-EET are the most synthesized in the mouse brain 
(Sanchez-Mejia et al., 2008) and have been suggested to underlie the antinociceptive effects in 
rat neuropathic and inflammatory pain models (Wagner et al., 2013). Interestingly, a study 
demonstrated strong antinociception in rats after microinjection of 14,15-EET into the 
periaqueductal gray (PAG), a brain region involved in opioid antinociception, presumably by 
activating endogenous endorphin release (Terashvili et al., 2008). The potential involvement of 
14,15-EET in opioid-mediated antinociception was further supported by studies demonstrating 
the attenuation of morphine-mediated and stress-induced antinociception in transgenic mice with 
neuron-specific ablation of CYP-reductase. CYP-reductase is indispensable for CYP activity and 
its ablation would render all neuronal CYPs (including CYP-epoxygenases) inactive (Conroy et 
al., 2010; Hough et al., 2014). In addition, microinjection of a CYP-epoxygenase inhibitor, CC12 
in the rostral ventromedial medulla of WT mice also attenuated morphine-mediated 
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antinociception suggesting the requisite of functional CYP-epoxygenase for opioid-mediated 
antinociception (Conroy et al., 2013). Furthermore, a recent study employed a cluster knock out 
strategy, wherein the genetic ablation of CYP-2C cluster (noted for its epoxygenase activity) 
reduced subcutaneously administered morphine-mediated antinociception by 41%. However, 
genetic ablation of the non-epoxygenase cluster, CYP-2D and CYP-3A did not alter morphine-
mediated antinociception (Hough et al., 2015).  
These studies collectively point towards the potential involvement of CYP-epoxygenases-derived 
FA epoxides(s) in opioid-mediated antinociception. Moreover, these findings taken together with 
an earlier report of 14,15-EET-mediated antinociception in rats (Terashvili et al., 2008) suggest 
that 14,15-EET might potentiate opioid signaling. The potential effect of 14,15-EET on opioid 
signaling might be mediated via one of the following mechanism(s):  
1. 14,15-EET might enhance the endogenous opioid release as suggested by (Terashvili et al., 
2008). 
2. They might facilitate agonist binding or allosteric modulation of mu-opioid receptors (MOR). 
3. The might alter downstream signaling component(s) to enhance MOR signaling. 
sEH-catalyzed hydrolysis is a major determinant of the bioavailability of FA epoxides including 
14,15-EET and genetic ablation or inhibition of sEH have been shown to prolong the bioactivity 
of these epoxides in vivo (Anandan et al., 2011; Zhang et al., 2007). Therefore, we used sEH KO 
mice to test the potential influence of metabolic stabilization of sEH substrates in opioid-
mediated antinociception using the tail flick paradigm. Furthermore, to investigate the potential 
influence of 14,15-EET on MOR signaling, we heterologously expressed MORs and its effector 
G-protein coupled inwardly rectifying K+ (GIRK) channels in host cells. 
4.2. Materials and methods 
4.2.1. Nociceptive testing  
4.2.1.1. Animals  
Adult, 8 weeks old, C57BL/6J and Ephx2 null (sEH KO) mice were used for nociceptive testing. 
The sEH KO mice (Sinal et al., 2000) were provided by Dr. Frank Gonzalez (National Institute of 
Health, Bethesda, USA) and C57BL/6J mice were obtained from Charles River Laboratories 
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(Germany). sEH KO mice were backcrossed with C57BL/6J for at least 7-9 generations. The 
genotype was confirmed by using standard polymerase chain reaction as described here 
(Marowsky et al., 2017). Sexually dimorphic expression of sEH has been shown in the 
experimental mice (Qin et al., 2015). Therefore, we exclusively used male mice. Mice were 
group-housed in a room with 12 hours light/dark cycle and had ad libitum access to standard 
chow-food and water. Animal experiments were carried out according to the Swiss Federal Law 
under the license 196/2012 granted by the Kantonale Veterinärsamt Zürich, Switzerland. 
4.2.1.2. Tail flick experiments 
The tail flick paradigm is widely employed for assaying efficacy of pharmacological agents on 
supraspinal heat-induced thermal pain in rodents. In the present study, mice were allowed to 
acclimatize to the experimentation room before experiments. All animal experiments were 
carried out at the same time of the day (9 am to 2 pm) to avoid diurnal variations. Each mouse 
was placed in a Plexiglas tube and the ventral surface of the tail (between 3 and 5 cm from the 
tip) and was exposed to the radiant heat to induce thermal pain. The tail flick analgesiometer 
(IITC, Chicago, USA) was used to record tail withdrawal latency (in seconds) as a readout for 
radiant heat-induced thermal pain. Heat intensity was calibrated to keep the basal tail withdrawal 
latency between 3-4 seconds. Three baseline latency readings were recorded before subcutaneous 
(sc) application of either saline or morphine. Tail flick latencies were recorded at 20, 40, 60 and 
90 minutes post-injection. In the absence of tail withdrawal, a 10 s cut-off was exercised to avoid 
permanent tissue damage. The experimenters were blinded to the drug(s) injected and genotype 
of the animals to avoid bias. Data are presented as the percent maximum possible effect (% 
MPE). 
% 𝑴𝑷𝑬 =
(𝒑𝒐𝒔𝒕 𝒊𝒏𝒋𝒆𝒄𝒕𝒊𝒐𝒏 𝒍𝒂𝒕𝒆𝒏𝒄𝒚 − 𝒃𝒂𝒔𝒆𝒍𝒊𝒏𝒆 𝒍𝒂𝒕𝒆𝒏𝒄𝒚)
(𝟏𝟎 − 𝒃𝒂𝒔𝒆𝒍𝒊𝒏𝒆 𝒍𝒂𝒕𝒆𝒏𝒄𝒚)
 
4.2.2. In vitro electrophysiology in the heterologous expression system 
4.2.2.1. HEK-293T cell maintenance and transfection 
Heterologous expression system carrying functionally coupled MOR-GIRK in HEK-293T cells 
was established for electrophysiological assays. HEK-293T cells were maintained at 37°C in 
95% O2, 5% CO2, in DMEM medium (Invitrogen, USA), supplemented with 5% fetal bovine 
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serum. For transient transfections, 50,000 to 70,000 cells were seeded out on 12 mm glass 
coverslips placed in 3.5 cm plate and allowed to grow overnight before transfection. HEK-293T 
cells were transiently transfected with rat MOR (0.5-0.75 µg), together with the human [GIRK1 
(Kir 3.1)/GIRK2 (Kir 3.2A)] (1-1.5 µg) and eGFP (0.1-0.15 µg) cDNA using JetPei transfection 
reagent (Polyplus transfection, USA). MOR and GIRK plasmids were kindly provided by Dr. 
Volker Hoellt (Bailey et al., 2003) and Dr. Graeme Henderson (Johnson et al., 2006), 
respectively. HEK-293T cells were used for experimentation 24-48 hours post-transfection. A 
coverslip with HEK-293T cells was transferred to the recording chamber and superfused with an 
external solution throughout the experiment. Axiovert 200 fluorescence inverted microscope 
(Carl-Zeiss, Germany) was used to visualize the green fluorescing (eGFP expressing) HEK-293T 
cells. The eGFP expression was considered as a marker for MOR-GIRK expression and green 
cells were used for patch-clamp recording. Mock-transfected cells and non-GFP expressing cells 
did not respond to application of MOR agonist, DAMGO.  
4.2.2.2. Electrophysiological recordings 
A high potassium external solution containing (in mM) NaCl (125), KCl (30), MgCl2 (1.0), CaCl2 
(2), glucose (10) and HEPES (10) The pH was adjusted to 7.4 with 1N NaOH, and osmolarity 
was 315 mOsm) was used for electrophysiological recordings. Patch pipettes were pulled from 
borosilicate glass capillaries, (GC150F-10, Harvard apparatus, UK) and had a tip resistance of 2.5 
to 3.5 mΩ when filled with an internal solution containing the following (in mM) K-gluconate 
(145), Mg-ATP (5), Na-GTP (0.5), EGTA (1) and NaCl (5). The pH was adjusted to 7.3 with 1N 
KOH, the osmolarity was 305 mOsm. 
Whole-cell macroscopic currents were recorded using AM2400 patch-clamp amplifier (AM 
systems, USA) and digitized at 10 KHz using Digidata 1400 and pClamp 10 software suites 
(Molecular Devices, USA). After establishing the whole-cell configuration, whole-cell 
capacitance and series resistance were compensated using amplifier circuitry. The cell was 
clamped (Vh) at -80 mV; the calculated reversal potential was Erev=-40 mV for K
+ for the given 
external-internal combination. DAMGO-induced inward GIRK currents were measured as a 
readout for MOR activation.  
89 | P a g e  
 
4.2.2.3. Drug application system 
To avoid DAMGO-induced desensitization of MOR, DAMGO exposure to a patched cell was 
limited to five seconds. We employed two channeled, gravity-assisted application system 
comprising two fused silica capillaries. Two channels were operated close (~ 50-100 μm) to a 
patched cell so that the drugs could be delivered to the cell directly. The first channel was used 
exclusively for delivering drugs such as DAMGO or DAMGO+EETs, while the second channel 
was used for the external solution to wash the drug(s) off the cell. Fast solution exchange was 
achieved by switching quickly from first channel (drug) to the second (wash) using 
micromanipulator as shown in Fig.4.2A. The MOR antagonist-naloxone and the GIRK blocker 
barium chloride were used to validate the specificity of DAMGO-induced currents. 
4.2.3. Drugs and solutions 
14,15-EET was kindly provided by Dr. John Falck, University of Texas, Southwestern Medical 
Center, Texas, USA. All other drugs were obtained from Sigma-Aldrich except DAMGO ([D-
Ala2, N-MePhe4, Gly-ol]-enkephalin), which was obtained from Tocris Bioscience, UK. All the 
drugs were dissolved in water except 14,15-EET which was dissolved in dimethyl sulfoxide 
(DMSO). DMSO tends to be unstable during storage and therefore to avoid contribution of the 
nonspecific contaminants generated during storage, all the experiments investigating the 
influence of DMSO were carried out with the ultra-pure anhydrous DMSO supplied in 
individually packed light-protected containers from Life Technologies, Thermo Fischer 
Scientific, USA. All the drugs were prediluted in the external solution to yield desired 
concentration before application. 
4.2.4. Data analysis and statistics 
All data are expressed as mean±standard error of mean unless stated otherwise. All 
concentration-response curves were fitted with log10 (concentration of DAMGO in nM) vs. 
response using GraphPad Prism 5 (GraphPad Software, USA). Appropriate statistical tests were 
used for testing the significance, such as Student’s t-test for comparisons and two-way-ANOVA 
followed by a post hoc test for multivariate comparisons. 
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4.3. Results 
4.3.1. Sub-maximal dose of morphine exhibits higher antinociception in sEH KO compared 
to WT mice 
We tested the influence of metabolic stabilization of CYP-epoxygenase-derived FA epoxides 
such as EETs in sEH KO mice. We measured supraspinal antinociception by using tail flick 
latency in response to the thermal heat as shown in (Fig. 4.1A). First, we tested for genotype-
specific differences in the thermal pain sensitivity between WT and sEH KO mice. No significant 
difference in baseline latencies between sEH KO vs. WT mice was observed, indicating the lack 
of influence of sEH substrates on basal opioid signaling (Fig. 4.1B). Stressful situations such as 
forced swimming and restraining are known to activate the endogenous opioid system and lead to 
‘stress-induced antinociception’ (Maier, 1986; Mogil et al., 1996). In our experiments, mice were 
briefly restrained in the Plexiglas tube for tail flick latency measurements. Interestingly, we 
observed a significantly higher restrain-induced antinociception in saline-treated sEH KO mice 
60 min post-saline injection compared to the saline-treated WT counterparts (Fig. 4.1C). This 
finding suggests a potential involvement of FA epoxides in stress-induced antinociception in line 
with a recent report, which implicated neuronal CYP-epoxygenase activity in stress-induced 
analgesia (Hough et al., 2014).  
Further, we studied the effect of metabolic stabilization of epoxygenated FAs on morphine-
mediated antinociception. We observed significantly higher antinociception (measured as % 
MPE) at (1 mg/kg) of morphine administered SC in sEH KO as compared to WT mice (Fig. 
4.1D). This finding suggests the potential involvement of bioactive FA epoxides such as EETs in 
the potentiation of MOR signaling in sEH KO mice. 
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4.3.2. The MOR-GIRK heterologous expression system to study the MOR signaling in vitro 
We built a two-channel gravity-assisted drug application system to minimize agonist exposure to 
MORs (Fig. 4.2A). Further, we validated the functional coupling of MOR-GIRK system by 
recording DAMGO-induced inward GIRK currents (Fig. 4.2B). We also verified the inward 
rectification - a unique biophysical signature of DAMGO-induced GIRK currents by recording 
current-voltage curve (Fig. 4.2C and D). Additionally, we used the MOR antagonist naloxone 
and the GIRK blocker barium chloride to validate the specificity of DAMGO-induced inward 
GIRK currents. 
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4.3.3. 14,15-EET does not directly activate MOR or GIRK channels in HEK-293T cells  
First, we verified the expression of functional GIRK channels in HEK-293T cells using a positive 
control, n-propanol, 100 mM (Fig. 4.3A). Application of n-propanol activated GIRK channels 
directly, confirming the functional expression of GIRK channels in these cells. Further, we tested 
the possibility of a direct effect of 14,15-EET (1 µM) on GIRK channels in HEK-293T cells. We 
did not observe any EET-mediated activation of GIRK (Fig. 4.3B). Moreover, we tested the 
possibility of a direct effect of 14,15-EET (0.3 and 3 µM) on MOR signaling in HEK-293T cells 
expressing both MOR and GIRK and we did not observe any MOR-GIRK activation by 14,15-
EET (Fig. 4.3C and D). Additionally, we confirmed the functional coupling between MOR and 
GIRK in these cells by application of the MOR agonist-DAMGO. These findings demonstrate 
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Fig. 4.2 Drug application system and characterization of DAMGO-induced GIRK currents in the heterologous 
expression system.  
(A) Schematic representation of the two-channel application system used for on cell application of drug(s) or 
washing. (B) A representative patch-clamp recording showing DAMGO-induced GIRK currents measured at Vh=-
80 mV in HEK-293T cells transiently expressing MOR and GIRK channels. DAMGO-induced GIRK currents are 
typically inwardly rectifying with a reversal potential of -40 mV, as shown s representative traces (C) and in a 
current-voltage plot (D). 
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that 14,15-EET does not activate MOR or GIRK directly and might potentiate the MOR signaling 
via other indirect mechanisms such as facilitation of agonist binding to MOR.  
 
4.3.4. 14,15-EET does not alter DAMGO concentration-response curve in HEK-293T cells  
We applied DAMGO using two-channeled application system which ensured faster solution 
exchange and minimized DAMGO-induced desensitization of MOR signaling (see material-
methods). We evaluated the effectiveness of our drug application system by carrying out two 
consecutive concentration-response curves (CRCs) of DAMGO (3, 10, 30, 100 and 300 nM) in 
the same cell expressing functionally-coupled MORs and GIRK channels (Fig. 4.4A). We did not 
observe significant desensitization of MOR responses when the CRC was repeated in the same 
cell, allowing to conclude that our experimental paradigm is amenable to study the potential 
influence of EET on DAMGO CRCs. CRCs were fitted with log10 (DAMGO concentration in 
nM) vs. normalized IGIRK, using three parameters fit using GraphPad Prism 5 suite to calculate 
EC50 values for DAMGO. The calculated EC50 for the first and second CRCs were 14.4 and 17 
nM, respectively (Fig. 4.4B).  
To evaluate the potential influence of 14,15-EET on DAMGO CRCs, we carried out two CRCs in 
a cell; the first CRC was carried out with DAMGO plus vehicle control (0.003%/0.03% DMSO) 
while the second one was with DAMGO plus 14,15-EET (0.3/3 µM dissolved in DMSO, 0.03 
and 0.003% final concentration of DMSO). Co-application of 14,15-EET (0.3 and 3 µM) did not 
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alter the DAMGO CRCs significantly. The calculated EC50 value for DAMGO in the presence 
and absence of 14,15-EET (0.3 µM) were 5.6 and 5.4 nM, respectively (Fig. 4.4C). Co-
application of 14,15-EET (3 µM) marginally shifted DAMGO EC50 from 7.5 to 5 nM (Fig. 
4.4D).  
 
4.3.5. DMSO (used as a vehicle) potentiated MOR signaling in the heterologous expression 
system. 
Unexpectedly, we observed that the calculated EC50 values in the presence of DMSO used as 
vehicle control (Fig. 4.4C and D, 5.6 and 5.4 nM, respectively) were lower than the one observed 
with the control CRC (Fig. 4.4B,14.4 nM) carried out in the absence of DMSO, suggesting the 
influence of DMSO on MOR signaling. To investigate the potential influence of DMSO on MOR 
activity, we tested the possibility of direct activation of MOR signaling by DMSO in the 
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Fig. 4.4 14,15-EET does not alter the concentration-response curve for DAMGO in MOR/GIRK-expressing 
HEK-293T cells. 
(A) A representative trace of a CRC obtained by applying 3, 10, 30, 100 and 300 nM of DAMGO. (B) Average 
CRC plot showing no desensitization in a control experiment where two consecutive CRCs (I and II) were 
recorded in the same cell. Effect of 0.3 µM (n=6) and 3 µM (n=5) 14,15-EET on DAMGO CRC compared to the 
corresponding DMSO controls is shown in (C) and (D), respectively.  
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heterologous system expressing functional MOR and GIRK. DMSO (0.001, 0.003, and 0.03%) 
did not activate MOR signaling in the absence of DAMGO. We ensured the functional MOR-
GIRK coupling by applying DAMGO at the end of every recording (Fig. 4.5A and B). 
 
Further, we investigated the potential effect of (0.001, 0.003% and 0.03%) DMSO on DAMGO 
CRCs. DAMGO CRCs were shifted significantly towards the left in the presence of 0.003% and 
0.03% of DMSO. The DMSO-induced leftward shift of CRCs was evident from the lower 
calculated EC50 values. The calculated EC50 values for control DAMGO CRC was 14.3 nM 
which was shifted to 5 nM and 7.9 nM by 0.003 and 0.03% DMSO, respectively (Fig. 4.5C and 
D). Effect of the lowest concentration of DMSO (0.001%) was not significantly different from 
the control CRC recorded in the absence of DMSO (Fig. 4.5D).  
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(A) A representative trace showing the effect of DMSO (0.03%) and DAMGO, 30 nM on IGIRK. (B) A scatter plot 
showing average change in DMSO/DAMGO-induced IGIRK (n=4 each). (C) A representative trace showing the 
effect of DMSO (0.03%) on DAMGO CRC. (D) Average CRC plot showing the effect of DMSO (0.001%, n=9; 
0.003%, n= 10; and 0.03%, n=12) on DAMGO CRC.  
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4.4. Discussion 
In the present study, we demonstrated that metabolic stabilization of epoxygenated FAs by 
genetic ablation of sEH leads to the potentiation of morphine-mediated antinociception in mice. 
Earlier reports implicated CYP-epoxygenase derived metabolite(s) in the regulation of opioid 
signaling and morphine-mediated analgesia. Our findings from sEH KO mice taken together with 
an earlier report of 14,15-EET-mediated antinociception in rats (Terashvili et al., 2008) suggest 
that 14,15-EET might enhance the MOR signaling and underlie the effects observed in 
CPR/CYP-epoxygenase and sEH transgenic mice. Therefore, we further investigated the 
potential effect of 14,15-EET on MOR signaling in the heterologous expression system 
expressing functional MOR and GIRK channels. Counterintuitively, 14,15-EET did not show any 
effects on MOR signaling in this heterologous expression system. Surprisingly, DMSO (used as a 
vehicle) potentiated MOR signaling in this system.  
4.4.1. Metabolic stabilization of FA epoxides potentiates morphine-mediated antinociception 
in vivo 
Morphine activates the opioid signaling to produce antinociception which can be measured in 
experimental animals using animal models of pain such as tail flick latency measurement. Using 
tail flick paradigm, we demonstrated that the potential metabolic stabilization of bioactive FA 
epoxides in sEH KO mice as suggested by (Wagner et al., 2017) resulted in a significantly higher 
antinociception with a sub-maximal dose of morphine compared to the WT mice. Moreover, we 
also observed significantly higher stress-induced antinociception in sEH KO mice compared to 
the WT mice. Both findings are compatible with prior reports which implicated CYP-
epoxygenase-derived metabolites in morphine-mediated and stress-induced antinociception 
(Conroy et al., 2010; Hough et al., 2014).  
Based on these findings, the present study implicates the role of CYP-epoxygenase generated FA 
epoxides which are also the substrate for sEH such as EETs in the modulation of opioid 
signaling. However, in addition to EETs, other CYP-epoxygenase derived bioactive FA epoxides 
such as EpDPEs, EpETEs, and EpOMEs are also good substrates for sEH (Morisseau et al., 
2010; Spector et al., 2015; Wagner et al., 2014). Amongst all the bioactive FA epoxides, EETs 
have been suggested to underlie antinociceptive effects in rat neuropathic and inflammatory pain 
models (Wagner et al., 2013). Of the four EET regioisomers, 14,15-EET is the most preferred 
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substrate for sEH (Imig, 2012; Morisseau et al., 2010) and has been shown to exhibit strong 
antinociception in rats (Terashvili et al., 2008). Our findings and an earlier report implicated that 
14,15-EET might be a relevant mediator and potentiate MOR signaling to underlie the 
potentiating effect observed in sEH KO animals. 
4.4.2. 14,15-EET does not potentiate MOR signaling in the heterologous expression system 
Further, we investigated the potential mechanisms for 14,15-EET-mediated potentiation of MOR 
signaling using the heterologous expression system. Contrary to expectations, 14,15-EET did not 
potentiate DAMGO-induced MOR activation in this heterologous system. This striking lack of 
14,15-EET effect in the heterologous system can be attributed to several possibilities as discussed 
below. 
1. The heterologous expression system may lack certain neuron-specific downstream effector(s) 
which might be critical for 14,15-EET to exert activity. For instance, regulators of G-protein 
signaling (RGS) belong to a family of GTPase-accelerating proteins, which accelerate GTP 
hydrolysis by the Gα subunit of heterotrimeric G proteins and thus shorten the duration of GPCR 
signaling (De Vries et al., 2000). RGS proteins such as RGS2, RGS4, RGS6, RGS7, RGS8, 
RGS9-2, RGS11, RGS19, and RGS20 have been reported as negative modulators of MOR 
signaling, of which RGS4 and 9-2 are the most commonly reported (Traynor, 2012). In addition, 
RGS9-2 enhances MOR signaling at the spinal site (Papachatzaki et al., 2011). The activity of 
these RGS proteins is further regulated through a multitude of mechanisms including altered 
expression, intracellular localization and posttranslational modifications (Kach et al., 2012). 
14,15-EET might regulate the activity of RGS4 and/or 9-2 to potentiate the MOR signaling and 
consequently opioid-mediated antinociception. This, however, needs to be evaluated in a suitable 
in vitro system expressing MOR and RGS4/9-2. 
2. The surface availability of MOR is an important determinant of magnitude and duration of 
MOR signaling. Trafficking of MOR to the membrane is a finely-tuned process which involves 
plethora of downstream proteins and mechanisms such as endosomal sorting (Zhang et al., 2015). 
Interestingly, EETs induce the translocation of transient receptor potential-C (TRPC) channels to 
the endothelial cell membranes via cAMP/PKA-dependent mechanism (Fleming et al., 2007). 
Similarly, EETs might enhance surface expression of MORs by altering their trafficking to the 
neuronal plasma membrane. 
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3. Alternatively, the observed effect of ablated CYP-epoxygenase and sEH on morphine-
mediated antinociception in mice could be attributed to other bioactive epoxy FA metabolites, 
such as EpDPEs, EpETEs, and EpOMEs. Interestingly, a recent study implicated that DHA-
derived EpDPEs are capable of suppressing diabetic neuropathic pain with the antinociceptive 
effect being antagonized by application of the MOR antagonist naloxone (Wagner et al., 2017). 
4.4.3. DMSO potentiates DAMGO-mediated MOR activation  
We found that DMSO lacks any direct effect on MOR activity in absence of the MOR agonist 
DAMGO: However, we observed a significant potentiation of MOR signaling by DMSO 
(0.003% and 0.03%), concentrations which are routinely used for in vitro and in vivo 
pharmacological assays. These findings suggest a potential role of DMSO as a positive modulator 
of DAMGO-induced activation of MOR signaling.  
Interestingly, some older studies suggested that DMSO itself could exhibit antinociception in 
animal models of nociception (Haigler et al., 1983; Haigler et al., 1981). However, these findings 
could not be confirmed in a recent study (Takeda et al., 2016). This observed lack of DMSO-
mediated antinociception is compatible with our in vitro observation that DMSO does not 
activate MOR signaling directly. Although DMSO lacks direct effect on MOR, it might 
potentiate DAMGO-induced MOR activation. This notion is further supported by a study that 
reported the lack of antinociceptive effect of DMSO when microinjected directly into the 
ventrolateral PAG. Interestingly, DMSO (2%) enhanced the potency of morphine when co-
administered in rats (Fossum et al., 2008) which is compatible with our observation of DMSO-
mediated potentiation of DAMGO-induced MOR signaling. Furthermore, DMSO-mediated 
potentiation of MOR signaling has been reported in the clinical settings as well; cancer patients 
concurrently receiving morphine and DMSO-cryoprotected hematopoietic stem cells transplant 
infusion unexpectedly showed severe respiratory depression, a classical side effect of morphine-
mediated MOR activation (Caselli et al., 2009).  
These reports, taken together with our findings strongly suggest the role of DMSO as a positive 
modulator of agonist-induced MOR signaling. Our findings recommend a caution for the 
concurrent use of DMSO and opioid agonists such as morphine or DAMGO for both, as a vehicle 
for pharmacological assays and as a cryoprotectant in the clinical settings.  
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Chapter 5  
General Discussion 
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Arachidonic acid (AA) serves as a source for several bioactive eicosanoids including 
epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids (DHETs). EETs have been 
shown to exert a plethora of bioactivities such as vasodilation, anti-inflammation, and 
angiogenesis. DHETs, on the other hand, are generally regarded less active or devoid of any 
bioactivity at all (Spector et al., 2015). The potential role of these lipid mediators on neuronal 
excitability, synaptic transmission, and their underlying molecular targets remained largely 
unexplored to date. In this dissertation, we investigated the potential role of 11,12-EET, 14,15-
EET and 11,12-DHET on neuronal excitability and synaptic transmission in the mouse 
hippocampal neurons Furthermore, we studied the effect of 14,15-EET on heterologously 
expressed MORs. Main findings of this dissertation are discussed extensively in respective 
chapters. This section addresses the unexplored aspects in the light of current literature.  
5.1. 11,12-EET and -DHET exhibit complementary effects in the hippocampal PCs via 
combination of pre- and postsynaptic effectors 
In hippocampal PCs, 11,12-EET (and to marginal extent 14,15-EET) suppressed excitatory 
synaptic transmission, whereas 11,12-DHET enhanced it. We identified 11,12-EET-mediated 
activation of hyperpolarizing G-protein coupled inwardly rectifying K+ (GIRK) channels via 
putative EET receptors (EETRs) as a postsynaptic effector underlying inhibitory effects of 
11,12-EET. Moreover, using heterologous expression system, we identified Kv1.2 and Kv4.2 as 
potential effectors for 11,12-EET/-DHET. 11,12-DHET exhibited significant block of Kv1.2 and 
Kv4.2 channels. The observed DHET-mediated block of Kv1.2 in heterologous cells indicates a 
potential modulation of neuronal Kv1.1/1.2 heterotetramers which are present in presynaptic 
terminals and regulate glutamate release (Geiger et al., 2000; Ovsepian et al., 2016; Trimmer, 
2015). By contrast, 11,12-EET exhibited a trend towards enhanced activation of these channels 
in the heterologous system which is consistent with opposite effects of 11,12-DHET and -EET 
observed on synaptic transmission at CA3-CA1 synapse. 
Moreover, postsynaptically expressed Kv4.2 hippocampal PCs have been implicated in the 
regulation of synaptic integration and dendritic excitability (Ramaker et.al., 2006, Trimmer 
2015; Jung et al., 2008). 11,12-DHET-mediated block of Kv4.2 in heterologous cells points 
towards potential block of Kv4.2 channels in neurons and thus serve as postsynaptic effectors for 
11,12-DHET effect (Fig. 5.1). 
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Our data also point towards the yet unidentified presynaptic effectors for 11,12-EET and allows 
us to hypothesize the presence of presynaptically expressed EETR(s), which might regulate the 
neurotransmitter release from presynaptic terminals. Indeed, several studies proposed and 
assessed the existence of putative EETR(s) underlying EET-mediated bioactivities. A few studies 
indicated that putative EETR(s) is Gαs-coupled and modulate calcium-activated BK (BKCa) 
channels (Fukao et al., 2001; Li et al., 1997; Li et al., 1999). This possibility is compatible with 
the existence of putative EETR(s) that modulate Kv channels. However, to date, definite 
identification of such high-affinity EETR(s) remains unknown (Liu et al., 2016; Spector et al., 
2015; Wong et al., 1997).  
Notably, presynaptic Kv channels such as Kv1.1/1.2 are reportedly regulated via known G-
protein coupled receptors (GPCRs) such as Mu-opioid receptors (MOR) in some neuronal 
circuits. MOR expression is primarily restricted to the GABAergic interneurons and it has been 
shown that activation of presynaptic MOR attenuates GABAergic synaptic inputs to central 
nucleus of amygdala projecting neurons in the basolateral amygdala, presumably via modulation 
of Kv1.1/1.2 channels (Finnegan et al., 2006). Similar attenuation of GABAergic inputs has been 
reported in rat subthalamic nucleus (Shen et al., 2002). These observations are compatible with 
the possibility that EETs might alter neurotransmitter release by activating presynaptically 
expressed known GPCR(s) or yet unidentified EETR(s) (Fig 5.1). 
5.2. Epoxide hydrolases as endogenous ‘switch’ between inhibition and excitation  
Our findings suggest that microsomal and soluble epoxide hydrolase (mEH and sEH) play a key 
role in the regulation of the ratio between inhibitory 11,12-EET and excitatory 11,12-DHET and 
thus, may serve as a ‘physiological switch’ between inhibition and excitation in the 
hippocampus. This hypothesis was supported by our findings showing higher basal synaptic 
transmission in slices from mice expressing a mEH variant with higher activity (mEH E404D), 
while it was reduced in mice lacking one of the main EHs (mEH and sEH KO). Moreover, we 
observed significantly higher miniature excitatory postsynaptic current frequency in CA1 PCs 
from mEH E404D slices. This potentiation in excitatory synaptic transmission in mEH E404D 
CA1 PCs might be caused by DHETs, which block presynaptic Kv channels and thus increase 
glutamate release at the respective synapse. Indeed, 11,12-DHET was able to block 
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heterologously expressed Kv1.2 channels significantly by 11.92±3%; at a test potential of +10 
mV. 
 
 
5.3. Mice lacking sEH exhibit higher morphine-mediated antinociception 
Several studies implicated CYP-epoxygenases-derived fatty acids (FAs)-epoxides such as EETs 
in opioid-mediated antinociception (Conroy et al., 2010; Hough et al., 2015; Hough et al., 2014; 
Terashvili et al., 2008). In our experiments with sEH KO, we observed significantly higher 
morphine-mediated antinociception which points towards the involvement of sEH substrates in 
the morphine-mediated antinociception. Our observation taken together with an earlier report of 
14,15-EET-mediated antinociception in rats (Terashvili et al., 2008) suggested that 14,15-EET 
might potentiate opioid signaling. However, 14,15-EET did not affect MOR activity, neither 
when applied alone nor in combination with the MOR agonist DAMGO in a heterologous 
expression system. Our results are compatible with an earlier report of no direct activity of 
14,15-EET on MOR (Terashvili et al., 2008). Furthermore, high throughput screening for 14,15-
EET GPCRs did not find high-affinity binding to MOR (Liu et al., 2016). These studies suggest 
Fig. 5.1. Working model of potential switch functions of EHs via EETs- and DHETs-mediated modulation of pre- 
and postsynaptic effectors.  
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indirect mechanism(s) for 14,15-EET-mediated potentiation of MOR. Alternatively, host cells 
used in our experiments may lack a crucial molecular component for enhancing MOR signaling 
by 14,15-EETs.  
Our finding of 11,12-EET-mediated activation of GIRK channels in CA1 PCs, through putative 
EETR(s), put forth an interesting hypothesis: 11,12-EET-mediated activation of GIRK via 
EETR(s) or EETR-MOR crosstalk could be an underlying mechanism for higher antinociception 
observed in sEH KO mice. This possibility, however, needs to be investigated in the relevant 
neuronal system such as peripheral nociceptors or neurons from the supraspinal regions involved 
in the endogenous opioid pathways such as periaqueductal grey (PAG) and central nucleus of the 
amygdala. 
5.4. Pathophysiological implications   
The potential ‘switch’ function of mEH and sEH could become even more pertinent under 
pathological conditions such as stroke, epilepsy, and hypoxia, when basal free AA levels are 
dramatically increased which might result in an increased levels of neuroactive EETs and/or 
DHETs in brain (Bazan et al., 1986; Bazán, 1970; Gardiner et al., 1981; Siesjö et al., 1989). In 
addition, EH activity is also altered under pathological conditions; expression of sEH has been 
shown to be increased in pilocarpine-induced epilepsy in mice (Hung et al., 2015). Moreover, 
mEH expression has been detected in tumor-associated glioma and in astrogliosis associated with 
epileptic seizures in human brain (Kessler et al., 2000). Furthermore, mEH expression is 
elevated in hippocampus of Alzheimer’s disease patients (Liu et al., 2006). Higher EETs 
generation coupled with higher epoxide hydrolase activity might tilt the physiological balance 
between inhibitory EETs towards the excitatory DHETs. Indeed, epileptic seizures induced by 
pentylenetetrazol resulted in altered EET:DHET ratio in favor of DHETs (Inceoglu et al., 2013).  
Moreover, our findings of inhibitory effects of EETs and excitatory effects of DHETs offer 
mechanistic insights to the prior studies reporting beneficial effects of sEH inhibition/ablation in 
several animal models of epilepsy such as GABA antagonist-induced delayed onset seizures 
(Inceoglu et al., 2013), tetramethylenedisulfotetramine (TETS)-induced tonic seizures (Vito et 
al., 2014), pilocarpine-induced and amygdala kindling-induced epilepsy (Hung et al., 2015). 
Similarly, genetic ablation/pharmacological inhibition of sEH is linked to the beneficial effects 
107 | P a g e  
 
in animal models of stroke, this effect is majorly attributed to the EETs-mediated 
antiinflammation and neuroprotection (Iliff et al., 2010; Zhang et al., 2007). In addition to the 
inflammation, stroke-associated excitotoxicity is one of the primary causes of neuronal death in 
stroke (Chamorro et al., 2016). Based on our findings, one can speculate that the reported 
beneficial effects of EETs in stroke models, at least in part, could be attributed to the EET-
mediated dampening of neuronal excitability. In the absence of characterized putative EETR(s), 
inhibition of sEH by small molecule inhibitors is actively being explored as a therapeutic target 
for pain, inflammatory and neurodegenerative diseases (Wagner et al., 2017). A better 
understanding of the functions and identification of molecular targets for these neuroactive lipid 
mediators might offer better avenues for therapeutic intervention. 
5.5. Outlook 
The potential role of mEH and sEH as a ‘switch’ between hippocampal excitation and inhibition 
can be further corroborated in alternate in vitro and in vivo experimental paradigms. Moreover, 
the underlying molecular mechanism(s) for higher morphine-mediated antinociception observed 
in sEH KO mice needs to be ascertained. This can be achieved by investigating the influence of 
FA epoxides on MOR signaling in suitable extracellular system expressing potential effectors. 
Amongst other possibilities, downstream regulation of RGS protein and in turn MOR signaling 
by FA epoxides such as EETs/EpOMEs is desirable. 
The possibility of putative G-protein coupled EETR has been evaluated by means of binding 
assays and high throughput screening with 14,15-EET against GPCR libraries, however, it did 
not result in the identification of high-affinity EETR to date (Li et al., 1997; Li et al., 1999; Liu 
et al., 2016). Our findings strongly suggest the possible existence of 11,12-EET-specific 
EETR(s) and this possibility can be explored by means of high throughput screening against a 
library of known and orphan GPCRs. Identification and characterization of these receptors could 
advance the basic research in this field and extend its impact to the possible clinical usefulness.  
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Abbreviations 
AA: arachidonic acid 
ACSF: artificial cerebrospinal fluid 
AHR: aromatic hydrocarbon receptor 
ALA: α-linolenic acid 
AMPAR: α-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid receptor 
APs: action potentials 
AUDA: 12-(3-adamantan-1-yl-ureido) 
dodecanoic acid  
BBB: blood-brain barrier 
BKCa: calcium-activated BK 
CA: cornu ammonis 
CB1: cannabinoid 1 receptor 
CHO: chinese hamster ovary 
CNS: central nervous system 
COX: cyclooxygenases 
cPLA2: cytoplasmic phospholipase A2 
CPR: CYP-reductase 
CRCs: concentration-response curves 
CYPs: cytochrome P450 
DGGCs: dentate gyrus granule cells 
DHA: docosahexaenoic acid 
DHET: dihydroxyeicosatrienoic acid 
DIC: differential interference contrast 
DiHOMEs: dihydroxy-12Z-octadecenoic 
acid 
DOR: delta-opioid receptor 
DSE: depolarization-induced suppression of 
excitation 
DSI: depolarization-induced suppression of 
inhibition 
 
 
 
DTx: dendrotoxin 
EC: entorhinal cortex 
EDH/RF: endothelium-derived 
hyperpolarizing/relaxing factors 
EETs: epoxyeicosatrienoic acids 
EEZE: 14,15-epoxyeicosa-5(Z)-enoic acid 
EHs: epoxide hydrolases 
EPA: eicosapentaenoic acid 
EpDPEs: derived epoxydocosapentaenoic 
acids 
EpETEs: eicosapentaenoic acid-derived 
epoxyeicosatetraenoic acid 
EpOMEs: epoxy-octadecenoic acids 
EPSCs: excitatory postsynaptic currents 
ER: endoplasmic reticulum 
ETYA: 5,8,11,14-eicosatetraynoic acid 
FAAH: fatty acid amide hydrolase 
FABPs: fatty acid binding proteins 
fEPSPs: field excitatory postsynaptic 
potential recordings 
FV: fiber volley 
GABA: γ-aminobutyric acid 
GDPβS: guanosine-5’-O(2-thiodiphosphate) 
GIRK: G-protein coupled inwardly 
rectifying K+ 
GPCRs: G-protein-coupled receptors 
HETEs: hydroxyeicosatetraenoic acids 
HF: hippocampal formation  
HpETEs: hydroperoxyeicosatetraenoic acids 
IA: A-type currents 
ID: D-type currents 
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Ihold: holding current 
IKCa: Ca2+ activated potassium channels 
INs: interneurons 
I-O: input-output 
IPSCs/Ps: inhibitory postsynaptic 
currents/potentials 
IR: immunoreactivity 
KAR: kainate receptors 
KChIPs: Kv channel interacting proteins 
kcat/Km: catalytic efficiency 
K2P: two-pore domain K
+ 
LA: linoleic acid 
LOX: lipoxygenases 
LTP: long-term potentiation 
MAGL: monoacylglycerol lipase 
mEH: microsomal epoxide hydrolases 
mEPSC: miniature excitatory postsynaptic 
currents 
Mfs: mossy fiber 
MfBs: mossy fiber boutons 
MOR: Mu-opioid receptor 
NADH: nicotinamide adenine dinucleotide-
hydrogen (reduced) 
NADPH: nicotinamide adenine dinucleotide 
phosphate hydrogen (reduced) 
NMDAR: N-methyl-D-aspartate receptor 
PAG: periaqueductal gray 
PCs: pyramidal cells 
PGH2: prostaglandins H2 
PLL: poly-L-lysine 
PPAR: peroxisome proliferator-activated 
receptor  
PPF: paired-pulse facilitation 
PPR: paired pulse ratio 
PTGER: prostaglandin E receptor  
PUFAs: polyunsaturated fatty acids 
RMP: resting membrane potential 
SCs: Schaffer collaterals 
sEH: soluble epoxide hydrolases 
sEHis: sEH inhibitors 
SEM: standard error of mean 
SNP: single nucleotide polymorphism 
SOCE: store-operated calcium entry 
tAUCB: trans-4-[4-(3-adamantan-1-y1-
ureido)-cyclohexyloxy]-benzoic acid 
TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin 
TEA: tetraethylammonium 
TETS: tetramethylenedisulfotetramine 
TP: thromboxane prostaglandin 
TRP: transient receptor potential 
TRPC: transient receptor potential-C 
TTQ: tertiapin Q 
TTX: tetrodotoxin 
TxA2: thromboxane A2 
VGCChs: voltage-gated calcium channels 
VGPChs: voltage-gated potassium channels 
VGSChs: voltage-gated sodium channels 
Vmax: maximum velocity 
2-AG: 2-arachidonoyl glycerol 
12-HPETE: 12-hydroperoxyeicosatetraenoic 
acid 
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